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Thesis summary 
Although strong protective immune response is essential for preventing invasion by 
pathogens, equivalent responses against antigens originating from commensal bacteria 
can lead to chronic inflammatory diseases, such as inflammatory bowel disease (IBD). 
Manipulating the mucosal immune responses with microbial antigens might be an 
excellent tool to IBD therapy or prevention. Our aim was to gain some insight into the 
regulation of the intestinal inflammation and to isolate bacterial immunomodulatory 
components that could be used in intestinal inflammation therapy and prevention. 
 One particular mechanism of how healthy colon tissue regulates the inflammation 
during acute experimental colitis is through modulation of bioavailability of 
glucocorticoids (GCs) in gut mucosa. Here, we show that intestinal inflammation changes 
the local GC metabolism, which ultimately leads to decrease in inflammatory readiness of 
cells in the gut mucosa and in mesenteric lymph nodes. This pre-receptor regulation of 
GC function could represent an important homeostatic function of the gut mucosa. 
 The actual triggers of intestinal inflammation in IBD seem to be either microbial 
dysbiosis or microbes with special “pathogenic” abilities, which both could be rectified 
by feeding with probiotics. Here, we report that oral feeding with live probiotic bacteria 
can protect mice from severe forms of acute colitis. Furthermore, we found that even the 
oral treatment with lifeless lysate of one of them, L. casei DN-114 001 (Lc), has a similar 
protective effect. This treatment also prevented some typical features of intestinal 
inflammation, such as production of pro-inflammatory cytokines in gut tissue and 
increase in intestinal permeability. Moreover, the lysate also significantly changes the gut 
microbiota composition. We conclude that antigens from Lc can reduce the intestinal 
inflammation by influencing both gut microbiota and the host’s immune system.  
 Next, we show that oral treatment of mice with lysate of one particular 
commensal, Parabacteroides distasonis, or its membranous fraction (mPd), have similar 
beneficial effect as the lysate of probiotic bacterium. We demonstrated that this beneficial 
effect is gut-dependent and that the mechanism is executed mainly by the adaptive arm of 
the immune system. Interestingly, unlike the oral treatment with Lc, mPd leads to the rise 
of specific antibodies in serum and regulatory T cells in mesenteric lymph nodes.  
 Compared with the use of live bacteria, bacterial lysates seem to be a safer and 
more convenient approach in IBD therapy. The differences in immunomodulatory 
properties of different bacteria also suggest the need to individualize such therapy. 
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Souhrn v češtině 
Zatímco silná imunitní odpověď je nezbytná pro zabránění infekce patogeny, stejná 
odpověď namířená proti antigenům komenzální mikroflóry může vést ke vzniku 
chronického zánětlivého onemocnění, jakým jsou idiopatické střevní záněty (IBD). 
Manipulace s imunitní odpovědí pomocí mikrobiálních antigenů představuje zajímavou 
metodu k prevenci a léčbě IBD. Naším cílem bylo rozšířit znalosti o regulaci střevního 
zánětu a izolovat bakteriální složku vhodnou k této manipulaci. 
 Jedním z mechanismů, jakým se střevní sliznice brání rozvoji chronického zánětu, 
je modulace lokálního metabolismu glukokortikoidů (GC). V našich pokusech jsme 
prokázali, že experimentální střevní zánět spouští zpětnovazebné mechanismy ve střevní 
stěně a mezenteriálních uzlinách, které snižují zánětlivou pohotovost v této oblasti a 
zesilují účinnek GC. Regulace účinku endogenních GC na pre-receptorové úrovni 
představuje významný homeostatický mechanismus v zánětem postižené střevní sliznici. 
 Vlastním spouštěčem střevního zánětu u IBD je buďto porucha složení střevní 
mikroflóry, nebo přítomnost doposud neznámých patogenních mikroorganismů. Oba tyto 
faktory mohou být napraveny podáváním probiotických bakterií. V našich pokusech jsme 
prokázali, že krmení myší probiotickými bakteriemi zvyšuje jejich rezistenci k vyvolání 
experimentálního střevního zánětu, a že podobného efektu lze dosáhnout i s lyzátem 
jedné z nich, L. casei DN-114 001 (Lc). Tato léčba také částečně zabránila vzniku 
některých změn, které jsou typicky spojované se střevním zánětem, jako je například 
vzestup lokální produkce prozánětlivých cytokinů, vzestup střevní propustnosti, a nebo 
výrazné změny ve složení střevní mikroflóry. Složky Lc dokáží ovlivnit střevní 
mikroorganismy i imunitní systém hostitele a tak snížit citlivost organismu ke střevnímu 
zánětu. 
 Dále jsme ukázali, že lyzát komenzální bakterie, Parabacteroides distasonis, a 
zejména její membranózní frakce (mPd), mají podobný protektivní efekt jako lyzát Lc. 
Pro tento efekt je nezbytné orální podávání a neporušený adaptivní imunitní systém. Na 
rozdíl od Lc léčba pomocí mPd vede k vzestupu specifických protilátek v séru a 
regulačních T lymfocytů v mesenteriálních lymfatických uzlinách. 
 V porovnání s živými bakteriemi je terapeutické podávání bakteriálních lyzátů 
jednoznačně bezpečnější a pohodlnější. Rozdíly v mechanismu účinku mezi jednotlivými 
bakteriemi a jejich lyzáty poukazují dále na nutnost přísné individualizace takovéto léčby.
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1. GENERAL INTRODUCTION 
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1.1 MUCOSAL IMMUNE SYSTEM OF THE GUT 
The human mucosal immune system comprises the lymphoid-associated structures of the 
nasal, bronchial, gastrointestinal and urogenital tracts, as well as the lacrimal, salivary and 
mammary glands. A significant part of this system is anatomically located in the gut. 
There are several structural, functional and regulatory features that set the mucosal and 
systemic immune systems apart. This distinction is largely due to the fact that the 
antigenic environment (commensal flora and dietary antigens) is vastly different from that 
experienced by the systemic immune system. These features include a) strongly 
developed mechanisms of innate defense, b) the existence of characteristic populations of 
unique types of lymphocytes (e.g. intraepithelial lymphocytes, lamina propria 
lymphocytes, and γδ T cells), c) colonization of the mucosal and exocrine glands by cells 
originating from the mucosal organized tissues (Common mucosal system) and d) 
preferential induction of inhibition of responses to innocuous antigens (Mucosal 
tolerance) (Tlaskalova-Hogenova et al., 2002). 
 Mucosal immunity is most abundantly expressed in the gut, and the intestinal 
mucosa of an adult contains more than 80% of the body’s plasmatic cells. It is estimated 
that in healthy humans approx. 3 grams of IgA is transported to the gut lumen every day 
(Conley and Delacroix, 1987), which makes the gut the largest antibody producing organ 
in the body (Brandtzaeg et al., 1999). 
 To fulfill its digestive function, the gut has a huge surface area (approx. 300m2), 
but this huge area is covered by a single layer (approx. 30 µm thick) of tightly connected 
enterocytes, that literally separate the organism from its environment. Despite the fact that 
the gut epithelium is completely shed and replaced every 2–3 days, this layer maintains 
its integrity. 
 The epithelial cells are supported in their effort of maintaining integrity of the 
organism by a highly specialized system of immune cells forming mucosa-associated 
lymphoid system (MALT). MALT consists partly of organized tissue comprising both 
solitary and multiple lymphatic follicles (Peyer’s patches, appendix), which represents 
inductive site of immune system, and cells scattered in the mucosa responsible mainly for 
effector function. This system must be tightly regulated, discriminating between often 
very similar indigenous and harmful antigens (e.g. commensal and pathogenic E. coli).  
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 Dysfunction or dysregulation of the gut mucosal immune responses has been 
associated with a number of diseases including inflammatory bowel disease (IBD), celiac 
disease and food allergy. 
 
1.1.1 Barrier function 
Intestinal barrier prevents viable enteric bacteria and other antigens from excessive 
interaction with the immune system. The intestinal barrier is, rather than a rigid 
anatomical structure, dynamic and actively regulated apparatus formed by several 
components. These components include mucus layer, secretory immunoglobulins (Ig), 
intestinal epithelial cells (IECs), tight junction, and mucosa associated lymphoid tissue. 
While the proper function of the intestinal barrier is vital for our survival, the quality of 
an individual’s barrier function is influenced by many factors, such as the genetic 
background, age (especially in newborns), concurrent infection, interactions between the 
mast cells, nerves and neuropeptides, and the mucosa-shielding effect of SIgA produced 
in the gut or provided in the first months of life via breast milk (Brandtzaeg, 2009). 
1.1.1.1 Mucus layer 
The goblet cells, that can be found scattered in the entire gastrointestinal mucosa, produce 
abundantly glycosylated (up to 80% wt/wt) proteins called mucins. In humans, there are 
18 types of mucins identified so far, and MUC2 is the predominant type found in the gut 
(Tytgat et al., 1994). The NH2- and COOH-termini are rich in cysteine residues that allow 
these proteins to link together with disulfide bonds forming a thick, viscous and relatively 
impermeable gel layer on the apical surface of the epithelium – mucus layer (Roberts, 
1976). The thickness of this layer differs in the different parts of the gut ranging from 100 
µm to 800 µm, but the 30 µm-thick layer closest to the epithelial surface firmly adheres to 
the epithelial carbohydrates. In healthy individuals, this adherent layer is essentially 
bacteria free, but in areas of active inflammation, the mucus layer is weakened allowing 
the bacteria to reach the epithelium (Swidsinski et al., 2007). This barrier integrity is 
further strengthened by various antimicrobial compounds produced by gut mucosa. These 
compounds are concentrated in the mucus layer, preventing the proliferation of bacteria. 
These are, most notably, cationic antimicrobial peptides (defensins, cathelicidins and 
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calprotectins) produced by specialized epithelial cells – Paneth cells – and secretory 
antibodies. 
1.1.1.2 Secretory immunoglobulins 
The secretory Ig are typically present in mucosal secretions of all mammals. Their main 
source (local vs. distal production), isotype distribution and levels are, however, tissue 
and species specific (Mestecky et al., 2005). The dominant Ig isotype in the human gut is 
secretory IgA (SIgA) produced by lamina propria plasma cells. Other isotypes are of low 
importance and quantities, except for the secretory IgM (SIgM), which is of greater 
importance in newborns and adults with selective IgA deficiency (Brandtzaeg, 2009). 
Secretory Ig are produced as polymers, SIgA mainly as a dimer and SIgM as a 
pentamer, with subunits joined together by a small peptide called joining (J) chain. These 
polymeric antibodies are than transported to the gut lumen by enterocytes, as recently 
reviewed by Brandtzaeg (2009). This transport starts when the polymeric Ig receptor 
(pIgR) expressed at the basolateral surface of the enterocyte binds polymeric Ig 
molecules, the complex is then transported across the cell to be secreted at the apical 
surface, where the pIgR is enzymaticly cleaved. Part of the pIgR stays bound to the Ig as 
secretory component (SC), which significantly increases Ig’s stability (Crottet and 
Corthesy, 1998). In the lumen, these Ig are concentrated in the mucus fortifying the gut 
barrier function by shielding the internal body surfaces. Because the production of the Ig 
is stimulated by antigens that target the gut mucosa, the secretory Ig protects the gut 
surface against antigens found in the individual’s environment.  
Early after delivery, the production of secretory Ig is not sufficient to protect the 
suckling from environmental threads, so the SIgA from the mother’s milk and colostrum 
substitute its protective function (Dickinson et al., 1998; Arifeen et al., 2001). 
1.1.1.3 Intestinal epithelial cells 
The gut epithelium is an epithelium specialized for digestion and absorption of nutrients. 
To achieve its primary purpose it covers the considerable area of 300 m2, with a single 
layer of the cells. The dominant cell type in the epithelium is absorptive enterocytes, 
followed by the mucin-secreting goblet cells and enteroendocrine cells. To avoid 
intensive translocation of the potentially dangerous antigens or microorganisms, the 
epithelial cells are connected together with specialized intercellular junctions – Tight 
junctions (TJ) – that seal the apical part of the epithelium. This seal prevents the fluid 
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from moving through the intercellular gaps and separates apical membranes from the 
basolateral ones. These junctions are formed by several proteins connected to the 
epithelial cytoskeleton as shown on Figure 1.1. 
 
Figure 1.1 Schematic representation of the tight junction and its regulation by 
immune system in health and disease. 
 
The barrier function of the TJ can be regulated by pro-inflammatory cytokines - TNF-α 
and IFN-γ  (Madara and Stafford, 1989; Taylor et al., 1998). Both these cytokines have 
synergic effect, which seems to be mediated by the activation of myosin light chain 
kinase (MLCK) with subsequent phosphorylation of perijunctional myosin II regulatory 
light chain, which then opens TJ and enhances paracellular permeability (Wang et al., 
2005).  
Besides separating the host connective tissue from the external environment, 
epithelial cells participate in the effector function of the mucosal immune system and play 
The paracellular space between the 
enterocytes is sealed just below the 
base of microvilli by tight junctions. 
This complex is formed by several 
proteins, including claudins, zonula 
occludens 1 (ZO-1) and occludin which 
are connected to polymeric (F-) actin 
and myosin. Myosin light chain kinase 
(MLCK) is associated with the 
perijunctional actomyosin ring and its 
activity leads to the phosphorylation of 
myosin light chain (MLC) which results 
in TJ opening. This process can be 
initiated by high levels of pro-
inflammatory cytokines, TNF-α and 
IFN-γ. In healthy individuals, interaction 
between epithelium and immune cells 
in lamina propria (namely Tolerogenic 
Dendritic cells (DC) and regulatory T 
cells (Treg)) create anti-inflammatory 
millieu. Minor defects in the barrier 
allow immunostimmulatory 
bacterial/dietary antigens to cross the 
epithelium and enter the lamina 
propria, causing the production of the 
innflammatory mediators. If this 
reaction goes adrift, the tight junctions 
in the area start to leak, thereby 
allowing further stimulation of lamina 
proprie immune cells by bacterial and 
dietary antigens from the lumen, thus 
amplifying the cycle of inflammation. 
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an important immunomodulatory role. Enterocytes express molecules involved in antigen 
presentation to the gut lymphocytes, such as the class I and class II MHC and CD1d 
molecule (Gorvel et al., 1984; Blumberg et al., 1991). However, since the IECs do not 
express costimmulatory molecules, they cannot prime naive T cells and therefore supply 
the mucosal cells with tolerogenic signals (Sanderson et al., 1993). Moreover, when the 
IECs are stressed, they express MHC class I-related molecules MICA and MICB on their 
surfaces. This serves as an immune surveillance mechanism for the detection and 
destruction of damaged, infected, or transformed IECs by intestinal γδ T cells (Groh et al., 
1998).  
The IECs express a wide range of pattern recognition receptors (PRRs), including 
Toll-like receptors (TLRs), that recognize conserved microbial motifs. These microbial 
components, such as the lipopolysaccharide (LPS), lipoproteins, flagellin and 
unmethylated CpG-containing DNA, are shared among both dangerous pathogens and 
harmless commensals (see Table 1.1). In general, the PRRs react to these microbial 
components by activation of pro-inflammatory immune response. Therefore, the 
proximity of billions of microbes and IECs raises the question of why the IECs do not 
respond by inflammation to the commensals in gut lumen. Although this question is still 
not completely answered, several anti-inflammatory mechanisms have been proposed. 
First, the distance between the PRRs and gut microbes is extended by the mucus layer, as 
mentioned above. Second, under steady-state conditions, IECs downregulate the 
expression of LPS recognising TLR4/MD-2, minimizing the recognition of bacterial LPS 
(Abreu et al., 2001). Third, there is a different representation of PRRs in the apical and 
basolateral cell membrane. So while LPS recognising TLR4 is expressed on the luminal 
membrane, flagellin recognising TLR5 is expressed exclusively on the basolateral 
membrane (Gewirtz et al., 2001).  Flagellated bacteria cannot, therefore, trigger TLR5 
unless they actively penetrate the mucosa. This is in agreement with the findings that 
IECs dampen the pro-inflammatory immune response if the bacteria trigger the luminal 
PRR, but react with strong pro-inflammatory response if the basolateral PRRs are 
stimulated by invading bacteria (Artis, 2008). Fourth, some commensal bacteria were 
found to downregulate the pro-inflammatory cascade by interfering with regulation of 
NF-κB signalling cascade (Neish et al., 2000; Kelly et al., 2004). Fifth, IECs do not 
express costimmulatory molecules so they may act as tollerogenic cells maintaining the 
survival and activity of Treg (Mowat, 2003). 
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IECs produce a variety of cytokines that could also be responsible for the “anti-
inflammatory“ tuning of the gut mucosa. Stimulation of the CD1d expressed on the 
epithelial cells causes them to produce anti-inflammatory cytokine IL-10 and attenuate 
the pro-inflammatory IFN-γ signaling. This cytokine environment then downregulates the 
T cell response in the mucosa (Colgan et al., 1999). When challenged with some 
commensal bacteria, human enterocytes produce thymic stromal lymphopoietin (TSLP) 
and TGF-β, which cooperate in the induction of tolerogenic phenotype in the dendritic 
cells (DCs) (Zeuthen et al., 2008). On the other hand, when invaded by pathogenic 
microorganisms, they rapidly secrete a large number of cytokines and chemokines that 
draw inflammatory cells to the site of infection and help the organism to deal with the 
infection (Jung et al., 1995).  
 Another important effector function of IECs is executed by transporting secretory 
Ig from the lamina propria plasmatic cells to the gut lumen. During this transport, 
secretory Ig integrate SC into their molecule, as mentioned earlier in this chapter. 
 
1.1.2 Induction of the mucosal immune response 
1.1.2.1 Peyer’s patches  
Peyer’s patches (PP), together with mucosa-draining local/regional lymph nodes, 
represent the inductive site of the mucosal immune system. There is growing evidence, 
however, that the induction of mucosal immune response could occur in the absence of 
PP, probably through microscopic lymphoid aggregates (Hamilton et al., 1981). 
Structurally, the PPs are well organized structures of special epithelium and lymphoid 
tissue, found in the small intestine. Unlike the epithelium found in the rest of the intestine, 
the follicle-associated epithelium (FAE) is cuboidal in shape and contains few or no 
goblet and enteroendocrine cells. Approximately 10% of PP’s surface is covered by 
specialized microfold (M) cells. These M cells have characteristic ultrastructural features 
like irregular microvilli on the luminal surface and invaginations (or “pockets”) on the 
basal surface, harboring infiltrating lymphocytes. They closely collaborate with 
underlying MALT by transporting the antigen into the underlying follicles (Owen, 1977). 
Unlike the regular villous IECs, the M cells cannot transport secretory antibodies 
produced by the plasmocytes, because they do not express the SC (Bjerke and 
Brandtzaeg, 1988).  
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Right under the epithelial layer, there is a mixed cell zone called dome area, where 
most of the antigen presentation takes place (Kelsall and Strober, 1996). This zone 
contains several types of cells, including CD4+ T cells, plasma cells, dendritic cells (DCs) 
and small B cells with cleaved nuclei (centrocyte-like cells) which can infiltrate the 
overlying epithelium. The M cell’s associated B cells have a memory phenotype and 
resemble germinal centre B cells, so it seems that the B cells in M cell pockets are 
extensions of germinal centers (Yamanaka et al., 2001). The development of the PP is 
dependent on the B cells, because the already differentiated epithelial cells can be 
transformed into M cells when co-cultured with B cells, and B cell or RAG1 deficient 
mice (with no T or B cells) have very reduced size and numbers of PPs and only few M 
cells, while mice deficient in T cells have normal numbers and sizes of PPs and M cells. 
(Kerneis et al., 1997; Golovkina et al., 1999) 
Under the dome area, there is thymus-dependent area which contains lymphatic 
follicles, typically with germinal centers. The follicle center, supported by a network of 
follicular DCs, is populated mainly by the B cells and it is surrounded by the mantle of T 
cell–rich areas that merge into the mixed cell zone of the dome area. The interfollicular 
region contains CD4+ and CD8+ T cells, DCs and a dense network of high-endothelium 
venules that serve as entry and exit points for migrating cells (Kelsall and Strober, 1996). 
In the intestinal mucosa, these venules express mucosal vascular addressin cell adhesion 
molecule 1 (MAdCAM-1), which is specifically recognized by the α4β7 integrin on the 
mucosa-induced lymphocyte populations, and also, at least to some extent, by the L-
selectin (CD62L) expressed on naive T cells (Bargatze et al., 1995). 
1.1.2.2 Cryptopatches and isolated lymphocyte follicles  
As mentioned earlier, antigen presentation to the gut mucosal immune system could also 
occur outside PPs, in the microscopic isolated lymphatic follicles (ILFs) and in mice also 
in cryptopatches (CPs).  
CPs, first identified by Kanamori et al. (1996), are small lymphocyte follicles, 
approximately 100-150 µm in diameter, scattered in the small and large intestine of mice. 
Unlike the ILFs or PPs, CPs are smaller, do not contain mature T (CD3+) or B (B220+) 
cells, do not have germinal centers, and are not associated with M cells (Hamada et al., 
2002). Interestingly, CPs are populated primarily by precursor lymphocytes and the fact 
that they are present in germ-free mice and in immunodeficient SCID and athymic nu/nu 
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mice suggests that they are microbiota and thymus independent source of lymphocytes 
(Kanamori et al., 1996) 
 There are numerous ILFs scattered throughout the mucosa of both small and large 
intestine. Similarly to the PPs, these ILFs are mainly populated by antigen producing B 
cells with a close contact of APCs and their surface is covered with follicle associated 
epithelium containing M cells (Hamada et al., 2002). ILFs are, therefore, important for 
the humoral response to the luminal antigens. They can be formed de novo in adult 
animals and although they do exist in germ-free mice, they need exogenous stimuli, 
including normal bacterial flora, to become fully developed (Lorenz et al., 2003). 
 Besides M cells, the gut lumen is also actively sampled for antigens by intestinal 
DCs. These APCs can reach through epithelial layer by their long dendrites. To achieve 
this without disturbing the barrier function of the gut epithelium, they express ZO-1, 
Claudin-1 and Occludin, proteins involved in the TJs formation (Rescigno et al., 2001).   
 
1.1.3 Effector function 
There are two main effector functions executed by the mucosal immune system of the 
gut, depicted on Figure 1.2. First, there is a strong inflammatory response against 
invading microorganisms or potentially harmful antigens protecting the integrity of the 
organism. Second, the mucosa is protected from being destroyed by excessive 
inflammatory response by active anti-inflammatory mechanisms. This system is tightly 
controlled and regulated in order to keep the balance between these two, partially 
opposing, mechanisms.  
Mucosal immune system provides a first line of defense for the inner body surfaces. 
Most abundantly, the mucosal immunity is expressed in the gut. Effector functions of the 
mucosal surfaces are executed by cells in various histological compartments, most 
notably in the lamina propria and in the gut epithelium (Brandtzaeg and Pabst, 2004).  
 Although dendritic cells could enter the gut epithelium, this compartment is 
populated mostly by CD8+ T cells, with fewer CD4+ T cells. There are neither 
macrophages, nor B cells, nor plasma cells.  These Intraepithelial lymphocytes (IEL) are 
phenotypicaly distinct population, they could bear either αβ or γδ T-cell receptor (TCR), 
and they are of large portion thymus independent cells (Kunisawa et al., 2007). The γδ T-
cells represents 10% of IELs in healthy humans, and up to 50% of IELs in rodents 
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(Spencer et al., 1989; Guy-Grand et al., 1991). Although they are in constant contact with 
extensive amount of antigenic stimuli, these T cells are counterintuitively, markedly 
oligoclonal (Regnault et al., 1994). The T cells in newborns have polyclonal repertoire, 
but soon after birth, they become increasingly restricted. This restriction is antigen driven 
and the resulting repertoire is unique and quite stable for every individual (Chowers et al., 
1994). 
 
Figure 1.2 Schematic representations of the main mechanisms of mucosal immune 
response. 
 
Antigen may enter through the microfold (M) cells to the Peyer’s patch (a), and after transfer to local dendritic 
cells (DCs), might then be presented directly to T cells (b). Alternatively, antigen or antigen-loaded DCs from 
the Peyer’s patch may gain access to draining lymph, with subsequent T-cell recognition in the mesenteric 
lymph nodes (MLNs) (c). A similar process of antigen or antigen-presenting cell (APC) dissemination to 
MLNs may occur if antigen enters through the epithelium covering the villus lamina propria (e), but in this 
case, there is the further possibility that stimulation of the basolateral PRR of the enterocytes causes them to 
express MHC class II+, thus acting as local APCs (d). In all cases, the antigen-responsive CD4+ T cells 
acquire expression of the α4β7 integrin and the chemokine receptor CCR9, leave the MLN in the efferent 
lymph (e) and after entering the bloodstream through the thoracic duct, exit into the mucosa through vessels 
in the lamina propria. T cells which have recognized antigen first in the MLN may also disseminate from the 
bloodstream throughout the peripheral immune system. Antigen may also gain direct access to the 
bloodstream from the gut (f) and interact with T cells in peripheral lymphoid tissues (g). Antigen specific 
regulatory T cells than enter the lamina propria and render the LPL unresponsive to the gut commensals (h) 
by direct contact or by producing anti-inflammatory cytokines. Antigen specific T cells stimulate the 
production of SIgA by plasmatic cells (i) or stimulates the innate immunity cells, resident in gut mucosa, to 
clear the pathogens or potentially harmful antigens (j) by pro inflammatory cytokines. Based on Mowat 
(2003), SED, subepithelial dome; TDA, thymus-dependent area; DC, dendritic cell; IEL, intraepithelial 
lymphocytes; LPL, lamina propria lymphocytes; SIgA, secretory IgA. 
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The lamina propria (LP) is the layer of connective tissue between the epithelium 
and muscularis mucosa. This compartment contains a number of macrophages, dendritic 
cells and both T and B lymphocytes. This mixture of cells could therefore execute all 
functions of the mucosal immune system from antigen processing to the specific 
response. 
 LP T cells are mainly CD4+ T cells bearing αβ TCR, generated in the PP as a 
result of antigen stimuli. Interestingly, all of them are on pro-apoptotic pathway, 
expressing Fas, and sometimes even Fas Ligand on their surfaces (De Maria et al., 1996). 
The lack of direct antigen stimulation in the LP leads them to apoptosis. There are also 
some CD8+ αEβ7+ T cells, which are probably only transiting IELs (Farstad et al., 1996). 
Intestinal LP is richly endowed with IgA+ plasmocytes, which make up 30–40% of the 
mononuclear cells in humans. Most of the plasma cells are found in the region around the 
crypts (Brandtzaeg et al., 2005). The population of the LP by these cells is also antigen 
driven, because there are no plascmocytes in the LP at birth (Perkkio and Savilahti, 
1980). There is also considerable amount of macrophages and DCs in the LP, their main 
function is to phagocyte the invading pathogens, to present the antigens to T cells and to 
modulate the immune functions. Furthermore, it has been shown that subepithelial 
macrophages at the top of the villi contain debris of the apoptotic IECs, which suggest 
that these cells take part in the gut epithelium renewal (Nagashima et al., 1996). 
1.1.3.1 Defense mechanisms of the innate immunity  
The mucosa contains both effector arms of the immune system, innate and adaptive, 
which operate in synergy. This synergy allows proper activation of the immune system 
against pathogens and also long-term tolerance of commensal microbiota and other 
harmless antigens.  
 Strongly developed mechanisms of innate immunity are typical for protection of 
mucosa. Main effector functions of the innate immunity of the gut mucosa are executed 
by the production of cytokines, phagocytosis of the pathogens, production of the 
antimicrobial factors and presenting the antigens to the cells of the adaptive immunity 
(Tlaskalova-Hogenova et al., 2004). The innate immunity response against microbes and 
their components is initiated through the PRR, as mentioned earlier. They can be 
expressed on the cell surface, in the intracellular compartments, or secreted into the 
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bloodstream and tissue fluids (Medzhitov and Janeway, 1997). These receptors can 
recognize conserved structures on microbes called microbe-associated molecular patterns 
(MAMPs) so that the host could discriminate between different groups of microbes (see 
Table 1.1) (Janeway, 1989; Akira et al., 2006).  
These receptors are found in many cell types, including those responsible for gut 
mucosa protection - macrophages, DCs, neutrophils and previously mentioned IECs. 
Once PRRs are triggered by microbial components, the cells start to produce cytokines 
essential for both pathogen elimination and initiation of subsequent adaptive immune 
response (Tlaskalova-Hogenova et al., 2005).  
 
Table 1.1 TLR recognition of microbial components 
Adopted from Akira et al. (2006) 
 
Microbial density in the gut lumen is controlled by the production of the 
antimicrobial peptides, because these small cationic peptides are concentrated in the 
mucus layer. These peptides are produced mainly by IECs, but also by other cell types 
resident to the intestinal mucosa – e.g. mastocytes (Di Nardo et al., 2003). These 
antimicrobial peptides are produced constitutively, but their production in IECs can be 
significantly increased in response to intestinal pathogens (O'Neil et al., 1999; Ayabe et 
al., 2000). 
1.1.3.2 Defense mechanisms of the adaptive immunity  
Gut mucosa is effectively protected from potentially dangerous antigens by defense 
mechanisms of both innate and adaptive immunity. While the innate immune system 
Receptor Ligand Species 
TLR1/2 Triacyl lipopeptides, Glycolipids Bacteria and mycobacteria 
TLR2 Peptidoglycan,  Phospholipomannan, Porins Gram-positive bacteria, Candida 
albicans,  Neisseria 
TLR2/6 diacyl lipopeptides, Zymosan, Lipoteichoic acid Group B Streptococcus, Yeast 
TLR3 polyinosinic–polycytidylic acid (polyI:C), dsDNA viruses 
TLR4 Lipopolysaccharide (LPS), Mannan,  
Glycoinositolphospholipids and others 
Gram-negative bacteria, Candida 
albicans, Trypanosoma 
TLR5 Flagellin Flagellated bacteria 
TLR7 and TLR8 ssRNA, imiquimod, loxoribine, others RNA viruses 
TLR9 Unmethylated CpG-DNA Bacteria 
TLR11 Profilin-like molecules Toxoplasma gondii, uropathogenic 
bacteria,  
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forms the first line of defense against invasive pathogens, the adaptive immune system is 
usually needed for clearing the infection and for prevention of the subsequent infection 
with homologous or related pathogens (Hughes and Galan, 2002). Although the adaptive 
mechanisms are very efficient, they require previous encounter with antigen and therefore 
needs time to develop.  
Humoral mechanisms of adaptive immune system involve mainly production of 
secretory Ig. Vast majority of secretory Ig protecting gut mucosa are polymeric SIgA and 
SIgM produced in the mucosa by resident plasma cells (Brandtzaeg, 2009). There is also 
a small portion of monomeric IgG produced in the mucosa and a small portion of 
monomeric Ig from the systemic circulation, but none of these molecules contain J chain, 
and therefore could not be transported through IEC in the way previously described 
(Brandtzaeg and Prydz, 1984). Microbes in the intestinal lumen are coated with secretory 
Ig. This agglutination leads to efficient neutralization of invading pathogens even before 
they reach the tissue and without starting the inflammatory response. This mechanism is 
called immune exclusion, and it is the key non-inflammatory homeostatic mechanism that 
controls the endogenous microbiota (Brandtzaeg, 2009). Therefore, the production of 
antibodies seems to be the most important mechanism for preventing infection. 
 Cell mediated immunity, on the other hand, is needed for clearing already 
established infections and protects the individual from intracellular pathogens, malignant 
tumors, as well as from excessive inflammatory response to harmless antigens from food 
and commensals. CD8+ cytotoxic T cells (CTLs) provide effective protection by 
destroying cells infected with viruses, malignantly transformed or damaged cells. CD4+ 
Th cells are known to provide help to B cells or CTLs, thereby augmenting the antibody 
production or cytotoxicity, but they also possess CTL-independent anti-viral activities in 
vivo, so they could function as antiviral effector cells (Doherty et al., 1997). 
 All subsets of Th cells are involved in the regulation of inflammatory response, by 
producing a wide spectrum of pro-inflammatory and anti-inflammatory cytokines, thus 
protecting the individual from both infection and excessive inflammation. Apart from 
already established Th1 and Th2 effector T cells, new lineage of CD4+ T-cells with 
distinct cytokine spectrum has been recently described and referred to as Th17. 
(Aggarwal et al., 2003). This new T-cell lineage, characterized by production of pro-
inflammatory cytokine IL-17, has been proposed to play an important role in the tissue 
inflammation and ultimately also in the pathogenesis of autoimmune diseases (Park et al., 
2005). Another functional subset of CD4+ T cells, natural regulatory T cells (Tregs), has 
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been shown to dampen the inflammation in the tissue and induce tolerance to the 
harmless antigens, as discussed later in this chapter. 
1.1.3.3 Common mucosal immune system 
Cells primed against environmental antigens in the inductive sites of mucosae have the 
ability to recirculate throughout the whole body, forming an interconnecting network of 
immune structures, called common mucosal immune system (CMIS). This system 
provides effective immunity to mucosal surfaces and exocrine glands and could even 
extend between two individuals through breast-feeding. It was originally found in rodents 
(McDermott and Bienenstock, 1979), but there is enough evidence that it exists also in 
humans (Czerkinsky et al., 1987). The exposure of the naive precursor cells to 
environmental antigens, and their subsequent migration to remote mucosae or glands, 
leads to dissemination of the adaptive immune response against these antigens throughout 
the body (Goldblum et al., 1975; Mazanec et al., 1993). The existence of this system 
could be exploited in the design of new vaccines protecting the whole organism including 
sites less accessible to vaccination (Mestecky et al., 1978). There is apparent 
compartmentalization within this system. It has been shown that after the intestinal 
priming with viruses, the whole respiratory tract is protected, but while the upper 
respiratory tract is protected mainly by the specific antibody producing plasmocytes, the 
lower respiratory tract is protected by CTLs (Zuercher et al., 2002). This suggests that 
different mechanisms protect different organs after mucosal immunization. Furthermore, 
there is a marked difference in the immune response profiles found in various secretions 
after oral versus rectal antigen administration, so the inductive sites of the CMIS seem to 
be compartmentalized as well (Kantele et al., 1998).  
The mechanisms behind the lymphocyte homing are not completely elucidated, but 
the tissue specific homing receptors and chemotactic signals seem to be of critical 
importance (Brandtzaeg et al., 2001). For trafficking to the gut, the MAdCAM-1 
addressin on the local venules and α4β7 integrin on the cells form the key receptor-
counter-receptor pair, and the chemotactic signals depend on the target cell type. It has 
been shown that thymus-expressed chemokine (TECK, CCL25) could attract CCR9 
expressing cells including IgA-producing cells and CD4+ or CD8+ T cells to the small 
intestine (Kunkel et al., 2000; Bowman et al., 2002). 
Mesenteric lymph nodes (MLNs) are the largest lymph nodes in the body. Similarly 
to the other lymph nodes in the body, MLNs are well designed for the immune response 
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induction. Circulation of the lymphocytes through the MLNs requires either α4β7 
integrin (expressed on the gut-committed cells) or L-selectin (expressed on the naive 
cells), and could therefore act as a crossroads between the mucosal and peripheral 
compartments (Mowat, 2003). This mechanism explains, how orally acquired antigens 
can induce systemic immunity or tolerance (see later). The further fate of the lymphocytes 
depends on the site of their initial priming. Lymphocytes primed in the gut exit the 
mucosa and reside and differentiate further in the MLNs. They loose expression of L-
selectin and start to express both α4β7 integrin and CCR9 which allow them to home 
back to the gut, while T cells primed in the periphery express P-selectin instead, and 
therefore cannot home to the gut (Campbell and Butcher, 2002). 
1.1.3.4 Mucosal vaccination 
Most pathogens invade us through our mucosal surfaces, yet the conventional ways of 
immunization often do not protect this area enough to prevent the pathogen invasion. 
Furthermore, the mucosal vaccination has also other appeals, such as easy and painless 
administration and reduced costs of production, storage and delivery, which makes it 
ideal for mass immunization in case of emergencies. There are few successful mucosal 
vaccines available in humans, such as the orally administered polio vaccine that was used 
to eliminate polio from the Americas, the Western Pacific, and Europe. There are also 
other mucosal vaccines available (at least in some countries), such as the nasal vaccine 
against influenza or oral vaccine against cholera, and many others are being developed 
(Boyaka et al., 2005). 
In order to achieve the systemic response to the mucosal vaccine, it must be delivered 
to the inductive sites of mucosal immune system; e.g. GALT in the intestine, bronchi-
associated lymphoid tissue (BALT) or nasopharynx-associated lymphoid tissue (NALT), 
otherwise it has only minor and localized effect (Boyaka et al., 2005). Unfortunately, the 
antigens administered to mucosa often cause unresponsiveness (mucosal tolerance) 
instead of protective immune response (see later). Moreover, the optimal doses of 
antigens are difficult to establish because of the often low and unpredictable absorption 
from the mucosal surfaces (e.g. intestine), interference with a vast array of other antigens 
or destruction of the antigen by enzymes in the mucosal secretions. To overcome these 
obstacles, they must be co-administered with a) suitable adjuvants that reverse the natural 
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unresponsiveness of the mucosa, and b) delivery systems that protect the administered 
antigen from proteases and mediate its preferential uptake.  
The most potent mucosal adjuvants are enterotoxins (e.g cholera toxin, heat-labile 
toxin of E. coli) that strongly increase the immune response to the antigen, but their use in 
humans is limited due to their toxicity. Therefore, many of these enterotoxins were 
modified to lose their toxicity. The main mechanisms of action of mucosal adjuvants and 
delivery systems are described in Table 1.2.  
  
Table 1.2. Most common mucosal adjuvants and delivery systems and their mode of 
action 
Adjuvants Mode of action Reference 
Cholera toxin, heat-labile 
toxin of E. coli and its 
derivatives 
Triggering TLR, MHC class II and increases the 
gut permeability, increases the antigen uptake 
by M cells. Increases the activity of APCs, CD4+ 
T cells and class switching in B cells.  
(Elson and Ealding, 
1984) 
TLR ligands (LPS and 
immunostimulatory DNA) 
Stimulation of TLR causes cytokine secretion 
favoring mucosal immunity, B cell proliferation 
and Ig synthesis. Their mechanisms of action 
are very complex, often opposite to each other. 
(Johnson et al., 1956; 
Kang and Compans, 
2003) 
Zonula ocludens toxin (ZOT) Increases the epithelium permeability (Marinaro et al., 1999) 
Cytokines and chemokines 
(IL-1, IL-12, GM-CSF, 
RANTES) 
Many functions, depending on the cytokine, 
often influences the APC-T cell interaction and 
B cell function. 
(Staats and Ennis, 
1999; Lillard et al., 
2001; Bradney et al., 
2002) 
Saponins (QS-21) Possibly increases antigen uptake. (Kensil et al., 1991) 
Liposomes Protects the antigen from being lysed, increase 
immunogenicity by the interaction of antigen 
with MHC inside the APC 
(Gregory et al., 1986) 
Biodegradable microspheres Protects the antigen from being lysed and 
possibly increase the antigen uptake by M cells 
(Moldoveanu et al., 
1993) 
Immunostimulating 
complexes 
Protection of the antigen from being lysed and 
immunostimulation  
(Morein, 1990) 
 
Indeed, the protection from the infection by known pathogens is the most obvious 
use of mucosal vaccines. However, since yet unknown microbe/microbial component 
triggers the inflammation in autoimmune disorders such as IBD (see chapter 3), it seems 
intriguing to employ the mucosal vaccination strategies in the prevention or therapy of 
these chronic diseases.  
1.1.3.5  “Oral (Mucosal) tolerance” 
Strong protective immunity is essential to prevent invasion by pathogens, but similar 
responses against dietary antigens or commensal bacteria can lead to chronic 
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inflammatory disease. In order to maintain homeostasis, the mucosal immune system has, 
through evolution, developed immunosuppressive mechanisms that inhibit overreaction 
against innocuous luminal antigens. This is achieved by mechanism called “oral (or 
mucosal) tolerance”, firstly described almost hundred years ago by Wells and Osborne 
(1911), who found that orally administered antigens induce systemic hyporesponsiveness 
to the same antigen. 
 The nature of the antigen greatly influences its ability to induce oral tolerance. 
Oral administration of viable organisms, such as viruses or bacteria, more likely provoke 
protective immunity but the same organism induce tolerance if administered killed or 
inactivated (Rubin et al., 1981). Furthermore, the mice fed by killed bacteria develop 
tolerance to the thymus-dependent K antigen but acquire protective immunity to thymus-
independent O antigen of the same organism (Stokes et al., 1979). Moreover, proteins are 
particularly easy to induce tolerance in native form, but often fail to do so when 
denaturated (Peng et al., 1995).  
In order to induce reliable and clinically usable mucosal tolerance, antigens also 
need special delivery system and mucosal adjuvant, although the nature of adjuvants is 
different from the ones suitable for vaccines. Most promising results are with nontoxic B 
subunit of cholera toxin, which has been shown to attenuate experimental models of 
multiple sclerosis, type 1 diabetes, rheumatoid arthritis when administered together 
(linked or chemically coupled) with myelin basic protein, insulin, collagen II or low dose 
of allergen respectively (Bergerot et al., 1997; Tarkowski et al., 1999; Rask et al., 2000; 
Sun et al., 2000). 
The mechanism how the tolerance is maintained depends also on the dose of the 
antigen. Approximately 10-100x higher doses of antigen are needed to suppress humoral 
immunity than cellular immunity and while high doses of antigen suppress the immune 
response preferentially by deletion or anergy of Th1 and Th2 clones, repeated low dose 
stimulates the active immune suppression by regulatory T cells (Mowat et al., 2005). 
Regulatory T cells are the key effector cells in the mechanisms of oral tolerance under 
physiological conditions. 
There are several types of regulatory T cells, each equipped with the ability to 
dampen the protective immune response, by cell-cell interaction and by production of 
anti-inflammatory cytokines (Table 1.3).  
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Table 1.3 Regulatory T cells in mouse, their markers and their mechanisms of action 
Name Marker Function/mechanisms Reference 
natural 
regulatory 
T cells 
CD4+ CD25+ 
FoxP3+ 
Direct contact, anti-inflammatory 
cytokines, maintenance of peripheral 
self tolerance 
(Thorstenson and 
Khoruts, 2001; 
Fontenot et al., 2003) 
Th3 cells CD4+ TGF-β TGF-β, low amounts of IL-10 and IL-4 (Chen et al., 1994) 
Tr1 cells CD4+ IL-10 IL-10, bystander suppression (Groux et al., 1997) 
NK-T cells αβTCR+, 
NK1.1+ 
Control immune responses via 
cytokines (e.g. IL-4, IFN-γ, IL-10) 
(Godfrey et al., 2000) 
γδ T cells γδ-TCR Protects from infection in the early 
phase (TNF-α) but also downregulate 
the inflammaory response (IL-10) 
(Ke et al., 1997; 
Andrew and Carding, 
2005) 
 
Oral tolerance is mediated by CD4+ T cells even if the pathogenetic mechanism is 
mediated by CD8+ cytotoxic T cells independently of CD4+ T cell help, as shown in the 
animal model of contact hypersensitivity (Garside et al., 1995; Dubois et al., 2003). 
Nevertheless, the CD8+ T cells play an important down-regulatory function during the 
oral tolerance in the gut mucosa, because oral administration of antigen can induce 
systemic, but not gut-localized hyporesponsiveness in CD8-deficient mice (Grdic et al., 
1998). 
 There are three main mechanisms, how regulatory T cells mediate their effect; 
bystander suppression, clonal deletion and clonal anergy. Most important mechanism of 
oral tolerance is bystander suppression, in which T cells specific for one antigen can 
suppress the function of T cells with other specifity, providing that both antigens are 
present at the same time (Miller et al., 1991). This effect does not require cell-cell contact 
and it is partially dependent on TGF-β or IL-10. This mechanism is crucial for keeping 
the homeostasis in the gut, because T cells in the gut mucosa indeed recognize the 
commensal bacteria, but their inflammatory reaction to them is in healthy individuals 
dampened by local regulatory T cells through IL-10 and/or TGF-β-dependent mechanism 
(Khoo et al., 1997). In mechanism of clonal anergy, T cells go through few divisions after 
encounter with the antigen but soon become unresponsive to this antigen, which is 
reversible by IL-2 (Whitacre et al., 1991). Clonal deletion, i.e. apoptosis of antigen 
specific T cell clone, is probably rare mechanism of oral tolerance; nevertheless, it has 
been reported after high oral dose of antigen (Chen et al., 1995).  
 Oral tolerance is a T cell dependent mechanism, but it is the way how and when 
the antigen is presented to T cells that drive the immune response towards immunity or 
tolerance (Mowat, 2003). The APCs involved in oral tolerance are DCs, and to a lesser 
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extent also MHC class II-expressing enterocytes and B cells. Their activity is greatly 
influenced by the local cytokine microenvironment and state of maturation. Interestingly, 
IECs can mediate the oral tolerance through small vesicles carrying MHC class II 
molecules with bound antigenic peptides sampled from the gut lumen, tolerosomes, 
without actually meeting the T cells (Karlsson et al., 2001). Many other APCs, such as 
DCs and B cell, can release similar vesicles that are capable to interact with T cells. 
Whether this interaction results in immunity or tolerance depends on the state of the 
particular APC, as mentioned earlier (Thery et al., 2002). 
 
1.1.4 Development 
1.1.4.1 Prenatal development 
The prenatal development of the gut mucosal immune system is tightly bound to the 
formation of the gut itself. All components of the mucosal immune system are in place by 
200th day of gestation, and although it needs postnatal activation by antigens to became 
fully mature, it is capable to mount the immune response (Gleeson and Cripps, 2004).  
First true component of the mucosal immune system to appear during the human 
development is SC, that could be detected as early as 40th day of gestation, but it is not 
until one week post partum when it reaches the adult level of production and distribution 
(Rognum et al., 1992). Also J chain could be detected at 40th days post partum in liver, 
and since 110 day of gestation it could be found in small intestine (Moro et al., 1991). 
The maturation of the B cells starting around 100th day of gestation, when IgM/IgD/CD5-
positive cells appear. At the same time, first T cells are observed in the human gut starting 
to organize themselves around B cells (Spencer et al., 1986). Around 120th day of 
gestation, gut B cells start to produce first IgA. First B cell follicles are apparent two 
weeks later, together with formed T cell zones, dome regions, high endothelium venules 
and FAE (Gleeson and Cripps, 2004). However, germinal centre formation is not seen in 
Peyer’s patches of the fetus and only develops after antigenic exposure at birth (Bridges 
et al., 1959). At the end of the gestation, T cells are appearing within the epithelial layer, 
but at this stage, they bear predominantly γδ TCRs (Spencer et al., 1989). 
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1.1.4.2 Postnatal development 
The newborn’s mucosal immune system can successfully mount immune response, but its 
effectiveness is not in par with the adult one. Nevertheless, regardless the gestational age 
at birth, it became fully mature within the 12 month of postnatal development. The rapid 
maturation of mucosal immune system is essential for protection against infection and 
allergen exposure in the postnatal life. This maturation is driven mainly by two essential 
factors 1) antigen stimulation of the mucosal immune system (colonization with 
microbiota and oral feeding) and 2) breast-feeding (see Table 1.4.) 
 
Table 1.4 Prenatal and postnatal factors influencing the development of the mucosal 
immune system in infancy  
Prenatal factors 
Genetic factors, particularly cytokine gene polymorphisms 
Maternal nutritional status 
Intrauterine infections 
Toxic chemical exposure (alcohol, products of smoking cigarettes and illicit drugs) 
Perinatal factors 
Hormonal influences at birth 
Infant feeding practices, particularly non-breast fed infants 
Timing of mucosal membrane closure (exclusion of antigenic stimulation) 
Bacterial colonization, particularly gut flora in response to feeding practices 
Up-regulation of regulatory T cell’s cytokines in response to antigenic stimuli 
Postnatal factors 
Composition of microbiota 
Level of protective antibodies in maternal serum and breast-milk 
Immunization 
Exposure to new infections (family members, particularly older siblings; day-care or child-
minding centers; hospitalization; commencing school) 
Exposure to cigarette smoke 
Inherited or induction of IgA-deficiency states 
Diet and nutritional status of infant, (adequate protein, essential vitamins and minerals) 
Exposure to physiological and psychological stressors 
Adopted from Gleeson and Cripps (2004) 
 
At birth, the B cells are found only in follicles and not in LP, and humans are born 
virtually IgA-deficient (Perkkio and Savilahti, 1980). Moreover, during the first two days 
of life, the mucosal epithelial barrier is not sealed, allowing the high amount of intact 
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macromolecules to reach systemic circulation (Bines and Walker, 1991). Speeded up by 
the maturation factors in the colostrum, the intestinal barrier closes, thus preventing 
overwhelming infection or inappropriate sensitization. During this critical period, the 
newborn can easily absorb any of the other important macromolecules from colostrum, 
which could positively influence the development of distant organ systems, such as 
central nervous system (Kverka et al., 2007). Furthermore, oral feeding per se provides 
important stimulus for mucosal immune development by influencing the gut microbiota 
composition and providing antigenic stimulation needed for fast population of LP with 
plasmocytes (Knox, 1986). 
 The IELs gradually expands until they reach the adult levels by 2 years of life, 
with preferential increase in αβ T cells over γδ T cells, ultimately leading to dominance 
of these T cells in IEL compartment (Cerf-Bensussan and Guy-Grand, 1991). Lack of the 
antigen is keeping the antigen-presenting cells in gut mucosa quiescent. Antigenic 
stimulation after birth drives the T cells to produce pro-inflammatory cytokines (most 
notably IFN-γ and IL-2) that stimulate the APCs to upregulate the MHC class II 
molecules (HLA-DR). This is probably the key element determining the immunologically 
reactive epitopes and cause of the above mentioned oligoclonality (Rognum et al., 1992; 
Lionetti et al., 1993; Gleeson and Cripps, 2004). In response to the bacterial colonization, 
the LP is started to be populated with IgM expressing plasmatic cells, shortly followed by 
IgA expressing plasmocytes, and since approximately 1 month after birth the latter starts 
to dominate (Perkkio and Savilahti, 1980). 
 
1.2 HOST-MICROBE INTERACTIONS IN THE GUT 
In all animals, microbiota forms a complex and open ecosystem, comprises of both 
resident and transiently present microbes. This ecosystem is formed by 1014 of microbes 
belonging to approximately 500 species of Eubacteria kingdom and similar number of 
species derived from Archibacteria and Fungi (Kuhbacher et al., 2006; Scupham et al., 
2006). Other classes of microbes in this ecosystem, such as the viruses or protists have 
not been systematically studied so far. Vast majority (>99%) of these microbes is present 
in the gastrointestinal system.  
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1.2.1 Gut microbial community 
The numbers and species distribution in various parts of the gastrointestinal tract differs, 
as shown on the Figure 1.3., depending on the prevailing specific conditions (Savage, 
2005).  
There is a consistent crosstalk between the microbiota and the host and among 
microbes themselves. Some bacteria can induce host gene expression to create more 
suitable environment for themselves. For example, when reaching critical density, 
common gut commensal B. thetaiotaomicron can enhances the synthesis of fucosylated 
glucoconjugates in the gut epithelium, which can than utilize as a source of energy (Bry et 
al., 1996). This strategy improves its chances to gather enough nutrition improving its 
chances to survive in the competitive ecosystem. 
 
Figure 1.3 Specification of bacterial communities in various parts of the alimentary 
canal and specific local conditions that shapes them. 
 
Adopted from Acheson and Nataro (2006) 
  
The microbiota composition is not entirely stable throughout the life. There are 
two key time periods shaping the gut microbiota composition: 1) birth and 2) weaning. 
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Fetal gut is sterile until it is colonized by microbiota at birth. The colonization with 
microbiota continues during first few years of life and after this period, the individual’s 
resident microbiota composition became relatively stable. The exact composition of the 
gut microbiota is shaped by the unique conditions found in the gut, but it also reflects the 
individual’s environment, especially during the first months of life. It is strongly 
influenced by the individual genotype, mode of delivery, diet composition, ingestion of 
pathogenic and non-pathogenic microbes, hygiene levels and medication (Zoetendal et 
al., 2001; Mountzouris et al., 2002; Fanaro et al., 2003). 
 Few days after birth, the infant gut is colonized by enterobacteriacae and 
bifidobacteria, but they are soon influenced by feeding habits. Breast-fed infants develop 
microbiota rich in bifidobacteria and poor on clostridia and bacteroides, formula fed 
babies develop microbiota poor on bifidobacteria with wider range of anaerobes (Fanaro 
et al., 2003). After weaning, the microbiota became quite stable in each individual, with 
predominance of Firmicutes and Bacteroidetes species (Savage, 2005). It seems that the 
observed stability is on the species level, but not on the strain level, which could fluctuate 
unpredictably (McCartney et al., 1996). To some extent, the microbiota composition also 
vary with age, with decreased Bifidobacterium and increased Bacteroides species 
diversity (Hopkins et al., 2002). 
 
1.2.2 The role of gut microbiota in human physiology  
Gut microbiota has several functions important for human health. Gut microbiota 
contribute to the host energy recovery from the diet, which could represent 18% of total 
energy intake in rodents and much more in ruminants (Wostmann et al., 1983). The 
effectiveness of the energy recovery seems to be dependent on the microbiota 
composition, which could give important advantage to some individuals during the 
outbreaks of famine but it might be the cause of the obesity in some individuals 
(Turnbaugh et al., 2009). 
This symbiosis between host and its microbiota goes all the way to the genome level. 
In a metagenomic study, Gill et al (2006) compared metabolic repertoire of gut 
microbiota with those of humans finding, that resident bacteria genome is significantly 
enriched for metabolism of amminoacids, glycans, xenobiotics and biosynthesis of 
vitamins and isoprenoids, while human genome is enriched for transport and metabolism 
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of inorganic ions and secondary metabolites. This reveal that the resident microbiota has 
evolved (or is regulated) to complement metabolic functions of the human gut. 
Studies on gnotobiotic (germ-free; GF) animals clearly showed that microbial 
colonization has profound influence on the immune system development (Tlaskalova et 
al., 1970). Therefore, the variation in microbiota composition could be the reason for the 
well documented variation in immune responses (O'Hara and Shanahan, 2006). 
Colonization with bacteria increases the production of Ig in general and of specific 
antibodies, substantially changing the gut lymphocyte populations, thus improving the 
host’s ability to fight pathogens (Weinstein and Cebra, 1991; Cebra, 1999). Some of these 
changes could be imitated by bacterial components in the food (Tlaskalova-Hogenova et 
al., 1983; Hrncir et al., 2008) 
Even simple presence of the massive amount of bacteria in the gut greatly increases 
the host’s resistance against pathogens (Zachar and Savage, 1979). This “colonization 
resistance” is executed by several mechanisms. Commensal bacteria compete with 
pathogens for limited resources and adhesion sites and interfere with pathogen‘s 
multiplication by decreasing the local pH via the production of organic acids and the 
production of specific antibacterial substances as recently reviewed by Stecher and Hardt 
(2008). 
 
1.2.3 Probiotics 
 Food and Agriculture Organization of the United Nations and World Health 
Organization defined probiotics in the 2001 report as "live microorganisms which when 
administered in adequate amounts confer a health benefit on the host."(FAO/WHO, 
2001). 
There are three main mechanisms, how probiotics contribute to human health and 
single probiotic bacterium could possess more than one. First, probiotics may exclude or 
inhibit the growth of certain pathogens, as mentioned earlier. Second, they may improve 
the barrier function, and third, they can modulate mucosal and/or systemic immune 
response (Lebeer et al., 2010). 
 Anti-microbial properties of probiotics are probably the best known mechanism. 
Probiotics, and some gut commensals as well, can produce H2O2, organic acids, 
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biosurfactants and antimicrobial molecules that are capable, more or less selectively, kill 
other bacteria as reviewed elsewhere (Servin, 2004).  
Certain probiotic bacteria may stabilize gut barrier function by increasing the 
production of antimicrobial peptide β-defensin 2 in the host’s IECs (Wehkamp et al., 
2004; Schlee et al., 2008). This mechanism could be triggered by PRR-ligands, such as 
flagellin, through NF-κB- and AP-1-dependent pathways (Schlee et al., 2007). Moreover, 
while Lactobacillus strain that is known to adhere to the IECs can induce mucin 
production in virto in these cells, another Lactobacillus strain that does not adhere cannot 
(Mack et al., 2003). Furthermore, L. rhamnosus GG produce two soluble proteins that 
inhibit cytokine-induced apoptosis in IECs in vitro, which could strengthen the intestinal 
barrier function even during ongoing inflammation (Yan et al., 2007). 
Probiotics have been shown to promote both pro-inflammatory (IL-12) and anti-
inflammatory (IL-10) mechanisms in human PBMC or monocytes in vitro. Their ability 
to induce either one is, however, strain dependent and may be still present in heat killed 
bacteria (Hessle et al., 1999). Furthermore, L. reuteri and L. casei, but not L. plantarum, 
are able to prime DCs to drive the development of Tregs by binding to their surface C-type 
lectin DC-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) 
(Smits et al., 2005). Hence, the clinical utility of probiotics depends greatly on the actual 
health status of the macroorganism and on whether we want to improve its resistance to 
pathogens or dampen the pathological inflammation.  
 The therapeutic potential of probiotics, suggested by in vitro and in vivo studies,  
is very broad, but at this time, the clinical indications based on clinical studies are much 
narrower (Goldin and Gorbach, 2008). On one hand, probiotics have been successfully 
used to treat several human diseases, including antibiotic-associated diarrhea, traveler’s 
diarrhea or ulcerative colitis (Oksanen et al., 1990; Arvola et al., 1999; Kruis et al., 2004), 
but in critically ill patients, live probiotic bacteria may be dangerous (Besselink et al., 
2008). 
 
1.3 ANIMAL MODELS OF IBD 
The two main forms of inflammatory bowel disease (IBD), Crohn’s disease (CD) and 
Ulcerative colitis (UC), are both complex chronic inflammatory diseases, each associated 
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with a typical phenotype. The description and pathogenesis of IBD is in details reviewed 
in chapter 3.  
 These mechanisms of IBD pathogenesis were, from large part, elucidated using 
rodent models of IBD. Although there are significant differences among species, as 
mentioned above, these animal models of human diseases are still crucial for 
understanding the diseases and for therapy development. There are several dozens of IBD 
models, but most of them are based on one of two crucial steps in the IBD pathogenesis a) 
intestinal barrier disruption or b) impaired regulation of immune system. From the 
different point of view most of these models could be roughly classified as chemically 
induced animal models, models in genetically modified animals, spontaneous models, and 
adoptive transfer models (see Table 1.5).  
Table 1.5 Summary of the most commonly used rodent models of IBD 
Further details and less common models were reviewed by Jurjus et al (2004) 
Model Description Reference 
DSS-induced 
colitis 
Mixed Th1/2-type of colitis caused by intestinal 
barrier disruption. 
(Okayasu et al., 
1990) 
TNBS-induced 
colitis 
Th1-type of the colitis caused by destruction of 
the mucosal barrier by ethanol followed by 
hapten-induced delayed-type hypersensitivity. 
(Morris et al., 1989) Chemically 
induced 
models 
Oxazolone-
induced colitis 
Atypic Th2-type of the colitis caused by 
destruction of the mucosal barrier by ethanol 
followed by hapten-induced delayed-type 
hypersensitivity. 
(Boirivant et al., 
1998) 
IL-10 KO 
Intestinal inflammation (affecting small 
intestine and ascending colon) due to the 
impaired immunoregulation caused by the loss 
of IL-10 regulatory function. 
(Kuhn et al., 1993) 
Interleukin-2 
KO/IL-2 receptor 
(R)α KO mice 
Colitis affecting distal colon caused by 
Impaired immunoregulation due to the 
defective apoptosis of activated lymphocytes 
in the gut. 
(Sadlack et al., 
1993) 
TCR mutant mice Th2-type colitis due to the defect in antigen presentation. 
(Mombaerts et al., 
1993) 
Genetically 
modified 
animals (gene 
knockout or 
transgenic) 
HLA B27 
transgenic rats 
Rats transgenic for human HLA-B27 develop 
chronic inflammation ranging from the stomach 
to colon. 
(Hammer et al., 
1990) 
C3H/HejBir mice 
Mice occasionally develop transient Th1 type 
of colitis caused by impaired regulation of 
microbiota sensing by Th cells. 
(Cong et al., 1998) 
Spontaneous 
colitis models 
SAMP1/Yit mice 
Spontaneously develop chronic Th1-type 
terminal ileitis and some even develop perianal 
fistulae similarily as in Crohn’s disease.  
(Rivera-Nieves et 
al., 2003) 
Adoptive 
transfer 
models 
CD4+CD45RBhi/
CD62L+ to SCID 
mice 
Th1-type of transmural colitis caused by the 
impaired immunoregulation caused by the shift 
in Effector T cell/regulatory T cell balance. 
(Morrissey et al., 
1993; Powrie et al., 
1993; Mudter et al., 
2002) 
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The presence and quality of the intestinal microbiota often plays a crucial role, 
because the intestinal inflammation is often less severe or even fails to develop in the GF 
conditions (Sadlack et al., 1993; Dianda et al., 1997; Hudcovic et al., 2001). Furthermore, 
colonization with specific bacterial species or limited microbiota may not make mice 
more susceptible to disease compared to the GF conditions, therefore the presence of 
specific bacteria and not bacteria per se, is needed for the disease to develop (Sadlack et 
al., 1993; Rath et al., 1996; Dianda et al., 1997; Hudcovic et al., 2007; Stepankova et al., 
2007). These studies show an important fact, that intestinal inflammation does not 
develop spontaneously and that the presence of the microbiota is often an integral part of 
the animal model explaining the problems to reproduce some animal models in different 
laboratories. In order to perform the experiments described in this thesis, we used the 
dextran-sulfate sodium (DSS)-induced model of intestinal inflammation. Since it was first 
described by Okayasu et al. (1990), the DSS colitis became one of the most commonly 
used animal models due to its simplicity, high reproducibility and fast induction of the 
inflammation. It has been successfully used in rats, hamsters, guinea pigs and many 
strains of mice. The clinical features of this model include weight loss, loose 
stools/diarrhea, and rectal bleeding. The histological evaluation of the colon shows severe 
ulceration, significant granulocyte and mononuclear infiltrate ranging from lamina 
propria to submucosa, tissue edema, and in chronic phase even dysplasia. These features 
resemble the ulcerative colitis. 
 The inflammation is induced by replacing the drinking water with 3% DSS 
solution of approx. 40-50kD DSS. Interestingly, almost every laboratory use own 
“titrated” concentration, usually ranging from 2-5%, which achieve best results. This 
further stress the importance of the gut microbiota composition in the animal models 
mentioned above. This model also could be use to mimic the chronic ulcerative colitis, if 
the DSS is administered in several 5-7 day long cycles followed by cycles of tap water 
(Okayasu et al., 1990). If it is not severe, most mice have a tendency to recover from the 
acute DSS-induced colitis within several weeks, but it has been reported that in C57BL/6 
mice the inflammation became chronic after one cycle of DSS (Melgar et al., 2005).  
 Acute DSS colitis starts with epithelial cell barrier dysfunction which causes the 
antigens from the gut lumen to enter the lamina propria and stimulate the immune 
response. The dysfunction of the epithelial barrier starts as early as 1st day after DSS 
treatment by gradual decrease in tight junction protein - ZO-1 - production, which results 
in increase of colon permeability (Poritz et al., 2007). Furthermore, Vetsuchi et al. (2002) 
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reported that there is a significant increase in epithelial cell apoptosis in DSS treated rats, 
and that this apoptosis is soon followed by dramatically increased proliferation, 
suggesting that a) injury to the epithelial cell destruction leads to the barrier dysfunction 
and b) that abnormal and persistent epithelial hyperproliferation could lead to the 
development of colorectal cancers. The finding, that long-term DSS administration could 
produces colorectal carcinoma in mice or hamsters has been also reported earlier. 
(Yamada et al., 1992; Cooper et al., 1993) 
 As a consequence of the enhanced epithelial barrier permeability and immune cell 
infiltration, epithelial and immune cells produce pro-inflammatory cytokines. There is a 
significant increase in mucosal expression of TNF-α, IL-1β, IFN-γ, IL-10 and IL-12, as 
early as the 1st day of DSS treatment (Yan et al., 2009). 
 It had been proposed that acute DSS colitis is driven mainly by innate immunity, 
because it also occurred in the absence of functional T, B and NK cells (Dieleman et al., 
1994; Axelsson et al., 1996). During the chronic phase, lymphocytes and macrophages 
attracted to the site of inflammation secrete high levels of both interferon (IFN)-γ and IL-
4, which suggests that activation of both Th1 and Th2 play a pathogenic role in chronic 
DSS-induced colitis (Dieleman et al., 1998). 
 
1.4 DOWNREGULATING THE INFLAMMATORY RESPONSE 
Besides the immunomodulation performed by regulatory and antigen-presenting cells, as 
described above, the inflammation could be also downregulated directly or indirectly by 
glucocorticoids (GCs). GCs are steroid hormones that are able to modulate various 
functions of the immune system. Both natural and synthetic GCs have the capacity to 
dampen the inflammation and these compounds are therefore, used as anti-inflammatory 
agents in many immune-mediated diseases since 1940s (Hench et al., 1949). In order to 
transmit their message, steroids need to bind to an intracellular receptor, which in 
response dissociate from the anchoring multiprotein complex and translocate to the 
nucleus. Here it binds to specific DNA sequences of the target genes, called 
glucocorticoid response element, and regulates gene transcription (Pratt, 1993). In 
addition to these mechanisms, GCs can interact with cell membrane-associated proteins 
(e.g. ion channels) through physiochemical or (possibly) receptor-mediated interaction, 
although the membrane GC receptor has not been found in normal human cells so far 
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(Buttgereit et al., 1998). These interactions may cause the changes in intracellular 
signaling pathways tuning and cytoskeleton reorganization, resulting in the impairment of 
cell adhesion and locomotion. The effectiveness of these mechanisms depends on 
intracellular concentration of GCs, which is determined by their extracellular 
concentration and their local metabolism. 
 
1.4.1 Prereceptor regulation of glucocorticoid function 
The local metabolism of GCs is controlled by the intracellular enzyme 11β-
hydroxysteroid dehydrogenase (11HSD), which has two isoforms with different 
characteristics– 11HSD1 and 11HSD2 (Table 1.6) (Draper and Stewart, 2005). 
 
Table 1.6 Direct comparison between the characteristics of human 11HSD1 and 
11HSD2 isozymes 
 11HSD1 11HSD2 
Chromosomal location 1q32·2 16q22 
Size of the gene 30 kb, 6 exons 6·2 kb, 5 exons 
Size of the protein 292 aa, 34 kDa 405 aa, 44 kDa 
Main tissue expression Liver, lung, gonads, brain, adipose tissue Kidney, colon, salivary glands, 
placenta 
Enzyme kinetics  Bidirectional (in vitro), mainly reductase 
(in vivo) 
Only dehydrogenase 
Cofactor NADP(H) NAD 
Main function Supplies cortisol to glucocorticoid 
receptor 
Protects mineralocorticoid receptor 
from cortisol 
Adopted from (Draper and Stewart, 2005) 
 
The 11HSD2 isoform is a unidirectional, NAD-dependant dehydrogenase, converting the 
biologically active cortisol (in humans) and corticosterone (in rodents) into their inactive 
11-oxo derivatives, cortisone and 11-dehydrocorticosterone respectively. Since cortisol 
and corticosterone, have similar affinity to mineralocorticoid receptor as natural 
mineralocorticoid aldosterone, and the circulating levels of GCs are several orders of 
magnitude higher than those of aldosterone, the ability of 11HSD2 to inactivate 
glucocorticoids in some tissues is therefore vital for the individual’s homeostasis (Arriza 
et al., 1988).  
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 11HSD1 is a low affinity NADP(H)-dependent bi-directional enzyme, capable of 
carrying out both 11-oxo-reductase and dehydrogenase reactions, interconverting inactive 
cortisone and active cortisol. In vivo, it predominantly catalyzes the conversion of inactive 
GCs to their active counterparts (Draper and Stewart, 2005).  
 While increasing the dosage of GCs could improve their immunosuppressive 
function it also brings along severe side effects. Our understanding of the pre receptor 
control of their function could not only increase our knowledge on natural anti-
inflammatory mechanisms, but it could also lead to more effective and less toxic anti-
inflammatory therapy. 
 
1.4.2 Regulation of the immune function with glucocorticoids 
GCs are major immunomodulatory agents with profound influence on the function of the 
immune system. They positively (e.g. TLR-2 and TLR-4) or negatively (e.g. IL-1 and 
CD40) regulate 21% of the genes expressed in human leukocytes (Galon et al., 2002). As 
immunosuppressive agents, GCs interfere with the inflammatory process on several 
levels. First, they influence the leukocyte development, second, they inhibit the access of 
leukocytes to inflammatory sites, and third, they interfere with the functions of 
leukocytes, endothelial cells, and fibroblasts at the site of inflammation (Ashwell et al., 
2000; Webster et al., 2002).  
Most of the immunosuppressive functions of GCs are mediated by repression of 
NF-κB, which is a key pro-inflammatory and pro-immune transcription factor, involved 
in the regulation of cytokines and other immune responses (McKay and Cidlowski, 1999).  
The mechanisms, how this inhibition is executed are not completely elucidated. It has 
been shown that GCs induce expression of inhibitory protein IκB that prevents 
translocation of NF-κB to the nucleus and that there is a direct cross-talk between GC 
receptor and NF-κB that prevents gene expression (Mukaida et al., 1994; Ray and 
Prefontaine, 1994; Scheinman et al., 1995). Another anti-inflammatory and 
immunosuppressive mechanism of GC action involves interaction of GC receptor with 
transcription factor activator protein-1 (AP-1) altering its interactions with DNA and 
expression of pro-inflammatory factors (Jonat et al., 1990; Adcock et al., 1994).  
 GCs mediate their anti-inflammatory response by modulating the transcription of 
many pro-inflammatory cytokines, e.g. IL-1, IL-6, IFN-γ and TNF-α (Kunicka et al., 
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1993; Steer et al., 2000). This effect could be either direct, by interfering with the 
cytokine mRNA or indirect, mediated by other cytokines or transcription factors. It has 
been shown that GCs can decrease the production of  IL-6 via NF-κB-dependent 
downregulation of TNF-α, because the TNF-α itself potentiate the production of IL-6 
(Lee et al., 1988; Steer et al., 2000; Vanden Berghe et al., 2000).  
 GCs reduce the trafficking of leukocytes to the areas of inflammation by 
interfering with the expression of protein molecules involved in both attraction and 
adhesion of leucocytes to the vessels in that areas. Indeed, GCs have been shown to 
inhibit the inflammation-induced expression of several adhesion molecules on the 
endothelium, including intracellular adhesion molecule 1 (ICAM-1), endothelial-
leukocyte adhesion molecule 1 (ELAM-1), which prevents the recruitment of leucocytes 
at inflammatory loci (Cronstein et al., 1992). Moreover, GCs inhibits the chemotaxis to 
the inflamed loci by interfering with the chemokine production (e.g. IL-8, MCP-1) by the 
resident cells (Miyamasu et al., 1998). 
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2. SIGNIFICANCE, AIMS AND OUTLINE OF THE THESIS 
2.1 SIGNIFICANCE OF THE STUDY 
 The human body is surrounded by enormous amounts of microbes. Most of them 
are carried in the gut, where the mucosal surface is exposed to both potential pathogens 
and beneficial commensal microorganisms. On one hand, the strong immune response 
against the microbes was one of the main forces that drove human evolution in the past. 
On the other hand, it is remarkable, how healthy humans are able to control this immune 
system and tolerate huge and often unpredictable load of antigens in the gut. The peaceful 
coexistence of the host and gut microbiota has evolved for millennia and its importance 
for the human physiology is well acknowledged. However, the mechanisms, how our 
immune system is keeping the balance are not well understood. When this carefully 
balanced interaction between host immune system and gut microbiota is broken, severe 
inflammatory disease could emerge. Better understanding of these interactions is not only 
important for the understanding of the pathogenetic mechanisms of those diseases, but it 
could also give us the tools needed for the development of new strategies for their 
prevention and therapy. 
 
2.2 AIMS AND OUTLINE OF THE THESIS 
This thesis has two main aims, to promote the better understanding of the host-microbe 
interactions during the state of inflammation and to set up the basis for the development 
of new therapeutic strategies based on this understanding. To achieve these aims, we have 
addressed several particular questions outlined in this thesis. Our hypothesis is that if live 
bacteria play a role in the gut homeostasis, could we achieve similar effect with their 
components? And if so, which mechanisms of mucosal immune response are responsible 
for this effect? 
Chapter 1 is review of current knowledge on mucosal immune system and related 
topics. In chapter 3, we review the pathogenetic mechanisms of IBD and how to 
influence the natural course of the disease by probiotics and bacterial components. In 
chapter 4, we discuss how the changes in microenvironment could change some 
important mediators of physiological and immune functions. In particular, what is the role 
of local metabolism of glucocorticoid and how might the pre-receptor regulation of 
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endogenous corticosteroids play a role in inflammatory processes. In chapter 5, we 
address the question if the preventive administration of live probiotic bacteria could 
decrease the severity of acute experimental colitis. This is further discussed in the 
chapter 6, where the hot question on whether the probiotic baceteria needs to be alive or 
not in order to have beneficial properties is discussed. While the use of well established 
probiotics seems to be an obvious choice, another question arises. While the effect of 
probiotics is strain specific, why most healthy individuals lack it. Is it simple lack of 
knowledge or could these properties be achieved by some common commensal? This 
question, and underlined mechanisms, are addressed in chapter 7, where we showed that 
oral treatment of mice with lysate of one particular commensal, Parabacteroides 
distasonis, could have similar beneficial effect. In chapter 8 a general discussion is 
presented on the impact of these novel findings by us and others on bacterial components 
as therapeutic agents. 
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3.1 SUMMARY 
Crohn's disease (CD) and ulcerative Colitis (UC), the two major forms of inflammatory 
bowel disease (IBD), are both severe chronic inflammatory disorders. Although the exact 
etiology and pathogenesis of both forms of IBD have yet to be completely understood, it 
is widely accepted that they result from a continuous microbial antigenic stimulation of 
pathogenic immune response in genetically predisposed individuals. Genome-wide 
association studies identified several defects in genes responsible for mucosal barrier 
function, bacterial sensing and killing and for the regulation of the inflammatory 
response. The changes in microbiota composition or abilities (epithelial adhesion and 
invasion) are supposed to be the trigger of the inflammation. These findings are further 
supported by conclusions of studies in both humans and experimental animals.  Those 
studies showed that impaired host reaction to commensal microbiota, or their abundant 
presence in the subepithelial layer, leads to the pathological stimulation of the mucosal 
immune system. 
 Several clinical studies as well as some interventional studies on animal models 
demonstrated that antibiotics, probiotics and bacterial components are useful in 
maintaining disease remission and in disease prevention. This effect is partially due to the 
changes in microbiota composition and partially due to imunomodulation.  
During many years of co-evolution with humans, the microbiota, indigenous as well as 
pathogenic, have acquired immunomodulatory mechanisms to bypass our mechanisms of 
protective immunity. Our aim is to isolate the immunomodulatory components from 
bacteria and use them in IBD therapy and prevention. Compared to use of live bacteria, 
this approach seems to be safer and easily applicable in practice. The differences in 
immunomodulatory properties of these components also suggest the need of 
individualized therapy. This review will focus on IBD pathogenesis and the possibility of 
influencing it by therapy with bacterial components.  
 
3.2 INTRODUCTION 
The two major forms of inflammatory bowel disease (IBD), Crohn’s disease and 
ulcerative colitis, are both severe relapsing inflammatory diseases of the intestine, each 
associated with a typical phenotype. Ulcerative colitis is characterized by diffuse 
continuous mucosal inflammation that extends proximally from the rectum to a varying 
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degree. Although it is located only in the large intestine, in some patients, the terminal 
ileum is also affected (so-called backwash ileitis). Patients typically suffer from bloody 
diarrhea, abdominal pain, rectal bleeding and malnutrition. Crohn’s disease is 
characterized by segmental and transmural inflammation, fistulas and granulomas in any 
part of the gastrointestinal tract, most commonly in terminal ileum. Crohn’s disease leads 
to strictures, abscesses and fistulas and the clinical manifestation depends mainly on the 
disease localization. The IBD usually starts to manifest in the second and third decades of 
life and the majority of affected individuals progress to chronic relapsing disease 
(Baumgart and Sandborn, 2007).  
 The IBD is a systemic disorder and in almost half of the patients other organs are 
affected by the disease as the extraintestinal disease manifestation or disease (therapy) 
complications. These manifestations and complications typically affect the 
musculosceletal system (peripheral arthritis, ankylosing spondylitis and osteoporosis), 
skin (erythema nodosum, pyoderma gangrenosum and fistulas), eye (iritis and uveitis) 
and biliary system (primary sclerotising cholangiopathy and gall stones) (Rothfuss et al., 
2006).  
 The highest prevalence of IBD is traditionally in North America, northern Europe 
and the United Kingdom, with averages ranging from 100 to 300 cases per 100 000 (Ehlin 
et al., 2003; Loftus, 2004). Recent epidemiological studies suggest that the increase in 
disease incidence has probably reached its plateau in these countries, however, there is a 
strong increase in IBD incidence in regions with traditionally low IBD prevalence (e.g. 
Asia and Latin America) (Linares de la Cal et al., 1999; Lee et al., 2000; Yang et al., 
2000; Yang et al., 2008). 
 Although the etiopathogenesis of the IBD remains obscure, IBD is thought to be a 
result of uncontrolled inflammatory response to indigenous intestinal microbiota in 
genetically predisposed individuals. The genetic predisposition is associated with genes 
related to host bacteria interaction, suggesting the crucial importance of intestinal 
microbiota in IBD pathogenesis. General intestinal dysbiosis, presence of some 
pathogenic bacteria or even enhanced virulence of certain commensal bacteria were all 
proposed to be the trigger of the IBD (Chiodini, 1989; Darfeuille-Michaud et al., 1998; 
Swidsinski et al., 2002; Seksik et al., 2003; Frank et al., 2007; Rabizadeh et al., 2007). 
The importance of intestinal microecology is further supported by the finding that 
manipulating intestinal microbiota using probiotics and antibiotics is effective in IBD 
therapy (Guslandi et al., 2000; Kruis et al., 2004; Rahimi et al., 2007). 
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 Some strains of probiotic bacteria also possess immunomodulatory properties, so 
their effect in IBD therapy could be mediated by modulation of the mucosal immune 
system or intestinal barrier function, rather than by intestinal ecology changes (Damaskos 
and Kolios, 2008). Therefore, we could use bacterial lysates or isolated bacterial 
components to mimic the therapeutic effect that probiotics have. Use of sterile bacterial 
components with immunomodulatory properties seems to be a safer and more practical 
approach than the use of live bacteria. 
 
3.3 IBD PATHOGENESIS 
The luminal antigens can initiate the pathogenetic inflammatory cascade in the gut only 
after four conditions are met. First, the host’s mucosal immune system must be 
genetically susceptible to recognize the antigens from indigenous microbiota and 
misinterpret them as potentially harmful. Second, the antigen must reach the 
gastrointestinal tract. Third, the antigen must pass through the intestinal barrier to reach 
the immunocompetent cells in the mucosa. And finally, the regulatory mechanisms of 
mucosal immune system must fail to control the inflammation. 
 
3.3.1 Genetics of IBD 
Family aggregation of IBD is a well known phenomenon; the life-time risk of developing 
IBD for first-degree relatives of a CD proband is 5 % and that of an UC proband 1.6% in 
white non-Jewish Euro-American population (8 % and 5.2% for Jews). The concordance 
in monozygotic twins is 28% and 16% for CD and UC respectively, and 4% for dizygotic 
twins for each (Halfvarson et al., 2003; Halme et al., 2006). On one hand, these data 
clearly indicate that genetic factors definitely contribute to IBD, but also that the 
environmental and developmental factors are more important in disease pathogenesis. 
Genome-wide association studies for IBD susceptibility genes performed in the 
last few years have reported many genes that contribute to disease susceptibility. 
Interestingly, most of these newly identified genes are related to the epithelial barrier 
permeability, bacteria sensing and killing, and regulation of the immune system (Duerr et 
al., 2006; Rioux et al., 2007). All these findings fit well into the current concept of IBD 
pathogenesis and stress the importance of host-microbiota interaction. 
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3.3.2 Microbiota in IBD  
Humans are colonized by huge number of microbes; microbial cells form 90% (1014) of 
all cells in adult humans (Savage, 1977). This colonization starts during the birth and 
continue during the first few years of life. After this period, the composition of the 
individual microbiota seems to be relatively stable. Although there are some 
representatives from archaea and eukarya, as well as viruses and bacteriophages, most 
members of gut microorganisms belong to the domain bacteria (Breitbart et al., 2003; 
Eckburg et al., 2003; Curtis and Sloan, 2004). Over 98% of all gut bacteria in mammals 
belong to the two divisions of Bacteria - Firmicutes and Bacteroidetes (Eckburg et al., 
2005). Although this uniformity probably reflects the specific conditions in the gut, the 
differences on a species level is striking, as it resembles an individual fingerprint. The 
diversity of individual microbiota is caused by many variables such as dietary habits, use 
of pharmaceuticals, health status and by microbial exposure of both mother and child 
during the child’s perinatal and infant period. Introduction of probiotic bacteria during 
this period could result in long term colonisation and could have impact on health later in 
adult life (Kalliomaki et al., 2001; Lodinova-Zadnikova et al., 2003). 
Although the microbiota composition has a distinctive pattern in every individual, 
under physiological conditions it serves important biological functions for all hosts. The 
microbiota prevent colonization with pathogens, providing important nutrients (vitamins 
and short-chain fatty acids), and modulate intestinal barrier maturation and development 
of the immune system (Chapman, 2001; Hooper et al., 2002; Tlaskalova-Hogenova et al., 
2004). Luminal microbiota also positively influence the development and preservation of 
oral tolerance in a strain-dependent manner (Gaboriau-Routhiau and Moreau, 1996; 
Moreau and Gaboriau-Routhiau, 1996; Prioult et al., 2003).  
The close link of intestinal inflammation to microbiota was proposed many years 
ago and later proven with animal models of IBD, which showed that intestinal 
inflammation is much milder or even fails to develop, if animals are reared under germ-
free conditions (Sellon et al., 1998; Hudcovic et al., 2001; Stepankova et al., 2007). These 
findings led to closer investigation of microbiota composition in IBD patients. Many 
studies initially focused on searching an individual pathogen responsible for IBD. The 
pathological similarity of Johne's disease in cattle to Crohn’s disease in humans led to a 
proposition that Mycobacterium avium subsp. paratuberculosis (MAP) is the causative 
agent of IBD. This hypothesis was supported by finding of MAP in inflamed tissue of CD 
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patients (Chiodini et al., 1984; Sanderson et al., 1992; Fidler et al., 1994). Although there 
were reservations about these studies, recent meta-analysis confirmed specific association 
of MAP with CD (Feller et al., 2007). The controlled trials for the therapy of CD with 
antimycobacterial drugs failed, so the question how this bacterium could influence the 
IBD pathogenesis remains unclear (Goodgame et al., 2001; Selby et al., 2007).  
Several ecological studies of gut microbiota showed that there is a difference in 
microbiota composition in IBD patients compared to healthy individuals. This dysbiosis 
or increase in some bacterial group was proposed to cause or at least perpetuate the 
intestinal inflammation in IBD. These studies also identified some candidate bacteria that 
could be responsible for the IBD development in susceptible individuals (Seksik et al., 
2003; Sokol et al., 2006). All these studies must be interpreted with caution, because the 
real trigger might be only transient and changes we are detecting are just secondary. 
There are also changes in mucosa-associated bacteria, suggesting the increased ability of 
bacteria to adhere to mucosa or some other changes in the bacterial metabolism could be 
responsible for IBD triggering (Darfeuille-Michaud et al., 1998; Swidsinski et al., 2002). 
To date, the question remains open whether these bacteria are introduced into the gut 
from the outside environment, or whether this new ability is introduced to intestinal 
microbial society by horizontal gene transfer or by another, yet unknown, signal.  
Although we do not completely understand the natural relations between intestinal 
microbiota, the success of antibiotics and probiotics in IBD therapy clearly shows, that 
manipulation with intestinal microecology might be the future treatment of at least some 
forms of IBD. 
 
3.3.3 Intestinal barrier function failure 
Several studies reported that the intestinal permeability is increased in inflamed as well as 
in noninflamed IBD mucosa of patients and even in first degree relatives of CD patients 
(Jenkins et al., 1988; Katz et al., 1989). These findings clearly demonstrate the 
importance of the intestinal barrier function, and its genetic control, in IBD pathogenesis. 
Increased intestinal permeability also has been shown useful in the prediction of relapse 
in asymptomatic CD patients (Wyatt et al., 1993; D'Inca et al., 1999). 
Several mechanisms might be involved in increased gut permeability. First, there 
is a defect in mucous production in IBD patients (Buisine et al., 2001). Mucus forms a 
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rather thick layer (approximately 100 µm in jejunum and over 800 µm in colon) on the 
gut epithelium (Atuma et al., 2001). This layer acts as a mechanical and antimicrobial 
barrier protecting the underlying epithelium. In healthy individuals, this layer contains 
high concentrations of secreted IgA, lysozyme and other antimicrobial components 
keeping the epithelial surface free of bacteria. 
Defensins, antimicrobial peptides produced by the Paneth cells in the base of the 
Lieberkühn's crypts, are concentrated in the mucus layer protecting vulnerable epithelium 
from invasive bacteria, yet allowing the presence of harmless enteric microbiota (Meyer-
Hoffert et al., 2008). The production of defensins is, however, significantly decreased in 
terminal ileum of CD patients, which may result in aberrant ileum colonisation causing 
the inflammation (Wehkamp et al., 2004; Wehkamp et al., 2007). 
Another mechanism, capable to increase the intestinal permeability is a 
downregulation of tight (ZO-1 and occludin) and addherens (E-cadherin and α-catenin) 
junctions’ proteins in the epithelium of IBD patients. The degree of this downregulation 
positively correlates with degree of inflammation, showing the importance of these 
proteins for intestinal epithelium integrity (Gassler et al., 2001).  
Another explanation for the increased intestinal permeability in IBD is increase of 
extracellular matrix degrading endopeptidases - matrix metalloproteinases (MMP). These 
enzymes were found upregulated in the inflamed gut tissue of IBD patients causing 
mucosal degradation and ulceration (Heuschkel et al., 2000). They are produced by 
activated gut myofibroblasts, macrophages and resident plasma cells in the presence of 
proinflammatory cytokines IL-1β and TNF-α (Okuno et al., 2002; Gordon et al., 2008).  
Although the defect in intestinal barrier function could be the initial defect in IBD 
pathogenesis, the production of TNF-α and IFN-γ secondary to the inflammation 
perpetuates the increased intestinal permeability by reorganizing the tight junction, 
causing further leakage of luminal content to submucosa (Ma et al., 2005; Wang et al., 
2005). This way, the vicious circle of inflammation is created. 
 
3.3.4 Mucosal immune system disregulation 
In healthy subjects, there is an immunological tolerance to intestinal flora from 
autologous but not heterologous intestine. This tolerance is, however, broken during 
intestinal inflammation (Duchmann et al., 1995). 
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There is an increase of activated macrophages and dendritic cells (DCs) and 
changes in cytokine production in the intestinal mucosa of IBD patients. The cytokine 
profiles are, however, unique for each form of IBD. While proinflammatory cytokines 
TNF-α, IL-1β and IL-6 are increased in both forms, the increase of IFN-γ, IL-12, IL-17, 
IL-23 and IL-27 are specific for CD and increase of IL-5 and IL-13 for UC (Fujino et al., 
2003; Fuss et al., 2004; Schmidt et al., 2005). On the other hand, the deficiency in IL-10 
and TGF-β signaling in the intestine might contribute to the development of IBD, because 
both cytokines are important in directing naïve T cell maturation to a regulatory pathway 
(Hahm et al., 2001). Moreover, local delivery of IL-10 with genetically engeneered 
bacteria, Lactococus lactis producing IL-10, shown good results in experimental colitis 
therapy (Steidler et al., 2000). 
Even under normal physiological condition, the microbes in the intestine make 
contact with the host’s immune system without inducing inflammation. It has been 
shown, that DCs in the lamina propria actively sample the gut lumen, but also there is 
active intake of IgA coated bacteria to the Peyer’s patches through the M cells (Rescigno 
et al., 2001; Mantis et al., 2002). 
There is also evidence that live commensal bacteria are shuttled by DC through the 
Payer’s patches to mesenterial lymph nodes causing specific mucosal, but not systemic 
IgA response (Macpherson and Uhr, 2004). 
All these observations shows that at least some intestinal microbes make contact 
with the mucosal immune system, but also raise the question of why this contact does not 
cause the inflammation as the loss of the intestinal barrier does. The answer is not known 
but it is thought, that the amount of antigen is too small to trigger the inflammation or it is 
well “guarded” by the unresponsive innate immunity cells. Once there is a big load of 
bacteria in the mucosa due to the barrier failure or the cells are more susceptible to the 
inflammatory response due to the defect in bacteria sensing, the mucosal immune cells 
overcome their unresponsiveness and the inflammation starts. Three immune mechanisms 
are involved in this process: defect in microbe sensing by the resident mucosal cells, the 
accumulation of the effector cell in the mucosa and a loss of the local tolerogenic signals. 
3.3.4.1 Microbe sensing by the resident mucosal cells  
Luminal antigens are continuously sampled by intestinal epithelium as well as by cells of 
innate immunity such as DCs using several evolutionarily conserved and structurally 
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related receptors, pattern recognition receptors (PRR). These receptors could be 
membrane-bound (e.g. Toll like receptor (TLR) 1, 2, 4, 5, 6, 10 or membrane bound 
CD14), residing in the cytoplasm (e.g. nucleotide-binding oligomerization domain 
containing (NOD) 2 protein, TLR 3, 7, 8 and 9) or even released from the cell (e.g. 
mannan-binding lectin or soluble CD14). These receptors are recognizing conserved 
structural motives on microbiota or microbe-associated molecular patterns such as 
lipopolysaccharide, peptidoglycan, lipoteichoic acide, single- and double-stranded RNA 
and methylated DNA (CpG-motives). 
Interestingly, epithelial cells are also expressing PRRs and are able to be activated 
in response to microbes and produce cytokines. This way, the epithelium could deliver 
the inflammatory signals to underlying cells in lamina propria. In normal gut, the 
epithelial cells are activated by invading pathogens yet maintain the tolerance to resident 
bacteria (Duchmann et al., 1995). 
Antigen-presenting cells (APCs; e.g. DCs and macrophages) are found in a resting 
(inactive) state in lamina propria and Peyer’s patches of normal gut. In this state the cells 
do not respond to bacterial stimuli and pro-inflammatory cytokines (Smythies et al., 
2005). They became activated with conserved structural motives, they migrate to the local 
lymph nodes and activate naive T cells. They also contribute to the T cell activation with 
production of IL-6, IL-12, IL-23 and TGF-β (Drakes et al., 2005). Interestingly, the 
expression of some of some PRR is dysregulated in the intestines of CD and UC patients. 
This may result in easier triggering of the inflammatory cascade in these individuals 
(Frolova et al., 2008). This is further stressed by the fact, that the IL-10-/- mice are 
resistant to spontaneous colitis, if they are lacking MyD88 - important adaptor protein in 
TLR signaling (Rakoff-Nahoum et al., 2006).  
3.3.4.2 Accumulation of the effector cell in the mucosa 
Pro-inflammatory molecules, responsible for tissue damage during the inflammation, are 
produced by effector cells that have accumulated to high numbers in the inflamed 
mucosa. There are two main mechanisms responsible for the accumulation of effector 
cells in the inflamed intestine: enhanced recruitment due to the upregulation of adhesion 
molecules or chemokines, and by increased cell recruitment and prolonged survival 
caused by decreased cellular apoptosis. 
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High levels of inflammatory cytokines (e.g. TNF-α, IL-1β and IL-6) in the 
mucosa of IBD patients increase the expression of chemokines and adhesion molecules 
(on endothelium as well as on circulating CD+ cells) causing circulating leucocytes to 
adhere to endothelium and enter to the inflamed mucosa (Burgio et al., 1995; Garcia de 
Tena et al., 2006). The presence of TNF-α and IL-6 in the inflamed mucosa also mediates 
T-cell resistance against apoptosis causing their accumulation and further tissue damage 
(Atreya et al., 2000; Neurath et al., 2001). 
3.3.4.3 Loss of the local tolerogenic signals  
While innate immunity is activated in both forms of IBD, the T cell response differs. In 
CD, there is upregulation of Th1 (characterized by IFN-γ) and Th17 (characterized by IL-
17) pathways. The Th1 response is iniciated by IL-12 and Th17 response is enhanced by 
the presence of IL-6, TGF-β and IL-23. These cytokines are produced by activated local 
APCs and other innate immunity cells upon bacterial colonization (Becker et al., 2003; 
Kamada et al., 2005). On the other hand, the UC is characterised by atypical Th2 
response, with increase IL-5 and IL-13 produced by natural killer T (NK-T) cells. These 
NK-T cells are stimulated by APCs bearing nonclassical MHC class molecule CD1d, 
which is specialised in presenting the lipids (Fuss et al., 2004). 
In normal gut, the inflammatory response of effector T cells is regulated by T 
regulatory cells. To date, there are three types of T regulatory cells identified in humans. 
Naturally occurring T regulatory cells (Treg) originate in thymus and typically express 
transcription factor forkhead box P3 (FoxP3) and high levels of CD25. These cells 
regulate the effector cells with cell-cell contact. The other two types, regulatory T cell 
type 1 (Tr1) and T helper type 3 (Th3), originates in intestine and react to luminal 
antigens with production of IL-10 and TGF-β on bacteria or food proteins respectively. 
The function of T regulatory cells is under close control of APCs and local cytokine 
milieu as recently reviewed by Belkaid and Oldenhove (Belkaid and Oldenhove, 2008). 
Interestingly, the anti-inflammatory TREG as well as pro-inflammatory Th17 cells could be 
induced locally in the intestinal mucosa from naïve T cells by TGF-β. The balance 
between these two functionally opposite subsets of T cells is kept with IL-6 and IL-21, 
because these cytokines promote the differentiation to Th17 by blocking the expression of 
FoxP3 in the naïve T cells (Fantini et al., 2007). 
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3.4 PROBIOTICS AND BACTERIAL COMPONENTS IN INTESTINAL 
INFLAMMATION THERAPY 
Recent advances in our understanding of IBD pathogenesis and mucosal immune 
response regulation led to a proposal of novel strategies in intestinal inflammation 
therapy. As mentioned before, the indigenous microbiota is crucial for induction and 
perpetuation of intestinal inflammation and manipulation with microbiota composition 
with probiotics and antibiotics is possible approach in IBD therapy. However, each 
probiotic strain have unique effect on immune system, therefore deeper insight into the 
particular microbe-host interaction and careful choice of particular strain for particular 
function might be needed for successful therapy (Maassen et al., 2000).  
Each strain could also have several mechanisms of action, interfering with one or 
more steps of IBD pathogenesis. Live probiotic bacteria could change composition of 
intestinal microbiota resulting in changes in host’s sensitivity to inflammation. These 
changes could be mediated by simple competition with other microbes for limited 
resources and limited number of receptors or they could produce antimicrobial peptides or 
even increase the host antibody production against other microbes (Kaila et al., 1992; 
Lievin et al., 2000; Hutt et al., 2006). Moreover, probiotic E. coli Nissle 1917 and 
Lactobacillus casei DN-114 001 have inhibitory effect on adhesion and invasion of 
adherent invasive E. coli isolated from patients with Crohn’s disease (Boudeau et al., 
2003; Ingrassia et al., 2005). The mechanism of this action could also be explained by 
recent findings, that L. acidophilus secrete molecule(s) capable of downregulating 
expression of genes involved in attachment of enterohemorrhagic E. coli to gut mucosa 
(Medellin-Pena et al., 2007). This indicates that we might be able to convert adherent 
bacteria into non-adherent simply by administering this bacterial component to the gut. 
Furthermore, treatment with L. casei or mixture of probiotic bacteria VSL#3 results in an 
improvement of intestinal barrier integrity and thus prevents enteric antigens from 
excessive stimulation of lamina propria immune cells (Madsen et al., 2001; Llopis et al., 
2005).  
Several probiotics have shown immunomodulatory properties on basically all 
levels of regulation, including downregulation of the PRRs expression, NF-κB signaling 
and pro-inflammatory cytokine production (Matsumoto et al., 2005; Sturm et al., 2005; 
Grabig et al., 2006; Sougioultzis et al., 2006). Interestingly, some of these effects could 
be achieved by soluble factor produced by these bacteria or their lysates. Lysate of 
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Lactobacillus brevis and Streptococcus thermophilus could induce apoptosis in immune 
cells, which could reverse the insensitivity to apoptosis of lamina propria immune cells in 
IBD patients (Di Marzio et al., 2001). Oral administration of lysate prepared from normal 
intestinal flora containing anaerobes reduces the severity of acute experimental colitis in 
mice which suggests that there might be some bacterial components with special anti-
inflammatory properties among commensals (Verdu et al., 2000).   
Interestingly, also some well known pathogens could decrease the immune 
response by dampening inflammatory signals or inactivating immune cells which help 
them to evade host’s immune system and establish infection or persistence (Ruckdeschel 
et al., 1997; Sansonetti and Di Santo, 2007; van der Velden et al., 2008). It would be 
therefore interesting to isolate the active component and to exploit it in the therapy of 
IBD with these components.  
Several recent studies showed that TLR-9 ligand, an immunostimulatory bacterial 
oligonucleotide (CpG-ODN), ameliorates experimental colitis and decreases the 
production of proinflammatory cytokines by human colonic mucosa, but this effect is 
present only in certain CpG-ODN (Rachmilewitz et al., 2002; Rachmilewitz et al., 2006). 
Experiments with isolated bacterial DNA showed that intestinal epithelial cells respond to 
pathogenic bacterial DNA by increasing surface localization of TLR9 and production of 
IL-8, but remain unresponsive to DNA isolated from commensal or probiotic bacteria 
(Ewaschuk et al., 2007). In dextran-sulfate sodium (DSS) induced colitis, exposure to 
CpG-ODN during acute inflammation was found to exacerbate the disease, whereas 
preexposition proved to be protective (Obermeier et al., 2003). These results could 
explain the observed positive correlation between IBD and domestic hygiene in infancy, 
and they also suggest that CpG-ODN is a promising candidate for the maintenance 
therapy, but not for the therapy of active disease. 
Another interesting approach is to think about bacteria that have been proposed as 
the IBD triggers as targets for vaccination. If we will identify the causative bacteria, than 
the protective immune response against this bacteria could prevent the IBD in otherwise 
susceptible individuals. Although B distasonis and mycobacteria were both proposed to 
be involveded in induction and perpetuation of intestinal inflammation, we found that 
introduction of B. distasonis lysate, its DNA or mycobacterial heat shock proteins by 
gavage led to decreased sensitivity of mouse to DSS colitis (Kverka et al., submitted). We 
still do not know whether we induce the oral tolerance to indigenous microbiota or 
protective immunity against some closely related potential pathogen causing the 
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inflammation, but this therapy promotes changes in cytokine production in the intestine. 
Recent findings on how could bacterial components beneficially influence the natural 
course of intestinal inflammation are summarized on Figure 3.1.  
It is important to mention that the reaction of the immune system to the addition of 
the bacterial component depends on the actual tuning of mucosal immune system. As 
shown on animal models the introduction of the bacterial component into the inflamed 
condition could lead to opposite effect. Although there are still mysteries about the role of 
microbe-host interactions in IBD pathogenesis, our deeper understanding of these 
underlying mechanisms is important for new strategies in IBD therapy. It seems that the 
use of immunomodulatory properties of microbiota could be fundament for that purpose. 
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Figure 3.1 Simplified diagram of IBD pathogenesis summarizing the possible 
mechanisms by which bacterial components could beneficially influence the natural 
course of intestinal inflammation 
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4.1 ABSTRACT 
The effect of glucocorticoids is controlled at the pre-receptor level by the activity of 11β-
hydroxysteroid dehydrogenase (11HSD). The isoform 11HSD1 is an NADP+-dependent 
oxidoreductase, usually reductase, that amplifies the action of glucocorticoids due to 
reduction of the biologically inactive 11-oxo derivatives cortisone and 11-
dehydrocorticosterone to cortisol and corticosterone. The NAD+-dependent isoform 
(11HSD2) is an oxidase that restrains the effect of hormones due to 11β-oxidation of 
cortisol and corticosterone to their 11-oxo derivatives. Although the immunosuppressive 
and anti-inflammatory effects of glucocorticoids are well known, the relationship between 
inflammation and local metabolism of glucocorticoids is not well understood. In this 
study, we demonstrated that colitis induced by dextran sulfate sodium modulates colonic 
11HSD1. Experimentally induced intestinal inflammation stimulated colonic NADP+-
dependent but not NAD+-dependent 11HSD activity. Colonic 11HSD1 mRNA was 
increased, whereas 11HSD2 mRNA was not changed. Additional parallel studies revealed 
a similar pattern of 11HSD1 mRNA induction in mesenteric lymph nodes and intestinal 
intraepithelial lymphocytes, but not in spleen and peritoneal macrophages. These data 
suggest that inflammation modulates local metabolism of glucocorticoid and support the 
notion that pre-receptor regulation of endogenous corticosteroids might play a role in 
inflammatory processes. 
 
4.2 INTRODUCTION 
Glucocorticoids are known to be essential modulators of immune and inflammatory 
processes. They influence the development and effector functions of the immune system, 
trafficking of immune cells through the vascular bed, and chemotaxis. At the cellular 
level, they modulate maturation, differentiation, proliferation, and activation of immune 
cells (Ashwell et al., 2000; Webster et al., 2002). One of the main effects of 
glucocorticoids is the downregulation of pro-inflammatory cytokines. These cytokines, 
such as tumor necrosis factor α (TNF-α) and interleukin-1 (IL-1), have been shown to 
link inflammation with glucocorticoid production by stimulating the hypothalamic–
pituitary–adrenal axis and elevating thereby the plasma glucocorticoid concentration 
(Besedovsky and del Rey, 1996). However, the biological activity of glucocorticoids 
depends not only on their plasma concentration, the number of receptors, and the 
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responsiveness of the target cell, but also on the local metabolism of glucocorticoids 
catalyzed by 11β-hydroxysteroid dehydrogenase (11HSD), which can change the 
concentration of active glucocorticoids within tissues and/or target cells. 
Two isoforms of 11HSD have been characterized. Isoform 2 (11HSD2) is a high-
affinity NAD+-dependent enzyme that operates exclusively as an oxidase inactivating 
biologically active glucocorticoids cortisol and corticosterone to their 11-oxo derivatives 
cortisone and 11-dehydrocorticosterone respectively (Stewart and Krozowski, 1999). In 
contrast, 11HSD1 is a low-affinity NADP(H)-dependent oxidoreductase whose reductase 
activity has been found in various intact cells (Seckl and Walker, 2001), but alterations in 
the NADP+/NADPH redox potential governed by the metabolism of glucose-6-phosphate 
via hexose-6-phosphate  dehydrogenase seem to determine whether 11HSD1 operates as 
a reductase or an oxidase (Hewitt et al., 2005). Thus, 11HSD2 decreases the local 
concentration of active glucocorticoids, whereas 11HSD1 increases it due to regeneration 
of biologically active steroids from the circulating inactive 11-oxo metabolites or 
decreases it due to oxidation of active glucocorticoids (Stewart and Krozowski, 1999; 
Seckl and Walker, 2001; Hewitt et al., 2005). Exposure to pro-inflammatory stimuli such 
as TNF-α and IL-1β increases 11HSD1 expression and enzymatic activity in some cells, 
while inducing a decrease of 11HSD2 in others (Cai et al., 2001; Heiniger et al., 2001; 
Thieringer et al., 2001; Tomlinson et al., 2001; Curtis and Sloan, 2004). The biological 
significance of this process was shown recently (Escher et al., 1997; Thieringer et al., 
2001; Zhang et al., 2005).  
With regard to the colon, 11HSD2 is expressed in epithelial cells, whereas 11HSD1 
is localized in the cells of lamina propria (Whorwood et al., 1994). This matches with the 
findings of 11HSD1 in fibroblasts (Hammami and Siiteri, 1991) macrophages (Thieringer 
et al., 2001), and lymphocytes (Zhang et al., 2005). Consistent with the effect of TNF-α 
and IL-1β on 11HSD1 and 11HSD2, we have shown in a rat model of colitis that 
11HSD1 mRNA expression and 11-reductase activity increased, whereas 11HSD2 
mRNA expression and 11-oxidase activity decreased during intestinal inflammation 
(Bryndova et al., 2004). Considering that colitis is accompanied by activation of mucosal 
immune cells and increased recruitment of leucocytes from the vascular space (Elson et 
al., 1995), one can hypothesize that the link between the upregulation of colonic 11HSD1 
mRNA and the increased ability of the tissue to reduce 11-dehydrocorticosterone to 
corticosterone might be the cells of the intestinal immune system. To address this 
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question, we used the dextran sulfate model of murine colitis and studied the changes of 
11HSD1 in colon and immune cells during intestinal inflammation.  
 
4.3 MATERIALS AND METHODS  
4.3.1 Animals and preparation of immune cells  
Female 3-month-old mice Balb/c (Velaz, Prague, Czech Republic) were used in this 
study. Experimental colitis was induced by adding 3% (w/v) dextran sulfate sodium 
(DSS, MW 36 000–50 000; ICN Biomedicals Inc., Cleveland, Ohio, USA) in drinking 
water (Okayasu et al., 1990). Mice were treated with DSS for 7 days and subsequently 
killed. Control animals received only tap water. The mice were killed by decapitation and 
the colon, spleen, and mesenteric lymph nodes were excised. Macrophages were collected 
by a peritoneal lavage and intraepithelial lymphocytes (IEL) as originally described by 
Lefrancois (2001) with some modifications. Briefly, the inflamed part of colon was 
dissected and the lumen gently flushed with cold physiological saline (4°C). The intestine 
was then incised longitudinally and cut into 5 mm pieces. The pieces were incubated in 
flasks containing RPMI-1640 medium supplemented with fetal bovine serum (12.5%) for 
20 min at 37 °C with stirring. The incubation step was repeated thrice, the supernatants 
were combined, and IEL were separated from epithelial cells by discontinuous Percoll 
gradient at the interface 67%/44%. The harvested cells were washed in RPMI medium 
and used for further analysis.  
The animal study was approved by the Animal Care and Use Review Committee of 
the Czech Academy of Sciences.  
 
4.3.2 Evaluation of colitis  
The clinical assessment of DSS-treated animals included body weight, colon length, 
evaluation of stool consistency, and the presence of blood in the stool. A clinical disease 
activity index representing the sum of separate scores ranging from 0 to 4 was calculated 
using the following parameters: body weight decrease (0, less than 5% decrease; 1, 5–
10%; 2, 10–20%; 4, more than 20%), stool consistency (solid 0, loose 2, diarrhea 3), and 
bleeding (none 0, macroscopic in colon 2, blood adhering to the anus 4) as described 
previously (Bendjelloul et al., 2000).  
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4.3.3 Quantitative analysis of 11HSD and cytokine RNA  
Total RNA from the colon was extracted by the guanidinium thiocyanate method. The 
isolated RNA was treated with DNase (Promega) to remove potential contamination by 
genomic DNA as mentioned earlier (Mazancova et al., 2003). Total RNA from the 
spleen, mesenteric lymph nodes, macrophages, and IEL was obtained using GeneElute 
Mammalian Total RNA Miniprep Kit (Sigma). cDNA was synthesized from 5 µg RNA 
and M-MLV Reverse Transcriptase reagents (Invitrogen GmbH). Amplification of the 
target cDNA was performed in the LightCycler (Roche) as previously reported 
(Mazancova et al., 2005) using QuantiTect Sybr Green PCR Kit (Qiagen GmbH) and the 
primers given in Table 4.1. Results were analyzed with LightCycler software using the 
second derivative maximum method to set CP. For the quantification of the target genes 
11HSD1, 11HSD2, TNF-α, and IL-1β, we performed the quantitative comparison of 
several candidate reference genes to select the most stable genes for gene normalization. 
The panel of five reference genes generally used in many physiological and 
pathophysiological conditions, such as β-actin (ACTB), hypoxanthine 
phosphoribosyltransferase 1 (HPRT1), ribosomal protein L13a (RPL13A), elongation 
factor 1a (EF1A), and peptidylpropyl isomerase B (cyclophilin B; PPIB), were tested 
(Table 4.1). Because of the high concentration of β-actin and 11HSD2, the samples were 
diluted 1/1000 before analyses of these RNA species. For other analyses, 1/10 prediluted 
cDNA was used as a template for PCR. Calibration curves were generated for each pair of 
primers from serial dilutions of standard cDNA. After statistical analysis of reference 
genes, the data of target gene expression were normalized according to the normalization 
factor calculated by the geNorm applet (Vandesompele et al., 2002).  
The expression of 11HSD1 mRNA in IEL was determined by the ABI PRISM 7000 
Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The probes 
and primers used for this experiment were developed as TaqMan Gene Expression Assays 
by Applied Biosystems. The reaction was carried out in a final volume of 20 µl using 
TaqMan Universal PCR Master Mix with AmpEraseUNG (Applied Biosystems) and 
Expression Assay. Target 11HSD1 mRNA was achieved using calibration curve method 
and the amount of mRNA was normalized to the level of 18S rRNA (Bas et al., 2004).  
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Table 4.1 Primers used for PCR 
Gene Sense (5’→3’) Antisense (5’→3’) 
11HSD1 GGTAGTGTCTCGCTGCCTTGAA CACGTTGACCTTGGTTATGTAGAGTT 
11HSD2 CCGGTTGTGACACTGGTTTTG GGGGTATGGCATGTCTCCTG 
TNF-α GGACAAGGCTGCCCCGACTAC TCTGAGCCATAATCCCCTTTC 
IL-1β TCCCAAGCAATACCCAAAGAAGAA ATCAGAGGCAAGGAGGAAACACAG 
β-actin GAACCCTAAGGCCAACCGTGAAAAGAT ACCGCTCGTTGCCAATAGTGATG 
Ppib AGGGGAGATGGCACAGGAGGAAAGAGC ACCCAGCCAGGCCCGRAGTGC 
EF1a TGACAGCAAAAACGACCCACCAAT GGGCCATCTTCCAGCTTCTTACCA 
RP13A CTCCCGAGGCCCCTACCACTT GGCCTTTTCCTTCCGTTTCTCCTC 
HPRT GCAGTCCCAGCGTCGTG TAATGTAATCCAGCAGGTCAGC 
 
 
4.3.4 Enzyme activity assays  
Colon homogenates were prepared in ice-cold buffers containing 10 mM Tris, 250 mM 
sucrose (pH 8.5; 11HSD2 assay) or 10 mM Tris, 5 mM EDTA, 0.5% Triton X-100 (pH 
7.5; 11HSD1 assay). After centrifugation at 500 g for 15 min, the supernatant was 
obtained and protein concentration was measured using the Bradford technique 
(Bradford, 1976). 11HSD1 and 11HSD2 activities were measured as NADP+- and NAD+-
dependent 11β-oxidation of corticosterone according to Livingstone & Walker (2003) and 
Gomez-Sanchez et al. (2003). 11HSD1 activity was measured in incubation buffer 
containing 50 mM Tris, 100 mM KCl, 1 mM NADPC, 480 nM corticosterone, and 20 nM 
1,2,6,7- [3H]corticosterone (pH 7.5). 11HSD2 activity was determined in a similar way, 
with 50 mM Tris, 100 mM KCl, 1 mM NADC, and 20 nM 1,2,6,7-[3H]corticosterone (pH 
8.5). The amounts of protein and the incubation times were determined in preliminary 
experiments to establish the optimal conditions, in order to work in the linear portion of 
the enzyme reaction. Steroids were extracted from the incubation buffer by SepPak 
cartridges (Waters, Milford, MA, USA) and separated by HPLC with on-line detection 
using a flow-cell detector (Radiomatic 150TR, Canberra Packard, Meriden, CT, USA). 
The separation was performed in a C18 column using a water methanol gradient (for 
details see Pácha et al. 2004 ).  
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4.3.5 Data analysis  
All data are expressed as means±S.E.M. or medians with 25th– 75th percentile values. 
The distribution–fitting procedure according to Shapiro–Wilk’s W-test of normality was 
applied and the comparison between the control animals and the mice with colitis was 
analyzed using unpaired Student’s t-test or Mann–Whitney U-test. The values P<0.05 
were considered statistically significant. For stability comparison of candidate reference 
genes and the calculation of normalization factor, the geNorm program was applied after 
conversion of CP values into relative quantities (Vandesompele et al., 2002). Using this 
approach, the normalization factor based on two candidate reference genes was 
calculated. Statistical analysis was performed using the statistical software Statistica v.6 
(StatSoft Inc., Tulsa, OK, USA).  
 
4.4 RESULTS  
The mice with colitis developed loose stools or diarrhea associated with blood in the stool 
and decreased colon length and body weight. Mortality was 10%. The index of disease 
activity is given in Table 4.2.  
Table 4.2 Disease activity of DSS-induced colitis in colon 
 Controls Acute colitis 
Symptom score 0.0 (0.0–0.0) 8.0 (6.0–10.0)* 
Diarrhea score 0.0 (0.0–0.0) 3.0 (3.0–3.0)* 
Blood score 0.0 (0.0–0.0) 4.0 (0.0–4.0)* 
Body weight 2.0±0.8 -11.4±1.5* 
Colon length 9.9±0.3 7.3±0.1* 
The data are given as medians and 25th–75th percentile values (score values) or mean±S.E.M. (body 
weight change, colon length) based on records of 10 control and 9 DSS-treated animals. The score values 
were calculated as mentioned in Materials and Methods section, colon length is given in cm, and body 
weight change is given by dividing body weight at day 7 by body weight at day 0 (starting body weight) and is 
expressed as a percentage. *P<0.05 compared with controls. 
 
To investigate whether metabolism of glucocorticoids is modulated in inflamed 
tissue, we used enzyme assay and quantitative reverse transcription (RT)-PCR. First, we 
evaluated the expression levels of five putative reference genes in the colon of healthy 
mice and in animals with colitis. These genes displayed a relatively wide range of CP 
(Fig. 4.1). Using the unpaired Student’s t-test or Mann–Whitney U-test, significant 
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differences in gene expression between healthy and inflamed colon were observed for 
EF1A and RPL13A. The geNorm program was then used to calculate the gene expression 
stability measure M of the remaining genes and the normalization factor based on the 
geometric average of the two reference genes (Vandesompele et al., 2002). We found 
ACTB and PPIB to be the most convenient reference genes and thus these two genes 
were used for normalization of mRNA expression levels.  
 
Figure 4.1 Expression levels of candidate reference genes in healthy and inflamed 
colon 
 
Data are shown as medians (points), 25th–75th percentiles (boxes), and ranges (whiskers). For the 
analyses, 1/1000 (ACTB) or 1/10 pre-diluted cDNA (RPL3A, EF1A, PPIB, and HPRT) was used as a 
template for PCR. 
 
To determine whether 11HSDs are modulated during inflammation, we measured 
colonic 11HSD1 and 11HSD2 mRNAs in control animals and in mice with colitis. As 
shown in Fig. 4.2, both groups of mice were found to express 11HSD1 and 11HSD2 
transcripts and the inflammation affected the expression. Colitis upregulated 11HSD1 
mRNA but did not significantly modulate the levels of 11HSD2 mRNA. To test whether 
the changes in transcript levels reflect changes in 11HSD1 and 11HSD2 enzyme 
activities, we used a colonic homogenate assay to analyze the  NAD+- and  NADP+- 
dependent conversion of corticosterone to 11-dehydrocorticosterone. The colon of 
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controls and the mice with colitis had similar level of NAD+-dependent 11HSD activity, 
but NADP+-dependent 11HSD activity was significantly increased in inflamed tissue 
(Fig. 4.3). To verify the presence of colonic inflammation in this tissue, we analyzed gene 
expression of pro-inflammatory cytokines, TNF-α and IL-1β mRNAs. As shown in Table 
4.3, the level of IL-1β transcript was significantly increased in inflamed colon but the 
level of TNF-α transcript was changed much less, in a similar way as in the study of 
Egger et al. (2000) and Kwon et al. (2005).  
 
Figure 4.2 (a) Colonic 11HSD1 mRNA and (b) 11HSD2 mRNA levels in control mice 
and in animals with colitis. 
 
The relative expression levels were normalized against normalization factor from the two most stable 
reference genes provided by geNorm (for details see the text). The data are given as means±S.E.M. (control 
(CTRL), n=10; colitis, n=9). *P<0.05 compared with controls. 
 
Table 4.3 Expression of TNF-α and IL-1β mRNAs in colon 
 Controls Acute colitis 
TNF-α mRNA 0.202±0.063 0.258±0.61 
IL-1β mRNA 0.023±0.002 0.356±0.183* 
The data are given as means±S.E.M. of 10 control and 9 DSS-treated animals.The expression of cytokines 
is given in arbitrary units. *P<0.05 compared with controls. 
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Figure 4.3 (a) NAD+- and (b) NADP+-dependent 11HSD activity in colonic 
homogenates of control mice and animals with colitis. 
 
Values are means±S.E.M. (control (CTRL), n=10; colitis, n=10). 11HSD activity is given in picomoles of 
corticosterone per hour per mg protein. *P<0.05 compared with controls. 
 
Next, we evaluated the changes in the level of 11HSD1 mRNA in the cells of gut-
associated lymphatic tissue. There was a significant increase in 11HSD1 mRNA in IEL 
isolated from animals with colitis (Fig. 4.3). Consistent with upregulation of 11HSD1 
mRNA in IEL, the lymphatic mesenteric nodes that contain large numbers of 
lymphocytes coming from the intestine demonstrated upregulation of 11HSD1 mRNA 
(Fig. 4.5), whereas 11HSD2 transcript was undetectable in the same nodes. In contrast to 
mesenteric lymph nodes, 11HSD1 transcript in spleen was not changed during colitis. 
Finally, to establish the potential contribution of macrophages to upregulation of colonic 
11HSD1 during inflammation, the peritoneal macrophage 11HSD1 transcript was 
quantified. 11HSD1 mRNA was detectable in macrophages, but this transcript was not 
affected by colitis (controls: 0.56±0.05 (n=10); colitis: 0.48±0.04 (9)). Taken together, 
these findings demonstrate similar changes in 11HSD1 mRNA in the colon, mesenteric 
lymphatic nodes, and IEL, but not in the spleen and peritoneal macrophages.  
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Figure 4.4 The relative expression levels of 11HSD1 mRNA in murine intestinal 
intraepithelial lymphocytes during DSS-induced colitis. 
 
Quantification of 11HSD1 gene expression was performed relative to the expression of 18S rRNA. *P<0.05 
compared with controls (control (CTRL), n=5; colitis, n=9). 
 
Figure 4.5 Expression of 11HSD1 in mesenteric lymph nodes (MLN) and spleen. 
 
The values were expressed as mentioned in Fig. 4.2. *P<0.05 compared with controls (control, n=10; colitis, 
n=9). 
4.5 DISCUSSION  
The present study revealed that inflammation is associated with changes in 11HSD1 
mRNA expression and enzyme activity in colon. The inflamed colon upregulated 
11HSD1 transcript and NADP+-dependent 11HSD activity without any significant 
changes in 11HSD2 transcript and NAD+- dependent 11HSD activity. As 11HSD2 is 
expressed only in epithelium, whereas 11HSD1 is expressed in the submucosal layer 
(Whorwood et al., 1994), it is likely that changes in 11HSD1 proceed in the intestinal 
compartment of lamina propria or gut-associated lymphatic tissue and not in the 
epithelium. 11HSD1 was found in macrophages (Thieringer et al., 2001), T cells (Zhang 
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et al., 2005), and fibroblasts (Hammami and Siiteri, 1991), and we have found an 
increased level of 11HSD1 mRNA in IEL and mesenteric lymphatic nodes of mice with 
colitis. The question is what is the direction of 11HSD1 reaction in intact cells in vivo? 
This direction (11β-reduction or 11β-oxidation) depends on the ratio of NADPH/ 
NADP+, which is determined by hexose-6-phosphate dehydrogenase and pentose-
phosphate pathway (Atanasov et al., 2004; McCormick et al., 2006). Thus, it is difficult to 
anticipate the reaction direction of 11HSD1 in inflamed colon. Considering that 11HSD1 
operates as a reductase in activated macrophages (Gilmour et al., 2006), lymphocytes 
(Zhang et al., 2005), and dendritic cells (Freeman et al., 2005), it is likely that colonic 
11HSD1 is increased by a shift in favor of the reductase activity. Further studies are 
needed to clarify the role of 11HSD isoforms of colonic wall in vivo by cellular 
distribution of 11HSDs in cell types of colonic mucosa and submucosa during 
inflammation and the effect of NADPH depletion during oxidative stress on the direction 
of the reaction catalyzed by 11HSD1 in immune cells.  
The exact mechanism of inflammation induced by DSS is not yet fully elucidated, 
but the pathogenesis seems to depend on the interaction between local immune reaction 
and environmental factors because animal models of inflammatory bowel disease reared 
in germfree conditions did not develop the disease (Tlaskalová-Hogenová, 1997; 
Hudcovic et al., 2001; Elson and Cong, 2002). Drinking of DSS generates in murine 
colon the upregulation of pro-inflammatory cytokines as well as reactive oxygen and 
nitrogen species and infiltration by polymorphonuclear and mononuclear cells (Okayasu 
et al., 1990; Kojouharoff et al., 1997; Arai et al., 1998). Previous data and our findings 
suggest that these processes are accompanied by upregulation of 11HSD1 in the cells of 
gut associated lymphatic tissue. First, activated macrophages and lymphocytes acquire 
increased capacity of glucocorticoid reactivation via 11HSD1 (Zhang et al., 2005; 
Gilmour et al., 2006). Secondly, our data show that NADP+-dependent but not NAD+-
dependent activity is increased in inflamed colon. Thirdly, the level of 11HSD1 transcript 
is increased not only in inflamed colon but also in IEL and in mesenteric lymphatic 
nodes. This upregulation of 11HSD1 is presumably induced by the pro-inflammatory 
cytokines, whose levels of transcript and protein are increased in colon of DSS-treated 
mice (Arai et al., 1998; Egger et al., 2000; Obermeier et al., 2002; Kwon et al., 2005). 
The cytokines TNF-α and IL-1β are known to increase 11HSD1 mRNA and 11-reductase 
activity in various cell types, such as glomerular mesangial cells (Escher et al., 1997), 
Glucocorticoid metabolism and inflammation 
 
79 
osteoblasts (Cooper et al., 2001), adipocytes (Tomlinson et al., 2001), and aortic smooth 
muscle cells (Cai et al., 2001). In addition, pro-inflammatory cytokines are important 
inducers of nitric oxide generation in macrophages and intestinal epithelial cells, and the 
interaction between the NO system and the 11HSDs has recently been demonstrated 
(Kolios et al., 1996; Saito and Nakano, 1996; Sun et al., 1997; Ruschitzka et al., 2001).  
It is well recognized that glucocorticoids effectively modulate a number of 
immunological processes, including positive or negative regulation of cytokine 
production (Hennebold et al., 1996; Ashwell et al., 2000). Therefore, changes in the 
metabolism of glucocorticoids within peripheral lymphatic organs and in immune cells 
could modulate not only the suppression of cell activation by proinflammatory cytokines 
but also other immunomodulatory processes (Elenkov and Chrousos, 1999; McKay and 
Cidlowski, 1999). Using glomerular mesangial cells exposed to IL-1β and TNF-α, it was 
demonstrated that the release of phospholipase A2, a key enzyme producing 
inflammatory mediators, is decreased by 11HSD1 activity (Escher et al., 1997). Similarly, 
the pharmacological inhibition of 11HSD in vivo greatly enhanced the susceptibility to 
progressive bacterial diseases and these changes in resistance following 11HSD inhibition 
correlated with changes in the patterns of inducible cytokines in lymphocytes and 
macrophages (Hennebold et al., 1997). Given the central role of 11HSD1 in 
glucocorticoid action, we can speculate that the increased expression of this enzyme may 
serve to enhance the exposure of immune cells to active glucocorticoids via the paracrine 
and/or intracrine pathway.  
In summary, our observations are consistent with the notion that inflammation is 
associated with changes in 11HSD1. Although the mechanism and accurate function of 
11HSD1 upregulation is equivocal, the findings suggest that the bioavailability of 
glucocorticoids in inflamed colon differs from the healthy tissue.   
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5.1 ABSTRACT  
Our study examined whether repeated preventive oral administration of live probiotic 
bacterial strains Escherichia coli O83:K24:H31 (Ec O83), Escherichia coli Nissle 1917 
O6:K5:H1 (Ec Nis) and Lactobacillus casei DN 114001 (Lc) can protect mice against 
dextran sodium sulfate (DSS)-induced colitis. A significant decrease in average symptom 
score was observed in Ec O83-, Ec Nis- and Lc-pretreated group (p < 0.05). Significant 
differences in body mass loss between Lc pretreated mice with DSS-induced colitis were 
found when compared with nontreated mice (p < 0.05). PBS pretreated mice had a 
significantly shorter colon than Ec O83-, Ec Nis- and Lc-pretreated mice (p < 0.05). 
Administration of Lc significantly decreased the severity of DSS induced histological 
marks of inflammation (p < 0.05). A significant difference (p < 0.05) was also found in 
specific IgA level against given probiotic in enteral fluid between colitic mice and healthy 
mice pretreated with Ec 083 and Ec Nis. 
 
5.2 INTRODUCTION 
The pathogenesis of IBD represents the outcomes of 3 essential interactive cofactors: host 
susceptibility, enteric microflora and mucosal immunity (Shanahan, 2001). There is 
increasing evidence that IBD results from an abnormal immune response to normal 
intestinal flora, with a break of tolerance towards non-pathogenic bacteria (Duchmann et 
al., 1995; Tlaskalová-Hogenová et al., 2004). Normal flora profoundly influences the host 
mucosal structure and function as well as the development of the whole immune system 
(Tlaskalová-Hogenová, 1997; Vancikova et al., 2003; Tlaskalová-Hogenová et al., 2004; 
Cebra et al., 2005). 
 Manipulation of the resident microflora provides an opportunity to influence 
mucosal cytokine signaling. This is best appreciated when comparing genetically 
engineered immunodeficient mouse models reared under germ-free and conventional 
conditions (Tlaskalova-Hogenova et al., 2004). When genes encoding T-cell 
immunoregulatory functions are deleted, spontaneous chronic inflammation of the gut 
mucosa develops in conventionally reared mice. For example, TCR α-chain-deficient 
mice, TCR β-chain-deficient mice and MHC class II-deficient mice, cytokine knockout 
mice lacking IL-2, IL-10 and TGF-β develop chronic inflammation (Strober and 
Ehrhardt, 1993). Another experimental model of IBD directly evidencing the role of T-
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cell subpopulations in gut immunoregulation has been described in SCID mice. Restored 
with CD4 CD45 RBhigh T cell subpopulation from conventional BALB/c mice they 
develop colitis whereas simultaneous transfer of the CD4 CD45 RBlow T-cell 
subpopulation prevented colitis (Powrie, 1995; Tlaskalova-Hogenova et al., 1998).  
 SCID mice also remained healthy after transfer of a pathogenic T-cell 
subpopulation when reared in germ-free conditions (Singh et al., 2001).  
 The finding that there is an abnormal T-cell responsiveness to indigenous 
microflora in human and experimental models awakened interest in the possibility that 
commensals may initiate and maintain IBD lesions. The use of animal models has 
provided a new insight into the influence of environmental, genetic and 
immunoregulatory factors involved in the development of IBD. In previous studies, we 
induced colitis by DSS in immunocompetent and immunodeficient mouse models. SCID 
and BALB/c mice reared in conventional conditions (colonized by microflora) developed 
signs of colitis (colonic bleeding, epithelial erosions, increase in the number of 
inflammatory cells in lamina propria and submucosa, reduction of the number of goblet 
cells) after 7 d feeding with DSS. Both strains of mice reared in germ-free conditions 
showed only minor changes after DSS feeding. These experiments suggest that in DSS-
induced colitis the presence of microflora augments the development of the inflammatory 
reaction which occurs even in the absence of specific components of the immune system 
(Hudcovic et al., 2001).  
 Here we addressed the question whether manipulation of intestinal microflora by 
probiotics could affect experimentally induced intestinal inflammation by examining 
whether repeated preventive oral administration of live probiotic strains Escherichia coli 
O83:K24:H31 (Ec O83), E. coli Nissle 1917 O6:K5:H1 (Ec Nis) and Lactobacillus casei 
DN 114001 (Lc) could protect mice against DSS-induced colitis.  
 
5.3 MATERIALS AND METHODS 
5.3.1 Preparation of bacteria. 
Strains were cultivated to the stationary growth phase. E. coli strains used by Cukrowska 
et al. (2002) as probiotics, i.e. Ec O83 and Ec Nis were cultured on tryptan-soya agar 
(Oxoid), L. casei (Lc) (provided by the Danone Institute) on MRS agar (Oxoid). The 
cells were harvested, washed 3× and diluted in PBS and their concen tration was 
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measured spectrophotometrically at 600 nm, final concentration being 1 CFU/pL (i.e. 109 
CFU/mL). 
 
5.3.2 Application of probiotics and induction of colitis. 
BALB/c mice aged 17 weeks (n = 60) were fed daily for 14 d by gastric lavage with 100 
µL of live bacterial suspension (n = 20 in the group for 1 bacterial strain), i.e. each of 
these mice received daily 108 CFU of live bacteria. Mice in the control group (n = 15) 
were fed daily with 100 µL of PBS. DSS colitis was induced by administering 5 % DSS 
(diluted in distilled sterile water) in drinking water for 7 d similarly as described by 
Bendjelloul et al. (2000) and Hudcovic et al. (2001) to 10 mice in every bacterial group 
and to 10 mice in the control group. Five control mice and 10 mice in each bacterial 
group drank water without DSS. After 6 d the mice were sacrificed and the severity of 
colitis was evaluated. There were 10 mice in every probiotic and DSS group, 10 mice in 
probiotic and water group, 10 mice in PBS and DSS group and 5 mice in PBS and water 
control group. The planned experiments were approved by the Commission for 
Experimental Animal Studies of the Academy of Sciences of the Czech Republic.  
 
5.3.3 Evaluation of colitis.  
The presence of rectal prolapse, rectal and colonic bleeding and mass loss was recorded. 
A symptom score (0–4) was constructed attributing 1 point to each of the following 
events: rectal prolapse, rectal bleeding, colonic bleeding and death. The length of the 
colon was measured and colonic samples were obtained for histopathology. The slides 
were reviewed by a pathologist unaware of the treatment schedule of the animals. The 
severity of the colitis was scored, attributing between 0 and 3 points to each of the 
following parameters: polymorphonuclear infiltrate, mononuclear infiltrate, edema, 
erosions and ulcerations, crypt abscess, crypt destruction and distribution of the 
inflammation (mucosa = 1, mucosa and submucosa = 2, transmural inflammation = 3) 
(Verdu et al., 2000). Photomicrographs of H&E stained paraffin sections of a 
representative sigmoid colon of a mouse from group PBS and water group, a mouse from  
PBS and DSS group and a mouse from Ec O83 and DSS group was taken.  
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5.3.4 Antibody levels. 
Sera and enteral fluid obtained by using 2 mL of PBS wash containing a mixture of 
proteinase inhibitors (Sigma) were collected. Px conjugated anti Ig serum was used. 
Concentration of specific antibodies against probiotic bacteria was evaluated by ELISA 
using bacterial sonicates similarly to Lodinová-Žádníková et al. (1991).  
 The results are mean values with 95 % CI, statistical analysis was performed by 
Student’s t-test, p < 0.05 (vs. PBS) being considered statistically significant. 
 
5.4 RESULTS 
5.4.1 Clinical and histological changes in DSS-induced colitis. 
Relative to animals from PBS and DSS group, colitic mice fed with probiotic strains 
exhibited a decrease in the symptom score (Table 5.1) and had significantly longer colon 
at the end of experiment. There was also significant decrease in mass loss of colitic Lc 
mice. While severe inflammation, crypt destruction and ulceration of the mucosa were 
observed in the PBS-fed group by histology evaluation (Fig. 5.1B), significantly less 
inflammation was observed in the Lc-fed group. Mice exposed to both strains of E. coli 
had the inflammation histology score comparable to PBS-fed colitic controls. Mice 
drinking water instead of DSS had no colonic inflammation regardless of the probiotic 
strain they had previously received, indicating that the administration of the probiotic 
strains had no intrinsic harmful effect on the colonic mucosa (data not shown). 
 
5.4.2 Antibody levels. 
There was a significant difference in IgA Ab content between Ec O83- and Ec Nis-DSS-
induced colitis mice and healthy colonized mice (Table 5.2). Ec Nis and Lc pretreatment 
therefore stimulated IgA Abs production in DSS colitic mice while Ec O83 stimulated 
intestinal IgA production in healthy mice.  
 No difference in specific IgM Ab production between mice with DSS-induced 
colitis and control animals was found (Table 5.2). There was a significant difference in 
specific IgG Ab production against Lc in DSS-induced colitis and healthy Lc-colonized 
mice.  
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Figure 5.1 Histopatological findings: photomicrographs of H&E-stained paraffin 
sections. 
 
A: Through a healthy sigmoid colon; well-preserved mucosal crypts; sparse focal cellular infiltration limited to 
the basal layer of tunica propria (cower center and top right); focal depletion of lymphocytes from the follicle 
(right); tunica submucosa is devoid of cellular infiltration. B: Through severely inflammated sigmoid colon in a 
mouse fed PBS before induction of DSS colitis showing edema of the submucosa and extensive 
inflammation and ulceration of the mucosal layer with subtotal destruction of the crypts and infiltrate in lamina 
propria (H&E); top right: remains of mucosal crypts with marked epithelial dysplasia; thickening of tunica 
propria with massive mixed cellular infiltration of granulocytes and mononuclear elements; purulent exudates 
in the lumen (center and top left), edema and mixed cellular infiltration of tunica submucosa (bottom); 
inflammatory grade 1.5. C: Transversal section through sigmoid colon – moderate DSS colitis in a mouse 
pretreated with probiotic Ec O83 strain showing well-preserved mucosa and normal crypts; mixed (mainly 
mononuclear) infiltration involving the deep layer of tunica propria, focally spreading to the middle and 
superficial areas (upper center); focal edema and cellular infiltration of tunica submucosa (lower center); 
inflammatory grade 1. bars correspond to 50 µm. 
Inflammation scores in colonic samples of DSS-treated mice: 
treatment score 
Ec O83 0.98 ± 0.27 
EC Nis 1.03 ± 0.24 
LC 0.86 ± 0.23 
PBS 1.23 ± 0.17 
none 0.35 ± 0.23 
 
Inflammation was maximal in mice pretreated with PBS instead of bacterial strains; administration of Lc 
significantly decreased the severity of DSS-induced inflammation (p < 0.05 vs. PBS); average measure with 
95 % CI; no differences between healthy control mice and DSS-untreated mice pretreated  with bacterial 
strains (data not shown). 
 
Table 5.1 Clinical signs of colitis (Ec O83, Ec Nis, Lc and PBS groups): 
Symptom scores, mass loss (g) and length of the colon (mm)a 
Quantity Ec O83 Ec Nis Lc PBS Hb 
Symptom score 1.44±0.33 0.85±0.54 0.65±0.32 2.2±0.18 – 
Mass loss 1.7±0.34 1.7±0.32 1.09±0.24 2.17±0.36 0.82±0.11 
Colon length 82.7±3.3 82.1±3.3 82.8± 3.7 72.1±1.4 108.0± 4.3 
aMean ± CI (n = 10); for further details see Materials and Methods.  bHealthy (control mice). 
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Table 5.2 Antibody levels: 
Specific IgA Abs in enteral content, specific IgM Abs in serum and total specific IgG Abs in serum against Ec 
O83, Ec Nis, and Lc in DSS-treated mice (first rows) and healthy mice (non-DSS mice; second rows) 
pretreated with Ec O83, Ec Nis and Lca 
Ig Ec O83 Ec Nis Lc PBS 
12.0±2.3 18.0±3.4 20.0±2.0 8.0±1.50 
IgA 
18.5±3.5 11.5±3.4 15.0±1.50 10.0±0.35 
23.5±1.57 11.5±1.55 16.0±5.6 14.5±2.3 
IgM 
25.0±2.6 12.0±2.4 21.5±4.6 12.5±0.75 
14.5±1.96 6.0±1.86 50.0±2.7 41.5±5.6 
IgG 
16.0±1.86 7.0±1.58 45.0±3.7 36.0±1.31 
aMean ± CI; for further details see Materials and Methods. 
5.5 DISCUSSION 
Probiotic microorganisms are defined as viable nutritional agents conferring benefits to 
the health of the human host (Reid et al., 2003). In human disease, the beneficial effects 
of various probiotics were demonstrated and used for the treatment of a variety of 
disorders such as infectious rotavirus-induced diarrhea in infants, amelioration of the side 
effects of antibiotic therapy and prevention of atopic disease. Comparative studies of 
probiotics trying to select proper bacterial probiotic strains useful in specific conditions 
are still scarce (Strompfova et al., 2004). Clinical trials have also suggested a potential 
role of different probiotic preparations in the treatment of inflammatory bowel disease 
(Schultz et al., 2003b). Interesting data exist for Ec Nis in the maintenance of remission 
of ulcerative colitis. Treatment with Ec Nis demonstrated beneficial effects equal to those 
of mesalazine (Rembacken et al., 1999; Kruis et al., 2004). 
 However, the mechanisms by which Ec Nis or other probiotics mediate their 
effect are not fully understood. Changes in the intestinal microflora composition 
(Tannock et al., 2000; Mego et al., 2005) and other effects including local and systemic 
immunomodulation (Mack et al., 1999; Lammers et al., 2002) or barrier enhancement 
(Madsen et al., 1999; Schultz et al., 2003a; Bujnakova et al., 2004) have been described. 
Moreover, lactic acid bacteria secrete anti-inflammatory metabolites (Menard et al., 
2004); lipoteichoic acids from Lactobacillus johnsonii strain La1 and L. acidophilus 
strain La 10 antagonize the responsiveness of human intestinal epithelial cells to 
lipopolysaccharide (Vidal et al., 2002) 
 The gnotobiotic animal model is a useful tool for evaluating the role of bacterial 
species or strains in the development of intestinal inflammation (Kozakova et al., 2001). 
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DSS-induced colitis is a well established model. Affected animals manifest body mass 
loss, bloody diarrhea, and a hunched posture, and the histological phenotypes (patchy 
mucosal damage, including focal crypt loss, followed by acute transmural infiltration with 
inflammatory cells) are similar to those of human IBD (Tsuchiya et al., 2003). The 
mechanism by which DSS induces colitis is not well defined, but seems to result from an 
alteration of colonic epithelial cells, and from an alteration of neither T nor B cell 
responses, because DSS colitis develops in SCID mice (Dieleman et al., 1994). However, 
DSS colitis also seems to be dependent on the intestinal microflora (Rath et al., 2001). 
This suggests that DSS modifies either the nature or the sampling of luminal antigens 
(Cooper et al., 1993). Antibiotics and probiotics have been used to prevent and ameliorate 
experimental colitis as well as IBD by changing the equilibrium of commensal bacteria in 
the intestinal flora (Madsen et al., 2001). 
 Our results demonstrate that manipulation of intestinal microflora could affect 
DSS-induced intestinal inflammation. Ec O83, Ec Nis and Lc caused amelioration of the 
clinical signs of intestinal inflammation, as was demonstrated by a lower symptom score, 
healthier clinical appearance of the animals and improving in colon length. Lc-
precolonized mice had also a significantly lower mass loss at the end of the experiment 
and lower histological inflammation score in comparison with untreated mice with DSS-
induced colitis.  No differences were observed between probiotics-colonized healthy 
animals and healthy uncolonized controls (data not shown). 
 A significant difference between probiotic-colonized mice with DSS-induced 
colitis and healthy probiotic-colonized mice was found in the level of specific IgA against 
bacterial strains in enteral contents. In the Ec Nis-pretreated group, the IgA concentration 
was significantly higher in DSS mice, while an opposite situation was found in the Ec 
O83-treated group. A difference in total specific IgG in serum between DSS-colitic and 
healthy mice was found in the Lc-pretreated mice. This difference could be caused by a 
higher ability o f Lc to translocate during inflammation 
 Our data corroborate the evidence that nonpathogenic luminal bacteria participate 
in the pathogenesis of chronic intestinal inflammation. Administration of probiotic 
bacteria influencing the composition of intestinal flora may be relevant to the 
development of novel strategy in the prevention and management of IBD patients. 
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6.1 ABSTRACT 
Probiotic bacteria can be used to treat human inflammatory diseases including 
inflammatory bowel disease. However, the nature of active component and exact 
mechanisms of this activity are not yet fully elucidated. Our aim was to investigate if 
lysate of probiotic bacterium L. casei DN-114 001 (Lc) and its fractions could influence 
the development of acute dextran sodium sulfate (DSS) colitis. 
BALB/c mice received lysate orally, in four weekly doses. Seven days after last 
dose, the acute colitis was induced by 3% DSS dissolved in drinking water for one week. 
Numbers of CD4+CD25+FoxP3+ regulatory T cells (Tregs) were measured by FACS 
analysis and cytokine production in various parts of the gut was estimated by tissue 
fragment culture with subsequent ELISA. Intestinal permeability for macromolecules was 
determined in vivo using a FITC-labeled dextran method and changes in microbiota 
composition in the stool was assessed by 16S rDNA denaturing gradient gel 
electrophoresis.  
Oral treatment with Lc and its membranous fraction (mLc) significantly reduces 
the severity of acute DSS colitis and decrease intestinal permeability for macromolecules. 
Neither Lc nor mLc treatment changed the number of Tregs in Peyer’s patches, mesenteric 
lymph nodes or spleen. Oral Lc lysate decrease production of proinflammatory cytokines 
TNF-α and IFN-γ, and anti-inflammatory IL-10 in Peyer’s patches and large intestine, 
and changes the gut microbiota composition. 
 Our study provided evidence that even nonliving probiotic bacteria can alleviate 
the development of colitis by strengthening integrity of intestinal barrier and stabilization 
of gut microenvironment. 
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6.2 INTRODUCTION 
Inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, are 
severe chronic inflammatory illnesses of the gastrointestinal tract. Although their etiology 
and pathogenesis is not fully understood, it is generally accepted, that the inflammation 
results from an aberrant immune response to antigens of resident gut microbiota in 
genetically susceptible individuals (Sartor, 2006). Dysbiosis, an imbalance in the 
intestinal bacterial ecosystem, has been found in IBD and linked to its pathogenesis 
(Packey and Sartor, 2009). It has been suggested, that this microbial imbalances and an 
aberrant immune response could be restored by oral feeding with certain beneficial 
bacterial species, probiotics (Sheil et al., 2007).  
 Probiotics, defined as live microorganisms which when administered in adequate 
amounts confer a health benefit on the host (FAO/WHO, 2001), have been successfully 
used in treatment of IBD (Guslandi et al., 2000; Kruis et al., 2004; Bibiloni et al., 2005). 
Using animal models of IBD, three main mechanisms of how these beneficial microbes 
protects from intestinal inflammation have been described and single probiotic bacterium 
could possess more than one depending on its unique specific metabolic activities and 
cellular structures (Lebeer et al., 2010). First, probiotics may exclude or inhibit the 
growth of certain pathogens (Servin, 2004), second, they may improve the gut barrier 
function (Gupta et al., 2000), and third, they can modulate mucosal and/or systemic 
immune response or metabolic functions (Reiff et al., 2009). The outcome of probiotic 
therapy also depends on stage of the disease and other and overall health status of the 
patient. Despite of the generaly safety profile of the probiotic therapy, use of live 
microorganisms always bring a possibility of severe infections and represent considerable 
risk especially in severely ill patients (Cannon et al., 2005; Besselink et al., 2008). There 
is increasing evidence, that similar beneficial effects could be achieved with microbial 
components isolated from probiotics or even commensals (Verdu et al., 2000; 
Rachmilewitz et al., 2004; Okada et al., 2006; Sokol et al., 2008). 
One of the most intensively studied and used probiotic are lactobacilli (Kleerebezem and 
Vaughan, 2009). Oral treatment with probiotic bacterium L. casei DN-114 001 has been 
found to reduce the duration and severity of diarrhea and common infectious diseases in 
children (Pedone et al., 2000; Agarwal and Bhasin, 2002; Merenstein et al., 2010). These 
studies clearly shows the benefitial potential of this bacterium, however, the clinical 
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utility of such approach remains controversial, as neither the specific mechanisms of 
action nor the active component responsible for its beneficial properties has not been 
established. In our previous studies we have shown that preventive treatment with well 
known probiotic bacterium L. casei DN-114001 protects mice from subsequent acute 
DSS-induced colitis (Kokesova et al., 2006). In the present study, we investigated if the 
preventive oral treatment with sterile lysate of this bacterium has similar effect and what 
is the underlined mechanism. 
 
6.3 MATERIALS AND METHODS 
6.3.1 Preparation of bacterial lysates 
Lactobacillus casei DN-114 001 (Danone Institute, France),  Lactobacillus plantarum 
(strain 185; Microbe collection of Institute of Animal Physiology and Genetics ASCR, 
Czech Republic), were grown in anaerobic chamber in De Man, Rogosa, and Sharpe 
(MRS) broth (Oxoid, Basingstoke, UK) at 37°C until the the cultures were in the late log 
phase of growth. Both lactobacilli were harvested by centrifugation (4000 x g, 30 min) 
and washed twice with sterile phosphate-buffered saline (PBS). After disruption of the 
bacteria with the French press, part of the lysate was separated by centrifugation (8500 x 
g, 30 min) into two fractions, membranous (insoluble; mLc) and cytoplasmic (soluble; 
cLc). The lysate and its fractions were lyophilised and diluted to a working concentration 
of 30 g/l. In order to kill all remaining viable bacteria, the lysate was heated to 60°C for 
30 min and the sterility of all components was verified by both aerobic and anaerobic 
cultivation before administration. 
 
6.3.2 Animals  
Female BALB/c mice (8-12 weeks old) were obtained from a breeding colony at the 
Institute of Physiology (Academy of Sciences of the Czech Republic, Prague, Czech 
Republic) and reared under conventional conditions at the Institute of Microbiology AS 
CR. All animal experiments were approved by the Animal Care and Use Committee of 
the Institute of Microbiology AS CR. 
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6.3.3 Study design and DSS colitis 
We administered 1.5 mg of different bacterial components (whole lysate, membranous or 
cytoplasmic fraction) or 200 µg of DNA in 50 µl of sterile PBS, by gavage. To reduce 
proteolytic activity in the gut, the components were co-administered with 1 mg of 
soybean trypsin inhibitor (Sigma-Aldrich, St. Louis, MO, USA) dissolved in 50 µl of 0.15 
M sodium bicarbonate buffer (pH 8.0). Control mice were given sterile PBS with soybean 
trypsin inhibitor in bicarbonate buffer. We repeated the administration every 7 days for a 
total number of 4 doses (on days 0, 7, 14 and 21). Acute colitis was induced 7 days later 
by 3% (wt/v) dextran sulfate sodium (DSS; mol wt = 36–50 kDa; MP Biomedicals, 
Irvine, CA, USA) dissolved in tap water for 7 days, and on the last day of the experiment 
the colitis was evaluated by using a clinical activity score, colon length, and histological 
scoring system as described previously (Kverka et al., in press).  
    
6.3.4 Intestinal permeability in vivo  
We measured intestinal permeability by determining the amount of fluorescein 
isothiocyanate conjugated dextran (FITC-dextran) in blood after it was orally 
administered as described previously (Wang et al., 2001). Briefly, each mouse received 
440 mg/kg of body weight of FITC-dextran (MW 4,400; Sigma-Aldrich) by gavage. A 
blood sample, obtained 5h later, was first centrifuged (3,000 rpm at 4°C) for 30 min, and 
serum was collected and added to a 96-well microplate. The concentration of FITC-
dextran was determined by spectrophotofluorometry (Safire2, Tecan Group Ltd., 
Switzerland) with an excitation wavelength of 483 nm and an emission wavelength of 
525 nm using serially diluted samples of the marker as standard.  
   
6.3.5 Evaluation of microbiota changes with PCR-DGGE  
We collected stool samples from five mice from the PBS and Lc-treated groups on day 0, 
28 (just before DSS administration) and 35 (the last day), and isolated total DNA with ZR 
Fecal DNA KitTM (Zymo Research Corp., Orange, CA) according to the manufacturer’s 
recommendation. Bacterial 16S rRNA genes were amplified from total bacterial DNA by 
following protocol: 1 µl of DNA template, primers fD1 (AGA GTT TGA TCC TGG CTC 
AG) + rP2 (ACG GCT ACC TTG TTA CGA CTT) (each 0.5 µM final concentration), 10 
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µl of Sigma RedTaq Ready mix and sterile dH2O to final volume 20 µl. PCR program 
was as follows: initial denaturation 4 minutes at 94C, 35 cycles (94°C 1 m, 52.5°C 1m, 
72°C 2min) and final elongation 7 minutes at 72°C (Weisburg et al., 1991). PCR products 
were then purified by QIAquick PCR Purification kit (QIAGEN GmbH, Hilden, 
Germany) and used for second PCR with primers 338GC and RP534 (Muyzer et al., 
1993).  
 PCR products were separated and analyzed on the DCodeTM Universal Mutation 
Detection System (Bio-Rad Laboratories, Hercules, CA, USA). The denaturating gradient 
was 35 – 60% and the electrophoresis was carried out for 18 h at 55 V. The gel was 
stained in SYBR Green I (Invitrogen)dye for 30 minutes and observed in digital imaging 
system (Vilber Lourmat, Marne la Vallee, France) under UV light. Banding patterns were 
converted to a binary matrix, taking into account the presence or absence of the individual 
bands. This binary matrix was used to calculate the distance matrix between individual 
samples (Nei and Li, 1979) using FreeTree software FreeTree (Pavlicek et al., 1999). This 
distance matrix was then used to calculate the similarity between the DGGE profiles from 
the same mouse at different time points using the Dice's similarity coefficient (DSC 
=[2j/(a+b)] x 100), where j is the number of DGGE bands found in both profiles, a is the 
number of bands at first time point, and b is the number of bands at the second time point. 
A DSC value of 100% indicates that the samples are identical.  
 
6.3.6 Gut tissue culture and measurement of cytokines  
We took sections of the distinct parts of the intestine from every mouse (Peyer’s patches, 
jejunum, ileum, caecum and colon). The intestines were then cut open longitudinally, 
washed in ice cold PBS containing antibiotics and cultivated for 48 hours at 37°C and 5% 
CO2 in complete RPMI medium with 10%  fetal bovine serum (Biochrom AG, Berlin, 
Germany) and 100,000 U/l penicillin, 100 mg/l streptomycin (Sigma-Aldrich), as 
described previously (Kverka et al., in press).  We then used commercially available 
ELISA sets to measure the levels of TNF-α, IFN-γ, TGF-β, IL-10 (Invitrogen Corp.) and 
IL-6 (R&D Systems Inc., Minneapolis, MN, USA) in these supernatants. All tests were 
performed according to the manufacturers’ recommendations. 
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6.3.7 Determination of specific antibodies  
We collected sera and small intestine (gut) washings for specific antibody evaluation. Gut 
washings were obtained by flushing the content of prepared small intestine with 2 ml of 
sterile PBS containing a mixture of proteinase inhibitors (Sigma-Aldrich). The samples 
were then vortexed and centrifuged at 4°C, and the supernatant was collected and stored 
at -80°C until analysis. To assess specific antibody response against Lc lysate in serum 
(IgG, IgM and IgA) and gut washings (secretory IgA; SIgA), we used indirect ELISA, 
optimized in our laboratory as previously described (Kverka et al., in press). Briefly, 
Nunc MaxiSorp 96-well plates (Thermo Fisher Scientific Inc., Rochester, NY, USA) 
coated overnight with Lc (100 µl/well at 10 mg/l in PBS) and blocked with 1% bovine 
serum albumin (BSA; Sigma-Aldrich) in PBS were incubated for 2 h with 1:50 serum 
samples or 1:10 gut washing samples, both diluted in 1% BSA. After washing (three 
times with PBS containing 0.05% Tween 20 (Sigma-Aldrich)), secondary antibodies (50 
µl/well) were added and incubated for 1 h at room temperature. We used 1:2000 rabbit 
anti-mouse secretory IgA (SIgA) (Uscn Life Science Inc., China), 1:2000 horseradish 
peroxidase (HRP)-labeled anti-mouse IgG (The Binding Site Ltd, Birmingham, UK), 
1:500 HRP-labeled anti-mouse IgM (The Binding Site Ltd) all three diluted in 1% BSA, 
or biotinylated anti-mouse IgA (Sigma-Aldrich) diluted 1:2000 in 1% BSA and 5% fetal 
bovine serum (BioClot GmbH, Aidenbach, Germany). After a washing step, we added 50 
µl/well of streptavidin-HRP (R&D Systems Inc.) diluted 1:200 in 1% BSA into the IgA 
plate or 1:500 in 1% BSA HPR-labeled anti-rabbit IgG (Cell Signaling Technology Inc., 
Danvers, MA, USA) into SIgA plate. The plates were developed with 3,3',5,5'-
tetramethylbenzidine (TMB; Sigma-Aldrich) and the optical density (OD) was measured 
at 450 nm. The OD of the background (1% BSA) was subtracted and resulting adjusted 
ODs of the treated groups were compared with those of PBS-treated groups. 
 
6.3.8 Flow cytometry  
We prepared single-cell suspensions of spleens, mesenteric lymph nodes and Peyer’s 
patches and stained them for regulatory T cells (Tregs) using FoxP3 Staining Buffer Set 
(eBioscience , San Diego, CA, USA) with fluorochrome labeled anti-mouse mAbs: CD4-
Qdot® 605 (Invitrogen, Carlsbad, CA, USA), CD8-BD HorizonTM V500 (BD 
Biosciences, San Jose, CA, 
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USA), CD3-FITC and FoxP3-Phycoerythrin (both from eBioscience) according to the 
manufacturer’s recommendation. Flow cytometric analysis was performed on LSRII (BD 
Biosciences), and data were analyzed using FlowJo software (Tree Star Inc., Ashland, 
OR, USA). 
   
6.3.9 Anti-inflammatory properties of Lc in vitro 
To test the anti-inflammatory effect of selected bacterial components, we cultured the 
LPS-activated macrophage cell line (RAW 264.7; ATCC TIB-71) in the presence of 
different concentrations of bacterial lysate, as previously described (Kverka et al., in 
press). The cells were then cultured for 24h (37°C and 5% CO2) in Dulbecco´s modified 
Eagle´s medium (Institute of Molecular Genetics AS CR, Prague, Czech Republic) 
containing 10% heat-inactivated fetal bovine serum (Biochrom AG), 4.5 g/l glucose, 1.5 
g/l sodium bicarbonate, 4 mM glutamine (Institute of Molecular Genetics AS CR)., 
100,000 U/l penicillin a100 mg/l streptomycin (Sigma-Aldrich). The cells were cultured 
together with Lc, L. plantarum (Lp) or sterile PBS in the presence or absence of LPS 
(Salmonella typhimurium, 1 mg/l, Sigma-Aldrich). After the cultivation, we measured the 
concentration of TNF-α in the supernatant with ELISA (Invitrogen). The nuclear proteins 
were extracted from stimulated RAW264.7 cells by a nuclear extract kit (Active Motif, 
Rixensart, Belgium) and used to quantify the DNA binding activity of p65 subunit using a 
TransAM NF-κB family transcription factor assay kit (Active Motif). In this experiment, 
we used only the concentrations of bacterial components with the strongest 
immunomodulatory properties, i.e. 10 pg/l of Lc and 100 pg/l mLc. All assays were 
performed according to the manufacturer’s recommendation. 
 
6.3.10 Statistical analysis  
One-way analysis of variance (ANOVA) with Dunnett's multiple comparison test was 
used to compare multiple experimental groups with the control group. Differences 
between two groups were evaluated using an unpaired two-tailed Student’s t-test. The 
data is presented as the mean ± standard deviation (SD) and differences were considered 
statistically significant at P ≤ 0.05. GraphPad Prism statistical software (version 5.0, 
GraphPad Software, Inc. La Jolla, CA, USA) was used for analyses.  
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6.4 RESULTS 
6.4.1 Components of L. casei attenuate acute colitis in BALB/c 
mice    
In our previous study. we showed that oral treatment with probiotics attenuates the 
severity of acute experimental colitis (Kokesova et al., 2006). To test if the lifeless 
bacterial have similar activity, we pretreated mice with four weekly oral doses of lysate or 
component from Lc and induced the colitis by DSS. We report here, that oral 
administration of either Lc or mLc, is effective in preventing acute DSS colitis in 
BALB/c mice, improving clinical and morphological markers of colitis (Table 6.1), the 
former being slightly superior to the latter. Oral cLc had only minor protective effect, 
improving only disease activity index (Table 6.1).  
 
Table 6.1 Pretreatment with Lc and mLc significantly improves the severity of DSS-
induced colitis. 
Experimental group  Colon length (cm)  Disease activity index  Histological grade  
DSS/PBS  6.35 ± 0.62  2.80 ± 0.68  1.59 ± 0.54  
DSS/Lc 7.14 ± 0.34***  1.67 ± 1.09**  1.20 ± 0.51*  
DSS/mLc  6.82 ± 0.38**  2.15 ± 0.84  1.15 ± 0.41*  
DSS/cLc 6.63 ± 0.51  1.97 ± 0.93*  1.54 ± 0.54  
Values are expressed as means ± standard deviations (20 mice per group) of one representative experiment 
out of three independent experiments. One-way ANOVA with Dunnett's multiple comparison test was used to 
evaluate the significance of differences between experimental groups and the PBS-treated control group 
(*P<0.05, **P<0.01, ***P<0.001). 
 
6.4.2 Components of L. casei prevents increase in intestinal 
permeability in acute colitis 
Increased intestinal permeability caused by impairment in gut barrier function drives the 
pathogenesis of intestinal inflammation in both DSS-induced colitis and human IBD 
(Munkholm et al., 1994; Kitajima et al., 1999). To investigate the effect of Lc and mLc 
on gut barrier function in acute DSS-induced colitis, we administered single dose of 
FITC–dextran by gavage and measure the intensity of fluorescence in the mouse serum 
5h later. Oral pretreatment with Lc or mLc significantly decreased the intestinal 
permeability to macromolecules at the last day of DSS (day 35) to the same extent as 
found in healthy mice (Figure 6.1). 
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Figure 6.1 Oral treatment with DSS/Lc or DSS/mLc strengthen the gut barrier 
function as compared to DSS/PBS control mice. 
 
One-way ANOVA with Dunnett's multiple comparison test was used to evaluate the significance of 
differences between experimental groups and the DSS/PBS-treated control group (*P < 0.05, **P < 0.01). 
Data represent means (bar) ± standard deviations (whisker) of five mice of one representative experiment 
out of two independent experiments. 
 
6.4.3 Oral treatment with Lc changes the gut microbial ecology 
To specify the impact of oral treatment with Lc on the intestinal microbiota, we collected 
feces before the treatment (day 0), before colitis induction (day 28), and at the end of the 
experiment (day 35). We found that oral treatment with Lc induced significant changes in 
intestinal microbial ecology (Figure 6.2). Marked changes in microbiota composition of 
similar magnitude were observed during DSS administration in both Lc-treated and PBS-
treated control group.  
 
6.4.4 Oral administration of Lc changes the immune response 
of gut mucosa 
The changes in cytokine microenvironment in gut mucosa can change the mucosal 
immune response to luminal antigens leading to the decrease in intestinal inflammation. 
We, therefore, investigated whether the protective effect of Lc lysates is associated with 
modifications in inflammatory response in the key compartments of the gut. So, we 
cultivated five distinct parts of the gut from either DSS/PBS- or DSS/Lc-treated mice for 
48h and then measure the cytokines in the supernatants by ELISA. We found that 
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pretreatment with DSS/Lc decreases the production of pro-inflammatory cytokines (IL-6, 
IFN-γ) and anti-inflammatory cytokine IL-10 in Peyer's patches, cecum and colon as 
compared with DSS/PBS treated mice (Table 6.2). 
 
Figure 6.2 Oral treatment with Lc changes the intestinal microbiota composition. 
(A) Example of fecal microbiota changes of one PBS and one Lc-treated mouse before the treatment (Day 
0), before colitis induction (Day 28) and at the end of the experiment (Day 35) as measured by 16S rRNA 
gene PCR-DGGE. (B) Comparison of changes in DGGE profiles between PBS and Lc-treated mice at 
different time points. The data are expressed as mean (bar) and SD (whisker) and the differences between 
PBS- and Lc-treated mice was calculated by unpaired Student’s t-test (***P < 0.001; n = 5 per group). 
 
Table 6.2 Pretreatment with Lc changes cytokine production (pg/mg of tissue) in 
different parts of the gut as measured by ELISA. 
Cytokine concentration (pg/mg of tissue)  
Group  Part of the gut  
IL-10  TNF-α  IL-6  TGF-β  IFN-γ  
Peyer's patches  13.7 ± 7.5  3.1 ± 4.4  17.3 ± 7.8  8.6 ± 6.3  10.3 ± 9.7  
jejunum  2.4  ±  2.4  0.3 ± 0.5  0.2 ± 0.2  0.7 ± 0.8  1.27 ± 1.8  
ileum  6.4 ± 3.7  1.7 ± 2.5  1.5 ± 1.3  2.1 ± 1.3  2.3 ± 3.0  
cecum  6.9 ± 5.7  1.5 ± 0.8  4.8 ± 3.1  1.3 ± 1.5  3.5 ± 3.1  
Control 
(DSS/PBS)  
colon  3.8 ± 3.0  2.5 ± 2.1  12.3 ± 14.2  1.0 ± 1.3  3.5 ± 2.0  
Peyer's patches  4.3 ± 2.7*  2.5 ± 2.8  1.7 ± 1.7*  5.6 ± 5.9  2.8 ± 4.0*  
jejunum  1.9 ± 1.1  0.8 ± 0.8  2.9 ± 3.7  0.9 ± 0.7  1.0 ± 2.0  
ileum  3.3 ± 3.4  2.4 ± 3.6  4.7 ± 5.8  2.4 ± 3.9  1.7 ± 2.6  
cecum  2.8 ± 1.2*  1.9 ± 1.0  5.0 ± 3.3  1.2 ± 1.1  1.1 ± 1.0*  
Treated 
(DSS/Lc)  
colon  2.3 ± 3.0  2.5 ± 1.5  5.1 ± 4.8*  1.4 ± 1.8  1.5 ± 1.4*  
*P < 0.05 between DSS/PBS- and DSS/Lc-treated mice in the same part of the gut was compared by 
unpaired Student’s t-test (n = 5 per group). 
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6.4.5 Oral administration of Lc does not change the specific 
antibody response in serum or in gut washings. 
Oral administration of microbial antigens can change the local and systemic antibody 
production. To examine the effect of oral Lc on humoral immune responses, we measured 
levels of Lc-specific antibodies of IgA, IgG and IgM isotype in serum and specific 
secretory IgA in gut washings. We found that oral treatment with Lc does not change 
serum titers of anti-Lc antibodies; as compared with PBS-treated control group (Table 
6.3). The levels of Lc-specific SIgA were generally around the detection limit of ELISA 
without any significant differences between DSS/PBS- and DSS/Lc-treated group.  
 
Table 6.3 Treatment with Lc did not induce specific antibody response in serum and 
gut washings. 
Isotypea  DSS/PBS  DSS/Lc Reference serumb  
IgA  0.07 ± 0.06 0.05 ± 0.06 0.05 ± 0.01  
IgG  0.01 ± 0.02  0.01 ± 0.02  0.01 ± 0.00  
IgM  0.16 ± 0.06  0.17 ± 0.05  0.06 ± 0.01  
SIgA 0.01 ± 0.01  0.02 ± 0.02  not done 
Values are means ± standard deviations of OD. There were no significantly significant differences between 
antibody titers in DSS/PBS and DSS/Lc-treated mice as compared by Student’s t-test (n=10 per group). 
aSecretory IgA (SIgA) measured in enteral washings and other isotypes in serum. bNormal Reference Serum 
was purchased from Bethyl Laboratories. 
 
6.4.6 Neither Lc nor mLc increased number of regulatory T 
cells  
Since the intestinal inflammation in acute DSS-induced colitis is triggered by microbial 
antigens (Hudcovic et al., 2001), the induction of oral tolerance to microbiota could be 
the potential mechanism of protective effect of Lc. The oral tolerance is maintained at the 
periphery by regulatory T cells, so we analyzed the changes in CD4+FoxP3+ Tregs in 
spleen, mesenteric lymph nodes or Peyer's patches of DSS/PBS, DSS/Lc and DSS/mLc 
treated mice. We did not find any statistically significant changes between these groups in 
any compartment we tested (Figure 6.3).  
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Figure 6.3 Oral treatment with Lc or mLc does not change the number of 
CD4+FoxP3+ regulatory T cells in spleen (SPL), mesenteric lymph nodes (MLN) or 
Peyer’s patches (PP) as analysed by flow cytometry. 
 
The plots shows the expression of CD4 versus FoxP3 on gated Th cells (CD3+CD8-), and the values within 
the plots represent the mean ± standard deviation of the total numbers of CD4+FoxP3+ T-cells from one 
representative experiment out of two independent experiments (3-5 mice per group). The numbers of  
CD4+FoxP3+ cells between DSS/Lc, DSS/mLc, or DSS/PBS group are not statistically significantly different 
in any organ as calculated by one-way ANOVA with Dunnett's multiple comparison test. 
 
6.4.7 Lysate of L. casei, but not L. plantarum, decreases the 
production of TNF-α in LPS activated macrophages in 
vitro. 
Because probiotics have an immunomodulatory effect on cells of innate immunity (Mileti 
et al., 2009) and because the macrophages play role in pathogenesis of DSS-induced 
colitis (Okayasu et al., 1990), we analyzed the anti-inflammatory effect of Lc in LPS-
activated macrophages in vitro. We found that doses below 100pg/l significantly 
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decreases the production of production of TNF-α by LPS-stimulated RAW 264,7 cells in 
vitro, while similarly prepared lysate of L. plantarum (Lp) did not (Figure 6.4A). 
Treatment with either bacterial lysate in the absence of LPS did not change the TNF-α 
production (data not shown).  
This suggests that Lc could interfere with the intracellular proinflammatory signaling 
cascade leading to activation of NF-κB transcription factor. To test this hypothesis, we 
isolated the nuclear extract from the untreated RAW 264.7 cells or from cells treated with 
either LPS (1 mg/l), or LPS with either Lc or mLc and measured the activity of the NF-
κB signaling pathway. Both Lc and mLc significantly decreased the NF-κB/DNA binding 
activity of p65 subunit as compared to the LPS-only treated cells (Figure 6.4B). 
   
Figure 6.4 The lysate of Lc have anti-inflammatory effect on LPS-activated 
macrophage cell line RAW 264.7 in vitro. 
 
 
(A) Lc decreases the production of TNF-α in LPS-activated macrophages while lysate of the L. plantarum 
does not. TNF-α production when cells are stimulated 1 mg/l of LPS is set as 100% and data are means ± 
standard deviation of three independent experiments. *P<0.05: the means were compared against a 
hypothetical mean of 100% by one sample t-test. (B) The effect of Lc components on NF-κB binding activity 
in LPS-stimulated RAW 264.7 cells. Lc and mLc were co-cultured with LPS-activated cells for 24 hours, and 
then the binding activity of NF-κB subunit p65 was analyzed by colorimetric assay. Lc and mLc lysate 
downregulate the activation of NF-κB subunit p65 as compared to LPS only activated RAW 264.7 cells. Data 
are mean ± standard deviation of three independent experiments. One-way ANOVA with Dunnett's multiple 
comparison test was used to evaluate the significance of differences between experimental groups and the 
LPS-treated cells group (***P<0.001). 
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6.5 DISCUSSION 
Oral treatment with probiotic bacteria has recently emerged as a potentially useful 
therapeutic strategy for human IBD (Kruis et al., 2004; Bibiloni et al., 2005). However, 
the clinical utility of such approach remains controversial, as the link between specific 
mechanisms of action and therapeutic effects of specific bacterium has been difficult to 
establish. We have previously shown that repeated oral administration of probiotic 
bacterium L. casei DN-114 001 protects mice from severe forms of acute intestinal 
inflammation. In this study we showed that not only live probiotics, but also the lifeless 
lysate of L. casei DN-114 001 (Lc) and its membranous fraction (mLc) can protect mice 
from severe forms of DSS-induced inflammation. This therapy significantly changes the 
gut microbiota composition, the immune response of gut mucosa, and strengthens the gut 
barrier function. 
Several studies showed that there is marked difference in microbiota composition 
in IBD patients compared to healthy individuals. This dysbiosis or increase in some 
bacterial group is proposed to cause or at least perpetuate the intestinal inflammation in 
IBD (Seksik et al., 2003; Sokol et al., 2006). Here, we report that oral treatment with Lc 
significantly changes the composition of gut microbiota. Similar effects have been 
already described as mechanisms how probiotics protects from intestinal inflammation 
(Tannock et al., 2000; Schultz et al., 2003; Ukena et al., 2007). Some of them are 
attributed to the fact, that probiotics can grow and colonize the gut, which could not be 
achieved with the bacterial lysate. Moreover, bacterial lysates are not probably present in 
the gut during the intestinal inflammation induction. The clear protective effect of 
bacterial lysates in intestinal inflammation is, therefore, rather indirect by shaping the gut 
microbial community or influencing the immune response. Nevertheless, similar 
mechanisms as in live bacteria could be employed to explain this effectivity. Probiotics 
(or certain bacteria in general) can produce substances with antibiotic properties, such as 
bacteriocins, and molecules capable to signal to other members of the ecosystem to adjust 
their growth (quorum sensing modifiers), as recently reviewed (Boyer and Wisniewski-
Dye, 2009). These molecules could be presented in the bacterial lysates and, quite 
selectively, modify the bacterial populations as showed by others (Jamuna and 
Jeevaratnam, 2004). Moreover, certain probiotics can induce long-term production of 
anti-microbial peptides in vivo, which can shape the gut microbiota composition long 
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time after the probiotic therapy has ended (Mondel et al., 2009). Both these mechanisms 
could explain the changes in bacterial populations during therapy we observed during the 
treatment with Lc. More favorable gut microbiota composition at the beginning of 
inflammation induction could then slow down the subsequent inflammatory response. We 
are currently trying to describe these microbiota changes in more details by high-
throughput sequencing of the whole gut microbiota populations. It is important to note, 
that we observed significant changes in the gut microbiota composition in both PBS and 
Lc-treated group during colitis induction. Although the changes were of similar 
magnitude in both groups, the banding pattern was different, suggesting that the actual 
differences in microbiota composition were unique for each group. These differences 
could be, however, also caused indirectly, by decreased inflammation in Lc-treated mice 
caused by different mechanism.  
Intestinal barrier prevents viable enteric bacteria and other antigens from 
excessive interaction with the immune system. The disruption of gut barrier function has 
been identified as one of the crucial steps in IBD pathogenesis, causing this excessive 
interaction during the initial phases of the IBD (Munkholm et al., 1994). Protection of the 
gut barrier from disruption by induction of changes in expression and distribution of tight 
junction proteins was proposed as a key mechanism of probiotic function (Ukena et al., 
2007; Chen et al., 2010). Here we report that oral treatment with Lc or mLc significantly 
strengthen the gut barrier function during acute DSS inflammation. Elucidation of this 
mechanism on the molecular level is a subject of our ongoing studies  
Induction of oral tolerance is crucial for keeping the homeostasis in the gut. This 
mechanism is mediated on the periphery mainly by regulatory T cells (Tregs) whose 
protective role in intestinal inflammation has been clearly established (Singh et al., 2001). 
Although the co-administration of live L. casei with collagen can potentiate the oral 
tolerance and led to increase in Tregs in collagen induced arthritis model, oral treatment 
with live L. casei alone cannot (So et al., 2008; Chiba et al., 2010). Since oral tolerance is 
easier to achieve with killed or inactivated mirobes rather than live ones (Rubin et al., 
1981), we decided to measure the changes in Treg numbers after the treatment with Lc. We 
did not find any differences in Treg numbers neither in spleen, mesenteric lymph nodes, or 
Peyer’s patches of the mLc- or Lc-treated mice as compared to controls. This would 
suggest that the stimulation of oral tolerance does not play significant role in Lc-induced 
protective effect, we observed in vivo. We observed, however, tendency for redeployment 
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of Tregs from spleen to MLN in treated mice. This finding needs to be verified on larger 
groups of mice.  
 The cytokines produced in the gut mucosa microenvironment greatly influences 
the direction of the immune response. Production of the anti-inflammatory cytokines 
induces the mucosal unresponsiveness and tolerance and high levels of proinflammatory 
cytokines induce protective immune response and inflammation (MacDonald et al., 
2000). Here, we report that Lc treatment decrease the production of proinflammatory 
cytokines IL-6 and IFN-γ as well as anti-inflammatory cytokine IL-10 in both PP and 
large intestine. This suggests that Lc can influence both the induction and effector 
functions of mucosal immune system. Decrease in IL-10 in DSS/Lc-treated mice could be 
simply secondary to decreased “need“ of the inflammation control as compared to clearly 
more diseased control mice. Interestingly, since IFN-γ has been shown to increase the gut 
permeability (Madara and Stafford, 1989), decrease in its local production can lead be 
responsible for strengthening of gut barrier function we found in Lc-treated mice. On the 
other hand, lower stimulation of cells in lamina propria by luminal bacterial antigens 
caused by gut barrier failure may lead to decrease in inflammatory response to luminal 
antigens. This is with agreement with findings that live L. casei can downregulate the 
proinflammatory mediators in the lamina propria of inflamed mucosa from Crohn’s 
disease patients during ex vivo cultivation (Carol et al., 2006; Llopis et al., 2009). 
 Acute DSS colitis is believed to be driven initially by innate immunity 
mechanisms and, in particular, the role of macrophages has been suggested (Okayasu et 
al., 1990; Dieleman et al., 1994; Murano et al., 2000; Hudcovic et al., 2001). We 
therefore tested the ability of bacterial lysates to decrease the inflammatory response of 
LPS-activated macrophages in vitro. We found that Lc, but not Lp, decrease the 
production of TNF-α, and the activation of NF-κB cascade, suggesting a possible direct 
effect of these lysates on the cells of innate immunity. This mechanism may contribute to 
the attenuation of acute DSS injury observed in vivo.  
In conclusion, our data provide evidence that even lifeless components of 
probiotic bacterium can protect from induction of intestinal inflammation, thus confer a 
health benefit for the host. This is achieved by mechanisms that comprise a) correcting 
the dysbiosis, b) modulation of the mucosal immune response and c) improving the gut 
barrier function. These immunomodulatory lysates may lead to the development of new 
therapeutic approaches for treatment of chronic intestinal inflammation. Moreover, oral 
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administration of sterile bacterial components, in contrast to live bacteria, may be safer in 
severely ill or immunocompromised patients.  
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7.1 ABSTRACT 
Commensal bacteria have been shown to modulate the host mucosal immune system. 
Here, we report that oral treatment of BALB/c mice with components from the 
commensal, Parabacteroides distasonis, significantly reduces the severity of intestinal 
inflammation in murine models of acute and chronic colitis induced by dextran sulphate 
sodium (DSS). The membranous fraction of P. distasonis (mPd) prevented DSS-induced 
increases in several proinflammatory cytokines, increased mPd-specific serum antibodies 
and stabilized the intestinal microbial ecology. The anti-colitic effect of oral mPd was not 
observed in severe combined immunodeficient mice and probably involved induction of 
specific antibody responses and stabilization of the intestinal microbiota. Our results 
suggest that specific bacterial components derived from the commensal bacterium, P. 
distasonis, may be useful in the development of new therapeutic strategies for chronic 
inflammatory disorders such as inflammatory bowel disease. 
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7.2 INTRODUCTION 
The current hypothesis for the pathogenesis of Crohn’s disease and ulcerative colitis, the 
two main forms of inflammatory bowel disease (IBD), involves an aberrant host 
immune response to luminal antigens. Although the precise cause of IBD remains 
unclear, the pathogenic mechanisms are multi-factorial and additional factors such as 
increased virulence of commensal bacterial species, disruption of the intestinal mucosal 
barrier and genetic susceptibility have been proposed (Sartor, 2008). 
Three lines of evidence suggest a crucial role of the intestinal microbiota in IBD 
pathogenesis. First, lesions in IBD predominate in areas of highest bacterial exposure 
(Seksik et al., 2006). Secondly, manipulation of luminal content using selective 
antibiotics, or fecal stream diversion, improves inflammation in IBD patients (Rutgeerts 
et al., 1991; Prantera and Scribano, 2009). Thirdly, in some models of IBD intestinal 
inflammation is attenuated, or fails to develop, if the animals are maintained under germ-
free conditions  (Sadlack et al., 1993; Taurog et al., 1994; Rath et al., 1996; Hudcovic et 
al., 2001; Stepankova et al., 2007). It remains to be determined whether IBD can be 
triggered by the presence of a disbalanced microbiota composition with enhanced 
proinflammatory capacity. Interestingly, the intestinal microbiota is altered (dysbiosis) in 
a proportion of patients with IBD, and fecal samples from patients with Crohn’s disease 
exhibit greater temporal instability (Seksik et al., 2003) and decreased number of 
commensal bacteria with reduction in the Firmicutes phylum (Scanlan et al., 2006). 
The current treatment of IBD targets the effector phase of the intestinal inflammatory 
response. In a proportion of patients, however, the disease is refractory to conventional 
medical treatment, or the effectiveness of the treatment is limited by serious side effects 
(Van Assche et al., 2006). Probiotics are commensal bacteria with proven health 
beneficial effects. Thus, several probiotic candidates have been evaluated as an alternate 
and safe treatment option for IBD (Mahida and Rolfe, 2004). Some randomized, 
placebo-controlled studies, using Escherichia coli Nissle 1917 and a combination of eight 
probiotic strains, have demonstrated a beneficial effect in IBD (Kruis et al., 2004; 
Mimura et al., 2004; Bibiloni et al., 2005). However, others have failed to demonstrate 
significant therapeutic benefit and therefore the overall efficacy of probiotics in active 
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chronic inflammatory conditions of the gut remains a matter of controversy (Seksik et al., 
2008). More importantly, mechanistic insight linked to a specific potential probiotic strain 
has been difficult to establish. Growing evidence indicates that experimental colitis can 
be mitigated not only with oral administration of live probiotic bacteria, but with bacterial 
components and by-products of bacteria as well (Obermeier et al., 2003; Rachmilewitz et 
al., 2004; Kokesova et al., 2006). Our previous results suggest that orally administered 
lysates from anaerobic microbiota decrease the severity of experimental colitis (Verdu et 
al., 2000). The aim of this study was to test the effect of oral administration of 
components of a specific anaerobic strain on experimental colitis, and determine the 
underlying mechanisms.  
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7.3 MATERIALS AND METHODS 
7.3.1 Mice  
Female BALB/c mice (6–8 weeks old) or female severe combined immunodeficient 
(SCID) mice BALB/cJHanHsd-SCID were obtained from a breeding colony at the 
Institute of Physiology (Academy of Sciences of the Czech Republic, Prague, Czech 
Republic) or at the Institute of Microbiology (Academy of Sciences of the Czech 
Republic, Novy Hradek, Czech Republic), respectively. Flow cytometry was used to 
exclude SCID mice that had detectable T cells. Mice were reared under conventional 
conditions at the Institute of Microbiology. The studies were approved by the Animal 
Care and Use Committee of the Institute of Microbiology.  
 
7.3.2 Identification of candidate anaerobic bacteria and 
preparation of bacterial components 
Anaerobic bacteria from mouse intestinal microbiota were grown at 37°C in liquid 
medium (see Supplementary materials and methods), separated into monocultures, lysed 
in a French press and tested for anti-inflammatory activity in an acute colitis model. To 
identify single candidate anaerobic strains for subsequent experiments, groups of mice (n 
= 5–10/group) were orally treated with isolates of anaerobic bacteria lysates 
(Parabacteroides distasonis, Bacteroides thetaiotamicron, Veillonella alcalescens, B. 
ovatus, B. vulgatus and B. stercoris; see supplementary data). Their individual 
effect on the prevention of acute dextran sulphate sodium (DSS) colitis was evaluated 
(see Supplementary Tables S7.4 and S7.5). Because only the crude lysate of P. distasonis 
significantly improved clinical parameters of acute DSS colitis, all 
subsequent experiments in the study were performed using this isolate and its 
components.After cell disruption with the French press, the lysate was separated by 
centrifugation into two fractions, membranous (insoluble) and cytoplasmic 
(soluble). Lipopolysaccharides (LPS) and DNA from P. distasonis were isolated as 
described previously (Westphal et al., 1952; Ali et al., 2005).  
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7.3.3 Evaluation of anti-inflammatory effects of mPd on 
macrophages in vitro    
Because macrophages have been proposed to play a role in acute intestinal inflammation 
(Okayasu et al., 1990; Murano et al., 2000), we tested the antiinflammatory effect of 
bacterial components on the LPS-activated macrophage cell line, RAW 264·7.We 
cultured the cells in the presence of LPS and different concentrations of P. distasonis 
lysate or its components (see Supplementary materials and methods) and measured 
tumour necrosis factor (TNF)-α in supernatants by enzyme-linked immunosorbent assay 
(ELISA). 
 
7.3.4 Induction and evaluation of acute and chronic colitis 
Acute colitis was induced by 3% (wt/vol) DSS (mol wt = 36–50 kDa; MP Biomedicals, 
Irvine, CA, USA) dissolved in drinking water for 7 days ad libitum. For chronic colitis, 
mice received four cycles of DSS as described previously (Okayasu et al., 1990). Each 
cycle consisted of 3% DSS in drinking water for 7 days, followed by a 7-day interval with 
normal drinking water. Colitis was evaluated on the last day of the experiment using 
a disease activity index (DAI) described by Cooper et al. (Cooper et al., 1993), a 
histological scoring system (see Supplementary materials and methods), and by 
measuring colon length. The level of acute-phase protein haptoglobin was determined in 
mouse serum using the modified human haptoglobin ELISA quantitation kit (GenWay 
Biotech, Inc., San Diego, CA, USA) (see Supplementary materials and methods). Water 
consumption was measured during DSS administration. 
 
7.3.5 Overall study design  
To test whether bacterial components of P. distasonis prevent acute DSS colitis, we 
administered 1.5 mg of whole lysate, LPS, membranous or cytoplasmic fraction or 200 µg 
of DNA in 50 µl of sterile phosphate-buffered saline (PBS) to mice by gavage. To reduce 
proteolytic activity in the gut, the components were co-administered with 1 mg of 
soybean trypsin inhibitor (Sigma-Aldrich, St Louis, MO, USA) dissolved in 50 µl of 0.15 
m sodium bicarbonate buffer (pH 8.0). Control mice were given sterile PBS with soybean 
trypsin inhibitor in bicarbonate buffer. We repeated the administration every 7 
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days for a total of four doses (on days 0, 7, 14 and 21). Seven days after the last dose we 
induced acute DSS colitis, as explained above. 
To determine whether a gut-dependent pathway is necessary for bacterial 
components to modulate acute colitis, additional mice were treated by four intraperitoneal 
(i.p.) or subcutaneous (s.c.) injections with mPd before acute colitis induction [5 mg of 
mPd or PBS, together with incomplete Freund’s adjuvant (Difco Laboratories, Detroit, 
MI, USA)]. The dose of mPd was chosen based on preliminary experiments 
that determined an optimal antibody response when doses of 2.5 to 1500 µg were used. 
To investigate mechanisms underlying the anti-colitic effect of mPd, serum 
transfer experiments from orally treated mice to untreated mice were performed. 
Specifically, 200 µl of the serum from either PBS or mPd-treated mice were transferred 
intravenously to untreated mice before acute DSS colitis induction. 
To test the possible effect of mPd administration on established and chronic colitis, we 
administered 21 doses (as described above) of mPd by daily gavage once chronic DSS 
colitis had been induced, starting after the third cycle of DSS.  
 
7.3.6 Assessment of P. distasonis antibodies by ELISA 
We used indirect ELISA assay, optimized in our laboratory, to compare serum antibody 
[immunoglobulin (Ig)G, IgM and IgA] titres against P. distasonis lysate between PBS and 
mPd-treated groups (see Supplementary materials and methods).  
 
7.3.7 Gut tissue culture and measurement of cytokines 
Five sections of the intestine were obtained (Peyer’s patches, jejunum, ileum, caecum and 
colon), and cultivated for 48 h in complete RPMI-1640 media (see Supplementary 
materials and methods). The supernatants were collected and frozen at -20°C until 
analysis for cytokine production. To evaluate changes in cytokine levels induced by DSS 
treatment and mPd therapy in the colon, we used the RayBioTM Mouse Cytokine Array II 
(Raybiotech, Inc., Norcross, GA, USA) capable of detecting 32 cytokines, chemokines 
and growth factors (see Supplementary materials and methods; Table S7.2). We also used 
commercial ELISA kits to measure the concentrations of selected cytokines [interleukin 
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(IL)-10, TNF-α, transforming growth factor (TGF)-β, IL-6 and interferon (IFN)-γ] (see 
Supplementary materials and methods). 
 
7.3.8 Flow cytometry 
Single-cell suspensions of spleens, mesenteric lymph nodes and Peyer’s patches were 
prepared and stained for regulatory T cells (Tregs) using forkhead box P3 (FoxP3) staining 
buffer set (eBioscience, San Diego, CA, USA) with these fluorochrome-labelled anti-
mouse monoclonal antibodies (mAbs): CD4-Qdot® 605 (Invitrogen, Carlsbad, CA, USA; 
clone RM4-5), CD25-allophycocyanin (eBioscience; clone PC61·5) and FoxP3-
phycoerythrin (eBioscience; clone FJK-16 s) according to the manufacturer’s 
recommendations. Flow cytometric analysis was performed on LSRII (BD Biosciences, 
San Jose, CA, USA), and data were analysed using FlowJo software (Tree Star Inc., 
Ashland, OR, USA).  
 
7.3.9 Evaluation of intestinal microbiota   
We collected stool samples from five mice chosen randomly from PBS and mPd-treated 
groups on days 0, 28 (just before DSS administration) and 35 (the last day), and analysed 
the samples by polymerase chain reaction-denaturing gradient gel electrophoresis (PCR-
DGGE), as described (see Supplementary materials and methods). We used quantitative 
PCR to determine the content of all Eubacteria, Bacteroides-Prevotella group and P. 
distasonis in mouse faeces (see Supplementary materials and methods). 
 
7.3.10 Statistical analysis 
The distributions of variables were tested for normality using the D’Agostino-Pearson 
omnibus normality test. Differences in colon length,DAI, histological score, haptoglobin 
levels and TNF-α production of multiple groups were compared to the control group 
(PBS/DSS) by one-way analysis of variance with Dunnett’s multiple comparison test. 
Differences in specific antibody levels, bacteria numbers, DGGE profiles, cytokine 
production and Treg numbers between the two groups were evaluated using an unpaired 
two-tailed Student’s t-test. Serum levels of P. distasonis-specific antibodies were 
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compared to the amount of P. distasonis in the stool samples using the Pearson 
correlation coefficient (r). The values are expressed as means ± standard deviation (s.d.) 
and differences were considered statistically significant at P ≤ 0.05. GraphPad Prism 
statistical software (version 5·0; GraphPad Software, Inc., La Jolla, CA, USA) was used 
for analyses.  
 
7.4 RESULTS 
7.4.1 Anti-inflammatory properties of Parabacteroides 
distasonis in vivo and in vitro  
From the anaerobic lysates tested, only the crude lysate obtained from Parabacteroides 
distasonis, and especially its membranous fraction (mPd), was able to decrease disease 
severity significantly after induction of acute DSS colitis (Table 7.1 and Supplementary 
Table S7.4). 
 
Table 7.1 Evaluation of acute dextran sulphate sodium (DSS)-induced colitis in 
BALB/c and SCID mice orally treated with Parabacteroides distasonis components. 
Data are representative of one experiment. Similar results were obtained from three independent 
experiments. Values are expressed as means ± standard deviation from six to 10 mice per group. One-way 
analysis of variance with Dunnett’s multiple comparison test (in BALB/c mice) or unpaired Student’s t-test 
[severe combined immunodeficient (SCID) mice] were used to evaluate differences between experimental 
groups and phosphate-buffered saline (PBS)-treated controls. cPd: cytoplasmic fraction of P. distasonis 
lysate; mPd: membranous fraction of P. distasonis; LPS: lipopolysaccharide (*P < 0.05; **P < 0.01). 
 
To test whether the anti-colitic activity observed with P. distasonis lysate (Pd) and mPd 
involved innate immune cells, we treated LPS-activated RAW264·7 macrophage cells 
Mouse 
strain 
Experimental 
group 
Colon length 
(cm) 
Disease activity 
index 
Histological 
grade 
Serum 
haptoglobin (g/l) 
PBS (control) 5.97±0.46 3.13±0.74 2.05±0.58 1.49±0.64 
mPd 6.77±0.40** 1.77±0.97** 1.36±0.51* 0.38±0.35* 
cPd 5.96±0.42 3.47±0.53 2.14±0.69 0.84±0.80 
DNA 7.32±0.44** 1.57±0.61** 1.01±0.36** 0.05±0.06** 
LPS 6.70±0.36** 2.07±1.30* 1.68±0.43 0.36±0.08** 
mPd without DSS 8.97±0.40** 0.00±0.00** 0.15±0.13** 0.00±0.01** 
BALB/c 
PBS without DSS 9.26±0.41** 0.00±0.00** 0.10±0.20** 0.02±0.01** 
PBS (control) 6.20±0.55 4.00±0.00 2.69±0.49 Not done SCID 
mPd 6.13±0.63 3.89±0.17 2.58±0.46 Not done  
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with Pd or mPd in vitro. In concentrations above 10 ng/l, Pd and mPd decreased the 
production of TNF-α, suggesting that they can both directly decrease the inflammatory 
activity of RAW264.7 macrophages (Supplementary Fig. S7.5). Neither cytoplasmic 
fraction of P. distasonis lysate (cPd) nor DNA decreased TNF-α production in vitro (data 
not shown). 
 
7.4.2 Components of P. distasonis attenuate DSS colitis in 
BALB/c mice  
Both oral mPd and DNA isolated from P. distasonis were effective in preventing acute 
DSS colitis in BALB/c mice, improving clinical, serological and morphological markers 
of colitis (Table 7.1). This effect was seen only with oral administration and was not 
observed with intraperitoneal or subcutaneous administration of mPd (see Supplementary 
information; Table S7.6). In contrast to mPd and DNA treatments, oral administration of 
cPd did not have a protective effect (Table 7.1). Orally administered mPd did not prevent 
colitis in SCID mice (Table 7.1), suggesting that mechanisms of adaptive immunity are 
necessary for this effect. 
 Therapeutic administration of mPd improved colonic length and the severity of 
clinical scores, but did not affect histological scores (Table 7.2).  
 
Table 7.2 Evaluation of chronic dextran sulphate sodium (DSS)-induced colitis in 
BALB/c mice orally treated with Parabacteroides distasonis components. 
Data are representative of one experiment. Similar results were obtained from two independent experiments. 
Values are expressed as means ± standard deviation (10 mice per group). One-way analysis of variance with 
Dunnett’s multiple comparison test was used to evaluate differences between experimental groups and 
phosphate-buffered saline (PBS)-treated controls (*P < 0.05; **P < 0.01). mPd: membranous fraction of P. 
distasonis; cPd: cytoplasmic fraction of P. distasonis lysate; LPS: lipopolysaccharide. 
 
Experimental 
group Colon length (cm)  
Disease activity 
index Histological grade 
Serum 
haptoglobin (g/l)  
PBS 6.25±0.37 3.08±0.39 1.56±0.35 0.91±0.60 
mPd 6.79±0.51* 2.25±0.56* 1.59±0.28 0.20±0.15** 
cPd 6.46±0.40 3.08±0.39 1.63±0.31 0.09±0.05** 
LPS 6.96±0.34* 2.82±0.65 1.51±0.37 0.06±0.02** 
PBS without DSS 9.22±0.83** 0.73±0.26** 0.14±0.14** 0.01±0.01** 
mPd without DSS 8.89±0.60** 0.45±0.40** 0.32±0.20** 0.01±0.01** 
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7.4.3 Effect of oral mPd on specific antibodies in serum  
Serum titres of anti-P. distasonis antibodies were significantly higher (P < 0.001) in mice 
treated orally with mPd compared to PBS-treated mice (IgA: 0.19 ± 0.07 versus 0.05 ± 
0.02; IgM: 0.56 ± 0.19 versus 0.15 ± 0.05 and IgG: 0.46 ± 0.17 versus 0.02 ± 0.02; n = 
10). Furthermore, serum antibody titres correlated strongly with the amount of P. 
distasonis in faeces on day 28 (r = 0.99 for IgA, r = 0.92 for IgG and r = 0.90 for IgM; P 
< 0.01). The concentration of the specific co-proantibodies was below the detection level 
in all groups. 
To investigate the potential protective role of specific antibodies in serum we 
performed serum transfer experiments. Indeed, serum transfer from mice orally treated 
with mPd to naive mice decreased the severity of DSS colitis (Table 7.3). 
 
Table 7.3 Evaluation of acute dextran sulphate sodium (DSS)-induced colitis in 
conventional BALB/c mice, after transfer of serum from mice treated orally with 
membranous fraction of Parabacteroides distasonis (mPd) or phosphate-buffered 
saline (PBS). 
Experimental group Colon length (cm) Disease activity index Histological grade 
Serum from PBS treated 6.10±0.58 2.67±1.08 1.45±0.36 
Serum from mPd treated 7.82±0.15** 0.40±0.37** 0.35±0.06* 
Data are representative of one experiment. Similar results were obtained from three independent 
experiments. Values are expressed as means ± standard deviations (five mice per group). An unpaired 
Student’s t-test was used to calculate the significance of differences between the mPd-treated group and the 
PBS-treated group (*P < 0.05; **P < 0.01). 
 
7.4.4 The production of cytokines in gut tissues  
To determine the effect of mPd therapy on cytokine production, colonic cytokine profiles 
from PBS-treated healthy mice, DSS/PBS-treated mice and DSS/mPd-treated mice were 
compared using cytokine antibody array (Fig. 7.1). Treatment with mPd prevented DSS-
induced increases in several proinflammatory cytokines, including IFN-γ, IL-12, IL-17 
and IL-6. Similarly, an overall decrease in both proinflammatory and anti-inflammatory 
cytokines was detected in Peyer’s patches (IL-6, TGF-β and IFN-γ), caecum (IL-10, 
TNF-α, TGF-β and IFN-γ) and colon (IL-10, TNF-α, IL-6, TGF-β and IFN-γ) of 
DSS/mPd-treated mice compared to the DSS/PBS group (Fig. 7.2), as measured by 
ELISA. No significant differences in cytokine production were found in the ileum, 
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jejunum mucosa (data not shown) or spleen cells (data not shown). mPd treatment did not 
change the production of cytokines in SCID mice except for an increase in IL-10 
production in the colon (see Supplementary information; Fig. S7.6). 
 
Figure 7.1 Pretreatment with membranous fraction of Parabacteroides distasonis 
(mPd) decreases the dextran sulphate sodium (DSS)-related increase in cytokine 
production in colon tissue as measured by cytokine antibody array.  
 
Values represent the percentage of the intensity of positive control. Granulocyte colony-stimulating factor (G-
CSF), interleukin (IL)-1–12p40p70, macrophage inflammatory protein-1α (MIP), stem cell factor (SCF), 
growth-regulated alpha protein precursor (KC), tissue inhibitor of metalloproteinases-1 (TIMP), tumour 
necrosis factor-α (TNF), thrombopoietin (TPO) and vascular endothelial growth factor (VEGF). Data are 
means (bars) and standard deviation (whisker) of three samples [*P < 0·05 versus DSS/phosphate-buffered 
saline (PBS)] 
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Figure 7.2 Pretreatment with membranous fraction of Parabacteroides distasonis 
(mPd) decreases cytokine production (pg/mg of tissue) in different parts of the gut in 
orally treated BALB/c mice as measured by enzyme-linked immunosorbent assay 
(ELISA). 
 
*P < 0·05 between mPd and phosphate-buffered saline (PBS) (a) or dextran sulphate sodium (DSS)/mPd 
and DSS/PBS (b)-treated mice. (B.D.) Values below the detection limit; n = 5 mice per group. 
 
7.4.5 Effect of oral mPd on Tregs  
We measured the number of Tregs (CD4+CD25+FoxP3+ cells) in the spleen, mesenteric 
lymph nodes and Peyer’s patches of control and mPd-treated mice. We found that after 
DSS treatment, mice treated with mPd had significantly more CD4+CD25+FoxP3+ cells in 
their mesenteric lymph nodes (mean ± s.d.; 3.40 ± 0.50 versus 4.81 ± 0.30; P = 0.014) 
than PBS-treated (control) mice (Supplementary information; Fig. S7.3). There were no 
differences between mPd-treated and control groups in Tregs numbers in spleen or Peyer’s 
patches (data not shown). 
 
7.4.6 Oral treatment with mPd does not affect the P. distasonis 
or Bacteroides/Prevotela group stool content but stabilizes 
the gut microbial ecology 
Before colitis induction, the microbiota composition in PBS and mPd-treated groups was 
similar. In both groups Lactobacillus sp. and Bacteroides acidofaciens were present, as 
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assessed by PCR-DGGE (Fig. 7.3a). In contrast, marked changes in microbiota 
composition were observed during DSS administration in the PBS-treated control group, 
as demonstrated in Fig. 7.3b. 
Quantitative PCR on the Bacteroides/Prevotela group and P. distasonis showed a 
statistically significant increase of these bacteria during DSS treatment from 0.84 ± 
0.39% to 9.58 ± 6.12% (P < 0.05) and from 0.01 ± 0.01% to 0.13 ±_0.11% (P < 0.05) of 
total Eubacteria, respectively. However, no statistically significant differences in bacteria 
numbers were found between the mPd-treated and control groups on the same day of the 
experiment (Fig. 7.3c). 
 
Figure 7.3 Oral treatment with membranous fraction of Parabacteroides distasonis 
(mPd) stabilize the intestinal microbiota without changing the P. distasonis or 
Bacteroides/Prevotela group stool content  
 
(a) Changes in fecal bacterial 
populations of dextran sulphate 
sodium/phosphate-buffered saline 
(DSS/PBS) and DSS/mPd-treated 
mice were measured by 16S rRNA 
gene polymerase chain reaction- 
denaturing gradient gel 
electrophoresis (PCR-DGGE) before 
the treatment day 0 (before colitis 
induction), day 28 and at the end of 
the experiment (day 35). (b) 
Comparison of changes in DGGE 
profiles between PBS and mPd-
treated mice at different time-points. 
(c) Representative quantitative 
changes in the Bacteroides/Prevotela 
group or P. distasonis in stool were 
measured by quantitative PCR. Data 
are expressed as a percentage of total 
Eubacteria [bar (mean); whisker 
(standard deviation)]. Samples from 
the same mouse at different time-
points were arranged together. The 
bands marked with arrows were 
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7.5 DISCUSSION  
Manipulation of the intestinal microbiota by oral administration of probiotic bacteria or 
selective antibiotics has emerged as a potentially useful therapeutic strategy for 
human IBD (Kruis et al., 2004; Mimura et al., 2004; Bibiloni et al., 2005; Prantera and 
Scribano, 2009). However, the clinical utility of such an approach remains controversial, 
as the link between specific mechanisms of action and therapeutic effects of specific 
strains or bacterial components has been difficult to establish. We have shown previously 
that oral administration of crude lysates from anaerobic bacteria attenuates the severity 
of experimental colitis (Verdu et al., 2000). In this study we identified a specific 
anaerobic lysate of P. distasonis and its cellular components with anti-inflammatory 
capacity. We investigated the possible mechanisms of action using in vitro techniques 
and in vivo acute and chronic DSS colitis. 
 The intestinal microbiota is a complex ecosystem which consists of high levels of 
obligate anaerobes (making upmore than 90% of the microbiota). This system is in 
constant interaction with the host’s immune system. Commensal bacteria play an essential 
role in mucosal immune system development, and dysregulated immune responses to 
opportunistic commensals have been suggested to play a role in intestinal inflammation 
(Hudcovic et al., 2001; Tlaskalova-Hogenova et al., 2004; Monteleone et al., 2006; 
Williams et al., 2006; Sartor, 2008). Moreover, it has been proposed that microbiota 
composition can be regulated by the host’s immune system (Williams et al., 2006; 
Petnicki-Ocwieja et al., 2009; Salzman et al., 2010).  
 We found that oral administration of the membranous fraction of P. distasonis 
(mPd) and its DNA were effective in suppressing acute DSS colitis. mPd also attenuated 
chronic colitis; however, the effect was less marked. The results are consistent with 
previous observations that prevention of inflammatory bowel disease is achieved more 
easily than treatment of ongoing inflammation (Obermeier et al., 2003). Several 
mechanisms may underlie the protective effect of oral mPd in colitis. We investigated 
whether oral mPd (a) changes local gut cytokine production, resulting in a nonspecific 
anti-inflammatory milieu (b) stimulates adaptive immune mechanisms (vaccination 
effect) and/or (c) stabilizes intestinal microbiota composition, thereby rendering 
the mice less susceptible to DSS colitis. Acute DSS colitis is believed to be driven 
initially by innate immunity mechanisms and, in particular, the role of macrophages has 
been suggested (Okayasu et al., 1990; Dieleman et al., 1994; Murano et al., 2000; 
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Hudcovic et al., 2001). We tested the ability of Pd and mPd to decrease the TNF-α 
production by LPS-activated macrophages in vitro. We found that at concentrations above 
10 ng/l both Pd and mPd decreased TNF-α production by macrophages, suggesting a 
possible direct effect of Pd and mPd on innate cell immunity. This mechanism may 
contribute to the attenuation of acute DSS injury observed in vivo by Pd and mPd. 
Because probiotics and their isolated DNA have been shown to attenuate the DSS colitis 
via Toll-like receptor (TLR)-dependent pathways (Rachmilewitz et al., 2004; Grabig et 
al., 2006), the involvement of pattern recognition receptors in the initiation of the 
protective effect by mPd and DNA cannot be ruled out 
 Our results show that oral mPd decreases the production of many 
proinflammatory cytokines, including TNF-α, but also of anti-inflammatory cytokines in 
the colon of treated mice. The changes were observed in Peyer’s patches, caecum and 
colon of mPd-treated mice compared to control mice, suggesting local mucosal effects of 
mPd throughout the intestine. This immunomodulatory activity of mPd may interfere with 
both leucocyte accumulation in intestinal mucosa and with barrier function failure, and 
contribute to decrease inflammation (Atreya et al., 2000; Wang et al., 2005). Our results 
are consistent with previous work that reported a decrease in proinflammatory, as well as 
anti-inflammatory, cytokine production in mice treated with DSS and live probiotic E. 
coli Nissle 1917 (Grabig et al., 2006).  
 It is known that some components of the indigenous microbiota have 
immunomodulatory properties and affect cytokine production (Rachmilewitz et al., 2004; 
Okada et al., 2006; Hrncir et al., 2008; Sokol et al., 2008). Mazmanian et al. have shown 
that changes in local cytokine production caused by the common commensal bacterium B. 
fragilis and its polysaccharide A protected mice from experimental colitis (Mazmanian et 
al., 2008). Unfortunately, changes in microbiota composition or a polysaccharide A-
specific immune response were not investigated in that study. Anti-TNF-α-based 
therapies have been shown to be effective in flare-ups of chronic inflammatory 
disorders, including IBD and rheumatoid arthritis (Papadakis and Targan, 2000; Siddiqui 
and Scott, 2005).  
 The presence of serum antibodies directed against commensals in IBD patients 
suggests that some patients may exhibit systemic priming against microbiota (Adams et 
al., 2008). The pathophysiological significance of this priming remains unclear, but may 
suggest a role of adaptive immune mechanisms in the luminal containment of microbiota 
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components in patients with mucosal damage. Indeed, a recent study has proposed that 
systemic immune responses may compensate for innate immune deficiency and constitute 
a novel homeostatic mechanism in host–microbiota mutualism (Slack et al., 2009). 
Antibodies could occur as a consequence of increased penetration of microbiota 
components through impaired mucus and epithelial layers. These antibodies may play not 
only a diagnostic (Adams et al., 2008), but also a protective role against microbes that 
could perpetuate intestinal inflammation. Moreover, if bacterial epitopes are shared 
among several bacterial species (molecular mimicry), generation of antibodies against 
common commensals could constitute potential therapeutic targets in IBD. After oral 
administration of mPd, we found increased levels of P. distasonis-specific antibodies in 
sera compared to controls, suggesting the possibility that specific immune responses to P. 
distasonis are protective against experimental colitis. The identification of the specific 
antibody fraction responsible for this effect is being examined currently in our 
laboratories. Although both oral and parenteral forms of administration of mPd increased 
the levels of specific serum antibodies, only oral administration had an effect on colitis 
prevention. This suggests that the gut microenvironment during antigen priming is 
essential for colitis prevention, but once established it can be transferred with serum. To 
investigate further the role of adaptive immunity in the anti-colitic effect of mPd, we 
studied immunodeficient mice lacking T and B lymphocytes. Although the severity of 
DSS-induced acute inflammation in SCID mice was similar to that in immunocompetent 
mice (Dieleman et al., 1994; Hudcovic et al., 2001), colitis was not prevented in SCID 
mice with oral mPd. One limitation of the comparison between BALB/c and SCID mice 
relates to differences in gut microbiota composition and/or innate immune cell activity 
between strains (Keilbaugh et al., 2005). The innate and adaptive immune systems work 
in synergy to mount appropriate immune responses to the commensal microbiota and 
maintain homeostasis (Slack et al., 2009). As suggested by our in vitro experiments, we 
cannot rule out the involvement of innate immune mechanisms in the initiation of mPd-
induced protection. However, the in vivo experiments show clearly that the adaptive 
immune response is required for mPd-induced protection.  
 Our results also suggest a role for Tregs in this mPd-induced protection. We show 
that there is an increase in both CD4+FoxP3+ and CD4+FoxP3– T cells in MLN of  mPd-
treated mice. The increase in CD4+FoxP3+ cells is, however, proportionally higher, 
therefore the increase in absolute numbers of Tregs cannot be explained solely by the 
increase in CD4+ cells. The significance of this finding requires confirmation in future 
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experiments. Previous work has proposed that the presence of microbiota and bacterial 
components in the gut can influence Treg activity (Singh et al., 2001; Hrncir et al., 2008). 
Thus, future studies will address the relative importance of induction of protective 
immunity (vaccination) and of tolerance induction in the prevention and treatment of 
acute and chronic colitis by mPd. 
 In accordance with previous work (Okayasu et al., 1990), we found that DSS 
colitis alters the intestinal ecosystem with an increase in P. distasonis. Interestingly, we 
found that oral treatment with mPd prevents the microbiota changes caused by DSS. The 
mechanism by which mPd stabilizes the microbiota composition during DSS is not clear, 
but could be secondary to improvement in inflammation. Alternatively, mPd may directly 
affect other bacteria, by a direct antimicrobial effect, or indirectly, by improving epithelial 
barrier function or regulation of the mucosal immune system. The latter has been 
demonstrated previously for probiotic candidates P. freudenreichii and F. prausnitzii 
(Okada et al., 2006; Sokol et al., 2008). 
In conclusion, oral administration of P. distasonis components (mPd) protects from 
experimentally induced intestinal inflammation through several innate and adaptive 
immunomodulatory mechanisms. Oral mPd promotes an increase in the level of mPd-
specific antibodies and in the numbers of Tregs. In addition, oral mPd inhibits TNF-α 
production by macrophages in vitro and stabilizes the intestinal microbiota. These results 
highlight the importance of individualizing and characterizing the potential capacity of 
commensal bacteria as immunomodulatory agents. Moreover, oral administration of 
sterile bacterial components, in contrast to live bacteria, may be safer in severely ill or 
immunocompromised patients. 
 Our results support the hypothesis that oral supplements consisting of components 
from specific commensals may lead to the development of new therapeutic approaches 
for chronic intestinal inflammation.  
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7.9 SUPPLEMENTARY MATERIALS AND METHODS 
7.9.1 Preparation of bacterial lysates and bacterial components 
Cultures were grown on Wilkins-Chalgren Anaerobe Agar (Oxoid, Basingstoke, 
UK) and enriched with defibrinated blood. After 24 hours (h) of incubation in an 
anaerobic atmosphere (Oxoid), a small portion of agar was cut out and placed into Brain 
Heart Infusion Broth (Oxoid) for 48 h at 37°C in an anaerobic atmosphere. The cells were 
harvested by centrifugation (4000 x g, 30 min) and washed twice with sterile PBS to 
minimise contamination of the sample with the culture media.  
After disruption of the bacteria with the French press, part of the lysate was 
separated by centrifugation (8500 x g, 30 min) into two fractions, membranous (insoluble; 
mPd) and cytoplasmic (soluble; cBd). The lysate and its fractions were lyophilised and 
diluted to a working concentration of 15 g/l. Lipopolysaccharide of the P. distasonis was 
isolated by phenol-water extraction according to the procedure described by Westphal et 
al (Westphal et al., 1952). DNA from P. distasonis was isolated using a shortened version 
of the cetyltrimethylammonium bromide (CTAB) DNA isolation method described 
previously (Ali et al., 2005). Sterility of all components was verified by both aerobic and 
anaerobic cultivation before administration. 
 
7.9.2 Evaluation of colitis 
Colitis was evaluated on the last day of the experiment using a clinical activity 
score, histological score and colon length measurement. The clinical activity score 
represents the sum of separate scores ranging from 0 to 4 and was calculated using the 
following parameters: body weight decrease (none 0 points, weight loss of 1 to 5% as 1 
point, 5 to 10% as 2 points, 10 to 20% as 3 points, and 20% as 4 points), stool consistency 
(solid 0 points, loose stool that did not stick to the anus 2 points, and 4 points for liquid 
stools that did stick to the anus), and bleeding (none 0, positive guaiacum reaction 2 
points, and 4 points for gross bleeding). These scores were added and divided by 3, 
forming a total clinical score that ranged from 0.0 (healthy) to 4.0 (maximal activity of 
colitis), as described previously by Cooper et al (Cooper et al., 1993).  
 Postmortem, the entire colon was removed (from caecum to anus) and placed 
without tension on a ruler and colon length measured. Colon descendens were fixed in 
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4% buffered formalin and embedded in paraffin for histological evaluation. Sections were 
stained with hematoxylin/eosin. Four transversal sections, separated with 100 µm gaps, 
were evaluated from each sample. Histological scoring was performed for each section in 
a blinded fashion by 2 expert pathologists (K. K. and P. R.) and a score combining the 
degree of leukocyte infiltration in lamina propria and submucosa and the extent of 
mucosal defect (Table S7.1 and Fig. S7.1) was obtained. The final score represents the 
mean of four sections ranging from 0 (no signs of colitis) to 3 (severe colitis). Evaluation 
of acute DSS-induced colitis in parenterally (s.c. subcutaneous, i.p. intraperitoneal) 
treated BALB/c mice is sumarised in table S7.6. 
 
Figure S7.1 Histological examples of different grades of mucosal damage in DSS 
treated mice (H&E stained colon descendens; magnification, ×40). See table S7.1 for 
detailed description. 
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Table S7.1. Detailed description of individual histological grades. 
 
7.9.3 Determination of serum and faecal antibodies  
 Faecal pellets were collected and processed as previously described (deVos and 
Dick, 1991). We then used indirect ELISA, optimised in our laboratory, to compare 
serum or fecal antibody (IgG, IgM and IgA) titres against P. distasonis lysate between 
PBS and mPd-treated groups. 
Briefly, 96-well ELISA plates (Nunc, Roskilde, Denmark) coated overnight with 
mPd (100 µl/well at 10 mg/l in PBS) and blocked with 1% bovine serum albumin (BSA; 
Sigma-Aldrich, St. Louis, MO, USA) in PBS were incubated for 2 h with serum samples 
diluted 1:50 (1% BSA was used as a blank, normal mouse serum as a negative control 
and a pool of the hyper-immune mouse sera as a positive control). After washing (three 
times with PBS containing 0.05% Tween 20 (Sigma-Aldrich)), secondary antibodies (50 
µl/well) were added and incubated for 1 h at room temperature. We used horseradish 
peroxidase (HRP)-labelled anti-mouse IgG (The Binding Site Ltd, Birmingham, UK) 
diluted 1:2000 in 1% BSA, HRP-labelled anti-mouse IgM (The Binding Site Ltd) diluted 
1:500 in 1% BSA, or biotinylated anti-mouse IgA (Sigma-Aldrich) diluted to a 
concentration of 1:2000 in 1% BSA and 5% fetal bovine serum (BioClot GmbH, 
Aidenbach, Germany). After a washing step, we added 50 µl/well of streptavidin-HRP 
(R&D Systems Inc., Minneapolis, MN) diluted 1:200 in 1% BSA into the IgA plate. The 
plates were developed with 3,3',5,5'-tetramethylbenzidine (TMB; Sigma-Aldrich) and the 
Grade Description 
0  normal mucosa Thin colon wall without oedema or infiltration, crypt without defects with well-
preserved mucus production. 
0.5  borderline Discrete focal infiltration by the crypt basis without any defect in mucosa. Also 
encountered in some control animals. 
1.0  mild Extension of cellular infiltrate to the superficial layer of lamina propria and to 
submucosa. Mild oedema of lamina propria and flattening of crypts without 
defects of epithelium. 
1.5 medium Confluence of inflammatory cells and oedema in lamina propria and patchy 
infiltrate in submucosa. The mucosa is markedly flat with discrete errosion(s) or 
ulcers covering less than 10% of colon diameter.  
2.0 medium to severe Same as above, but the ulcers extend to 10%-50% of diameter, mostly with the 
purulent exudate in the lumen. Crypts are regressed and the mucus production 
is suppressed. 
2.5 very severe Same as above, but the ulcers cover over 50% of diameter. Massive 
inflammatory infiltration and oedema of both lamina propria and submucosa with 
pseudoabscesses and intravascular leukostasis. 
3.0 extreme Same as above, but with subtotal/total denudation of the mucosa. 
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optical density (OD) was measured at 450 nm. The OD of the background (1% BSA) was 
subtracted and resulting adjusted ODs of the treated groups were compared with those of 
PBS-treated groups. We used 10 mice per group for the analysis of serum and 5 mice per 
group for analysis of coproantibodies. 
 
7.9.4 Determination of serum haptoglobin levels 
The level of the acute-phase protein haptoglobin was determined in mouse serum 
using a modified Human Haptoglobin ELISA Quantitation Kit (GenWay Biotech, Inc., 
San Diego, CA). Antibodies used in this kit have high cross-reactivity with mouse 
haptoglobin; the recovery for the mouse reference serum was 94%. The kit was used 
according to the manufacturer's recommendation, with minor modifications. Briefly, a 96-
well ELISA plate (Nunc) was coated with Chicken anti-Human Haptoglobin antibody 
(100 µl/well at 5 mg/l) diluted in 0.05 M Carbonate-Bicarbonate buffer (pH 9.6) and 
incubated for 1 h at room temperature. After washing (three times with PBS containing 
0.05% Tween 20), the plate was blocked with 1% nonfat dry milk in PBS. The samples 
were diluted 1:1000 in 1% nonfat dry milk and incubated for 1 h at room temperature. 
Serial dilutions of mouse reference haptoglobin serum (ICL, Inc., Newberg, OR, USA) 
were used as calibrator instead of the pure human haptoglobin provided in the kit. Then 
the plates were washed five times and incubated with HRP conjugated detection antibody 
(100 µl/well at 61.3 µg/l) for 1 h. The plates were developed with TMB (Sigma-Aldrich) 
and the OD was measured at 450 nm. The quantitative determination was performed 
between 39-2500 µg/l. 
 
7.9.5 Gut tissue fragment culture 
Five sections of mouse intestine were obtained (Peyer’s patches, jejunum, ileum, 
caecum and colon), cut open longitudinally, washed in PBS containing penicillin and 
streptomycin and weighed.  
The tissue fragments were then cultivated for 48 h in a humidified incubator at 
37°C and 5% CO2 in RPMI-1640 (Sigma-Aldrich) containing 10% fetal bovine serum 
(BioClot GmbH, Aidenbach, Germany) and 1% Antibiotic-Antimycotic solution (Sigma-
Aldrich). The supernatants were collected and stored at -20°C until analysis. During our 
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preliminary experiments, we found that there is still significant production of IL-10 and 
TGF-β after 48h cultivation (Fig. S7.2).  
 
7.9.6 Macrophage cell line culture 
Mouse macrophage RAW 264.7 cells, originally obtained from the American 
Type Culture Colection (ATCC TIB-71), were cultured in Dulbecco´s modified Eagle´s 
medium (Institute of Molecular Genetics AS CR, Prague, Czech Republic) supplemented 
with 10% heat-inactivated fetal bovine serum (Biochrom AG, Berlin, Germany), 
penicillin (100 U/ml), streptomycin (100 mg/l, Sigma-Aldrich), 4.5 g/l glucose, 1.5 g/l 
sodium bicarbonate and 4 mM glutamine (Institute of Molecular Genetics AS CR). The 
cells were cultured in a humidified incubator at 37°C and 5% CO2. Cell viability was 
evaluated by flow cytometry. The cell density was then adjusted to 106 cells/ml and the 
cells were seeded in the wells of flat-bottom, 96-well plates (200 µl/well). The plates 
were incubated with LPS (Salmonella typhimurium, 1 mg/l, Sigma-Aldrich), LPS 
together with either bacterial lysate from P. distasonis, or mPd or cPd or DNA for 24 h 
(37°C, 5% CO2). To address the question of dose dependence, serial decreasing dilutions 
of lysate and mPd were used, ranging from 1 µg/l to 100 fg/l. Supernatants were collected 
and stored at - 20°C until analysis. The supernatants were screened semiquantitatively 
with the RayBioTM Mouse Cytokine Array 3 (Raybiotech, Inc., Norcross, GA), capable of 
detecting 62 cytokines, or quantitatively for TNF-α with ELISA (Invitrogen Corp., 
Carlsbad, CA), similarly as described below. 
 
7.9.7 Determination of cytokine production 
To determine the changes in cytokine spectra induced by DSS treatment and mPd 
therapy in the colon of mice, we used the RayBioTM Mouse Cytokine Array II 
(Raybiotech, Inc.) (see Table S7.2 for array layout). For this purpose, we used three 
samples of media after 48 h of colon cultivation (see above) from healthy, DSS/PBS 
(sham) and DSS/mPd-treated groups of mice. Chemiluminescence was detected by a 
luminescence detector LAS-1000 (Fujifilm, Tokyo, Japan), and quantitation of spots was 
performed by AIDA (3.28, Raytest, Straubenhardt, Germany) software as described 
previously (Kverka et al., 2007). Values from different arrays were first normalized using 
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the intensity of positive controls, which are made of biotinylated antibody directly spotted 
on the array. Furthermore, the levels of selected cytokines were determined using 
commercially available ELISA sets purchased from Invitrogen (TNF-α, IFN-γ, TGF-β, 
IL-10; Invitrogen Corp.) or R&D Systems (IL-6; R&D Systems Inc., Minneapolis, MN). 
All tests were performed according to the manufacturers’ recommendations. 
 
Table S7.2 Layout of the RayBioTM Mouse Cytokine Array II 
Abbreviations used in this table stand for the following cytokines: 6-Ckine, 6-Cysteine chemokine; 
CTACK, Cuteaneous T-cell attracting chemokine; G-CSF, Granulocyte-colony stimulating factor; 
GM-CSF, Granulocyte-macrophage colony stimulating factor; IFN (Interferon) -γ, IL (Interleukin) -
2, -3, -4, -5, -6, -9, -10 , -12p40p70 (detects both p70 and p40), -12p70 (detects only whole 
cytokine IL-12), -13, -17, KC, Growth-regulated alpha protein precursor; MCP (Monocyte 
chemoattractant protein)-1, -5; MIP (Macrophage inflammatory protein)-1α, -2, -3β, RANTES, 
Regulated upon activation, normal T cell expressed, and presumably secreted; SCF, Stem call 
factor; sTNFRI, Soluble tumor necrosis factor-α receptor 1; TARC, Thymus and activation-
Regulated chemokine; TIMP (Tissue inhibitor of metalloproteinases)-1; TNF (Tumor necrosis 
factor)-α; TPO, Thrombopoietin; VEGF, Vascular endothelial growth factor  
 
Figure S7.2 Cytokine production by colon tissue of healthy mice during the first, 
second and third days of ex vivo 
cultivation. Three colon samples were 
cultivated for 72 h in complete RPMI 
medium. Every 24 h, the tissue was 
gently washed in fresh media and 
transferred to the new cultivation well 
for next 24 h. The supernatant after the 
first, second and third 24 h of 
cultivation was stored for cytokine 
analysis. 
 A B C D E F G H I J K L 
1 
2 
Positive 
control 
Positive 
control 
Negative 
control 
Negative 
control 6-Ckine CTACK Eotaxin G-CSF GM-CSF IL-2 IL-3 IL-4 
3 
4 
IL-5 IL-6 IL-9 IL-10 IL-12p40p70 IL-12p70 IL-13 IL-17 IFN-γ KC Leptin MCP-1 
5 
6 
MCP-5 MIP-1α MIP-2 MIP-3β RANTES SCF sTNFRI TARC TIMP-1 TNF-α TPO VEGF 
7 
8 
Blank Blank Blank Blank Blank Blank Blank Blank Blank Blank Blank Positive 
control 
Bacterial components and experimental colitis 
 
147 
Figure S7.3 Showing gating strategy in 3 mice (rows) from DSS/PBS and 3 mice 
from DSS/mPd treated group.  
 
Total number of Tregs is increased in mesenteric lymph nodes (MLN) of mPd treated mice is increased in 
cells (mean±SD; 3.40±0.50 vs. 4.81±0.30; P=0.014 for CD4+CD25+FoxP3+ or 4.29±0.26 vs. 5.36±0.10; 
P=0.019 for CD4+FoxP3+). First column shows gating on cells, second gating on CD4 and CD8 expression 
on these cells, third gating on CD4+CD25+ cells and fourth is a histogram of FoxP3 expression on these 
CD4+CD25+ cells. 
7.9.8 Evaluation of microbiota changes with PCR-DGGE  
Total bacterial DNA was isolated from mice faecal samples by using the ZR Fecal 
DNA KitTM (Zymo Research Corp., Orange, CA) according to the manufacturer’s 
description. Fragments of 16S rRNA genes were amplified from total bacterial DNA with 
primers 338GC and RP534 (Muyzer et al., 1993).  
PCR products were separated and analysed on the DCodeTM Universal Mutation 
Detection System (Bio-Rad Laboratories, Hercules, CA). The denaturating gradient was 
35 – 60% and the electrophoresis was carried out for 18 h at 55 V. The gel was stained in 
SYBR® green I dye for 30 minutes and observed in a Vilber Lourmat system under UV 
light. 
Banding patterns were converted to a binary matrix, taking into account the 
presence or absence of the individual bands. This binary matrix was used to calculate the 
distance matrix between individual samples (Nei and Li, 1979) and a dendrogram 
comparing all 30 samples was obtained with UPGMA (unweighted pair-group method 
with arithmetic averages) using FreeTree software (Pavlicek et al., 1999).  
The similarity between the DGGE profiles obtained from a single mouse at 
different time points was determined by calculating Dice's similarity coefficient (DSC 
=[2j/(a+b)] x 100), where j is the number of DGGE bands found in both profiles, a is the 
number of bands at first time point, and b is the number of bands at the second time point. 
A DSC value of 100% indicates that the samples are identical. 
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To identify the bacteria, bands of interest were cut from the gel, eluted with dH2O 
and amplified with PCR. The PCR product was purified with the QIAquick PCR 
purification kit and analysed on the 3100 Avant Genetic Analyser (Applied Biosystems 
Inc., Foster City, CA). 
 
7.9.9 Quantitative PCR 
 Faecal samples were weighed and total bacterial DNA was extracted by using a 
ZR Fecal kit (Zymo Research, USA) according to the manufacturer’s protocol. Real-time 
PCR analyses were performed on the Mx3005P system (Stratagene, USA) with the qPCR 
2x SYBR Master Mix (Top-Bio, Czech Republic). The qPCR reactions were performed 
in a 20 µL volume, and the primer concentrations were 0.5 µM each. The following 
bacterial groups were monitored: all Eubacteria (with primers Uni331F+Uni797R) 
(Bartosch et al., 2004), Bacteroides-Prevotella group (primers Bac303F+Bac708R) 
(Bartosch et al., 2004) and P. distasonis (Bd180F+Uni797R) (Kreader, 1995). We used 
these amplification conditions: initial denaturation at 95°C (3 min), 35 cycles of 
denaturation at 95°C (30 seconds) and annealing/elongation (30 seconds) (Table S7.3), 
and one final cycle at 95°C (30 seconds) followed by a dissociation curve from 55°C to 
95°C (1°C per cycle of 10 s). DNA isolated from a known number of cells from pure 
cultures of Bacteroides vulgates and P. distasonis were used as qPCR standards. Because 
the weight and the consistency of the stool differed among the samples, the results were 
normalised to the total number of Eubacteria and expressed as a percentage of total 
Eubacteria. 
 
Table S7.3 PCR primer sets used in the study. 
Target 
organism 
Primer 
set 
Sequence (5’-3’) Product 
size (bp) 
Annealing 
temp (°C) 
Reference 
338GC CGCCCGCCGC GCCCCGCGCC 
CGGCCCGCCG CCGCCGCCGC 
ACTCCTACGG GAGGCAGCAG 
(Muyzer et al., 1993) 
All eubacteria 
(PCR-DGGE) 
RP534 ATTACCGCGG CTGCTGG 
196 58 
(Muyzer et al., 1993) 
Uni331F TCCTACGGGAGGCAGCAGT All eubacteria 
(qPCR) 
Uni797R GGACTACCAGGGTATCTATCCTGTT 
466 58 
Bac303F GAAGGTCCCCCACATTG Bacteroides-
Prevotella 
group Bac708R CAATCGGAGTTCTTCGTG 
418 56 
(Bartosch et al., 2004) 
Bd180F AAT ACC GCA TGA AGC AGG (Kreader, 1995) Parabacteroide
s distasonis 
Uni797R GGACTACCAGGGTATCTATCCTGTT 
617 62 
(Bartosch et al., 2004) 
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7.10 SUPPLEMENTARY TABLES 
Table S7.4 Evaluation of acute DSS colitis in orally treated BALB/c mice. 
Experimental group Colon length (cm)  Disease activity index Histological grade 
PBS 9.31±0.88 3.33±0.49 1.44±0.71 
P. distasonis lysate 10.85±1.26** 0.90±0.77** 0.61±0.50** 
B. ovatus lysate 9.48±0.80 2.63±1.15 1.26±0.35 
V. alcalescens lysate 9.21±0.66 1.58±0.66 1.58±0.66 
Values are expressed as means ± standard deviation (10 mice per group). One-way ANOVA with 
Dunnett's multiple comparison test was used to evaluate differences between experimental 
groups and PBS-treated controls (*P<0.05, **P<0.01). 
 
Table S7.5 Evaluation of acute DSS colitis in orally treated BALB/c mice. 
Experimental group Colon length (cm)  Disease activity index Histological grade 
PBS 7.83±0.55 3.78±0.27 1.81±0.28 
B. vulgatus lysate 8.13±1.06 2.87±1.04 1.44±0.89 
B. stercoris lysate 8.60±0.60 3.40±0.80 1.33±0.41 
B. stercoris confidence level 
Capnocytophaga spp. lysate 9.00±0.70 3.13±0.65 0.63±0.25** 
B. thetaiotamicron lysate 8.90±0.81 2.13±0.96 1.25±0.47 
Values are expressed as means ± standard deviation (5 mice per group). One-way ANOVA with 
Dunnett's multiple comparison test was used to evaluate differences between experimental 
groups and PBS-treated controls (*P<0.05, **P<0.01). 
 
Table S7.6 Evaluation of acute DSS colitis in parenterally treated BALB/c mice. 
Values are expressed as means ± standard deviation (5 mice per group). One-way ANOVA with 
Dunnett's multiple comparison test was used to evaluate differences between experimental 
groups and PBS-treated controls (*P<0.05, **P<0.01). 
Experimental group Colon length (cm) Disease activity index Histological grade 
PBS/IFA s.c. 6.02±0.46 3.40±0.37 1.61±0.84 
mPd/IFA s.c. 6.20±0.51 2.87±0.80 1.43±0.53 
PBS/IFA i.p. 6.72±0.54 3.13±0.69 1.69±0.81 
mPd/IFA i.p. 6.72±0.83 2.73±0.89 1.29±0.62 
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7.11 SUPPLEMENTARY FIGURES 
Figure S7.4 Cytokine 
profiling of the 
supernatants after the 
cultivation of untreated 
RAW264.7 cells or cells 
after treatment with LPS, 
Pd+LPS or mPd+LPS, as 
measured by RayBio 
Mouse Cytokine Antibody 
Array 3. Only cytokines 
positive at least in one 
sample are shown. As 
compared with LPS-
activated cells, the Pd and 
mPd decrease TNF-α, IL-6, 
MCP-1 and MCP-5, and 
increase in CXCL16. 
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Figure S7.5 The effect of Pd and mPd on TNF-α production by LPS-activated 
macrophage cell line RAW 264.7 was measured by ELISA. TNF-α production with 
sterile PBS with 1 mg/l of LPS is set at 100%. Data are means of five independent 
experiments. Error bars are SEM. P < 0.05: a (for LPS+Pd versus controls); b (for 
LPS+mPd versus controls) using ANOVA with a Dunnett’s post-hoc test. 
 
 
Figure S7.6 Pretreatment with mPd decreases cytokine production (pg/mg of tissue) 
in different parts of the gut in orally treated SCID mice as measured by ELISA.  
**P<0.01: DSS/mPd versus DSS/PBS-treated mice; n = 5 mice per group. 
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8. GENERAL DISCUSSION 
The studies presented in this thesis provide novel information about the mechanisms 
of intestinal inflammation and possibilities to manipulate it with bacterial components. 
Since the main points are already discussed in individual chapters, I will focus on 
common mechanisms of immunomodulation. 
 
8.1 TARGETING THE GCS EFFECTS ON PRE-RECEPTOR LEVEL: 
HIDDEN OPPORTUNITIES FOR IBD THERAPY? 
In the study presented in chapter 4, we reported that there is a marked increase in 
11HSD1 mRNA expression and enzyme activity in inflamed colon, as compared with 
healthy tissue. These changes were also present in colonic IELs and in MLNs, but not in 
the spleen, suggesting compartmentalization of this immunomodulatory mechanism. 
Therefore, it might be possible to use this mechanism in therapy without the general 
(systemic) anti-inflammatory adverse effects of GCs. 
 Since the 11HSD1 amplifies the effect of endogenous GC in vivo, the higher the 
11HSD1/11HSD2 ratio is, the stronger anti-inflammatory effect the endogenous GCs 
have (Paterson et al., 2005). Regulation of substrate availability by the changes in the 
isoenzymes synthesis thus modifies receptor activation and effect of endogenous GCs. 
Similar mechanism preventing an overshoot of immune response during local 
inflammation has been recently reported also in TNBS-induced colitis and in adjuvant 
arthritis, suggesting that it is a common regulatory mechanism (Ergang et al., 2008; 
Ergang et al., 2010). Enhancing this natural defense mechanism with substances that are 
capable to counteract pro-inflammatory signals could be used in therapy of inflammatory 
diseases. It has been found that oral administration of glycyrrhizic and glycyrrhetinic 
acids isolated from licorice can change the 11HSD mRNA and potentiate the GCs 
immunomodulatory activities in rats (Whorwood et al., 1993).  
 
8.2 HOST-BACTERIAL RELATIONSHIPS IN THE GUT  
Human gut is colonized by a vast community of symbiotic, commensal bacteria that have 
important effects on immune function, nutrient processing, and a broad range of other 
physiological functions. Despite the current revolution in our knowledge about this 
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community, powered mostly by rapid advancements in technology, our understanding of 
host-microbe and microbe-microbe interactions in the gut is still limited.  
 It is estimated that human microbiome is composed of at least 1000 distinct 
bacterial species, out of which almost 50% cannot be cultivated ex vivo and therefore 
properly studied (Hooper and Gordon, 2001). Moreover, the gut microbiome, with around 
150times the number of genes in our genome, imparts to us new functional features that 
we have not had to evolve ourselves (Qin et al., 2010). Furthermore, using selective 
antibiotics and pre- or probiotics and by dietary interventions, we can manipulate with gut 
microbiome, hence selectively introduce, enhance or reduce some of these functional 
features. To do so in a controlled manner, we need to unravel the key mechanisms of 
host-microbiota interactions and answer a few fundamental questions: 
1) How do gut microbiota contribute to our normal physiology and how functionally 
redundant are the members of the human gut microbiota? 
2) How do they contribute to pathologic states?  
3) How can they be exploited to develop new therapeutic strategies? 
 Host–microbe interactions involve the complex interactions of various microbial 
molecules with various host receptors and adaptor molecules, and the final host response 
is therefore determined by the coordinated action of many different cell types (Lebeer et 
al., 2010). The nature of this action depends mainly on which receptors are triggered, the 
tuning of the cells in the microenvironment and the existence of tolerance or immunity to 
the particular microbe.  
Several physiological functions of gut microbiota are briefly reviewed in the first 
chapter of this thesis. The question of how the gut microbiota shape intestinal immune 
responses can be elegantly answered by comparing the immune responses of GF animals 
with those reared under conventional conditions. Known defects in mucosal immune 
system of GF mice are summarized in Table 8.1. 
 Certain bacteria were found to actively shape a healthy immune system. The 
importance of these microbes to the normal development of the immune system (and 
other physiological functions) supports the notion that the total information encoded by 
the mammalian genome is not sufficient to maintain health, and that microbial products 
are crucial for protection from various diseases (Zaneveld et al., 2008). This suggests that 
diseases could result from the absence of certain beneficial microbial molecules and that 
we might be able to treat them by supplementing these molecules. The molecules can 
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manipulate the immune system directly or indirectly, by influencing another bacterial 
species already present in the gut. 
 
Table 8.1 Intestinal immunological defects in germ-free mice 
Immunological defect Site Phenotype in germ-free mice compared with 
conventionally housed mice 
Peyer’s patches Fewer and less cellular 
Lamina propria Thinner and less cellular 
Germinal centers Fewer plasma cells 
Development of small intestine 
ILF Smaller and less cellular 
Development of MLN Germinal centers Smaller, less cellular and with fewer plasma cells 
CD8+ T cells IEL Fewer cells and with reduced cytotoxicity 
CD4+ T cells Lamina propria Fewer cells; decreased Th17 cells in the small intestine but increased Th17 cells in the colon 
CD4+CD25+ T cells MLN Reduced expression of FoxP3 and reduced 
suppressive capacity 
Expression of angiogenin 4 Paneth cells Reduced 
Expression of REG3γ Paneth cells Reduced 
Production of SIgA B cells Reduced 
Levels of ATP Intestine Reduced 
Expression of MHC class II 
molecules IECs Reduced 
Expression of TLR9 IECs Reduced 
Levels of IL-25 IECs Reduced 
Adopted from Round and Mazmanian (2009) 
 
8.3 THERAPEUTIC MANIPULATION WITH GUT MICROBIOTA 
Gut microenvironment is greatly influenced by microbiota populations and immune state 
of the mucosa. Dysbiosis, an imbalance in the intestinal bacterial ecosystem, is a common 
finding in patients with IBD, but it is difficult to say whether it is the cause or 
consequence of the inflammation (Frank et al., 2007). It has been reported that there are 
significant changes in the gut microbiota composition during DSS-induced colitis 
(Okayasu et al., 1990). In the study presented in chapter 5, we tested if repeated oral 
administration of well known probiotics could reduce the intestinal inflammation in the 
acute DSS colitis. All three probiotic bacteria we tested, L. casei DN-114 001 (Lc), E. 
coli Nissle 1917 (Ec Nis) and E. coli O83 (Ec O83), decreased the severity of acute DSS-
induced colitis. We did not observe any differences between the probiotic-colonized 
healthy mice and healthy non-treated mice. 
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 Bacterial populations in a complex ecosystem can act co-operatively, keeping the 
growth of own as well as other bacterial species in balance. They can produce substances 
with antibiotic properties, such as bacteriocins, and molecules capable to signal to other 
members of the ecosystem to adjust their growth (quorum sensing modifiers), as recently 
reviewed (Boyer and Wisniewski-Dye, 2009). These molecules can be produced by 
probiotic bacteria or be presented in the bacterial lysates and modify the bacterial 
populations. L. casei isolated from traditional Indian fermented vegetable pickle have 
anti-microbial activities against many microbes with the exception of L. plantarum. This 
effect is present even after autoclaving and it is attributed to bacteriocins produced also 
by other lactobacilli. Interestingly, even bacteriocins from closely related species, such as 
L. casei and L. acidophilus, have unique anti-bacterial spectra (Jamuna and Jeevaratnam, 
2004). This selective anti-microbial activity, presented in both live and dead bacteria, 
could be responsible for changes in gut microbiota composition during Lc therapy we 
reported in chapter 6. This could be the key to correcting dysbiosis or decreasing the 
number of potentially pathogenic bacterial species, thus reducing the subsequent 
inflammation.  
 Certain bacterial components can induce production of antimicrobial peptides or 
cytokines in the host mucosa, both of which often have immunomodulatory as well as 
selective antibiotic properties (Yang et al., 2003; Guani-Guerra et al., 2010). Moreover, 
cytokines produced in the gut can drive bacteria to change their gene expression, 
increasing their pathogenicity. For example, large amounts of IFN-γ produced by gut 
mucosa during inflammation can be recognised by P. aeruginosa and stimulate the 
production of factors capable of disrupting epithelial cell function in the bacterium, thus 
mounting effective countermeasure to immune activation by their host (Wu et al., 2005). 
 Interestingly, another probiotic bacterium we have used in our experiments – Ec 
Nis, has been recently found to increase the production of anti-microbial peptide in 
humans. The levels of β-defensin 2 (hBD-2) were significantly increased in stool samples 
from orally treated humans even 9 weeks after this therapy has ended (Mondel et al., 
2009). In their previous work, the authors found that, unlike other 40 strains of E. coli, Ec 
Nis or certain lactobacilli significantly increase the hBD-2 expression in human epithelial 
cells in vitro. Interestingly, while one isolate of L. acidophilus did induce remarkably 
high expression of hBD-2, other isolate of the same strain did not induce hBD-2 at all 
(Wehkamp et al., 2004). These results collectively show that a) probiotics could have 
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anti-microbial properties, b) these properties could be direct or indirect, and c) there could 
be significant difference in this activity even within one bacterial species. 
 The effect of bacterial lysates used in our experiments seems to be rather indirect. 
Unlike the live bacteria, e.g. both Ec Nis and Ec O83, which can colonize the gut and 
become resident members of gut microbe community (Lodinova-Zadnikova et al., 1991; 
Lodinova-Zadnikova and Sonnenborn, 1997), lifeless bacterial lysates are probably not 
present in the gut during the intestinal inflammation induction. This points to the fact that 
bacterial lysates contain some “signal molecules” capable of tuning the gut 
microenvironment. These molecules can either interact with gut microbiota or with 
mucosal immune system or both, thus correcting the dysbiosis, inhibiting the growth of 
yet unknown pathogen or promote the growth of beneficial bacteria.  
  
8.4 IMMUNOMODULATORY ACTIVITIES OF BACTERIAL 
COMPONENTS  
Microbial components interact with mucosal immune system on several levels. Here, we 
showed that oral treatment with live probiotics or lifeless bacterial components induces a 
broad array of immunomodulatory mechanisms. Apart from the above mentioned changes 
in microbial communities, these mechanisms could improve intestinal inflammation by a) 
induction of active anti-infection immunity against immunologically related pathogens, b) 
induction of oral tolerance to immunologically related microbe or c) rendering the 
mucosa less responsive to the pro-inflammatory stimuli.  
 In chapter 5, we have tested the changes in specific IgA response in the gut after 
the DSS-induced gut barrier breach. While specific IgA against Lc were not changed, gut 
barrier failure led to a significant increase or decrease in microbe-specific IgA in the gut 
washings after Ec O83 or Ec Nis treatment respectively. This suggests that  the mucosal 
immune system handles each of these probiotic bacteria in a different way. It seems that 
there is an established mucosal tolerance to Lc and Ec Nis that could not be changed even 
if the microbial antigens had (in theory) unrestricted access to LP. This is in agreement 
with known fact, that lactobacilli are generally well tolerated by the mucosal immune 
system in vivo (Tannock, 2004). The increase in IgA response against Ec O83 after the 
DSS-induced gut barrier disruption clearly shows that it is possible to mount a strong 
response against this particular bacterium. Interestingly, this bacterium has been shown to 
boost mucosal defense against pathogens, decreasing the number of nosocomial 
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infections and mortality in pre-term infants (Lodinova-Zadnikova et al., 1991; Lodinova-
Zadnikova and Sonnenborn, 1997; Cukrowska et al., 2002), and leads to decreased 
number of repeated infections and allergies later in life (Lodinova-Zadnikova et al., 
2003). 
 Not only live probiotic bacteria, but also bacterial lysates and components have 
immunomodulatory properties. Here, we report that oral pretreatment with either lysate of 
L. casei DN-114 001 (chapter 6) or Parabacteroides distasonis (Pd) (chapter 7) changes 
numerous immune responses as detected both in vitro and in vivo methods. The above 
mentioned question of whether there is an active anti-infection immunity against 
immunologically related pathogens is especially interesting in regard to oral treatment 
with Pd, because the members of bacteroidetes phylum were proposed to play a role in 
IBD pathogenesis (Rath et al., 1996; Saitoh et al., 2002; Swidsinski et al., 2002). We 
showed in chapter 7, that oral treatment with Pd lysate, and especially with its 
membranous fraction (mPd), protects mice from DSS-induced colitis. Interestingly, 
neither of the lysates from related commensals we tested (B. ovatus, B. vulgatus, B. 
stercoris, B. thetaiotamicron) showed this activity. Moreover, this effect is gut-
dependent, because neither intraperitoneal, nor subcutaneous administration protected 
mice from severe forms of intestinal inflammation. 
 All three isotypes of anti-mPd antibodies we have measured, IgA, IgM and IgG, 
are markedly increased in the serum of mPd treated mice. The intensity of this antibody 
response after oral treatment is as high as when the mPd is administered subcutaneously 
with adjuvants. Nevertheless, we could not detect the mPd-specific antibodies in 
intestinal washings, suggesting that the antigen exclusion does not play a significant part 
in the protective effect. Oral treatment with Lc lysate did not lead to increase in specific 
serum antibodies. This might suggest that the anti-bacteroides antibodies can protect the 
mucosa during the destruction of its barrier function from flood of microbes from the gut.  
Pathogen-specific serum antibodies can protect the host from the microbes already 
present in the mucosa (Underdown, 2005). Since the members of the bacteroidetes 
phylum represent the dominant antigenic stimulus during IBD (Saitoh et al., 2002), this 
mechanism could help with clearing the flood of microbial antigens from gut mucosa 
after gut barrier failure, thus interrupting the vicious circle of inflammation. This idea is 
further supported by our findings that this therapy does not work in mice lacking adaptive 
immunity (SCID) and that the effect of the therapy could be transferred between 
immunocompetent mice via serum. Similar results might be, however, obtained even if 
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the actual protective signal is transferred from the tolerized cells in the gut mucosa to 
lymphocytes via tolerosomes, since these particles can pass through 0.22 µm filter like 
antibodies (Karlsson et al., 2001; Thery et al., 2002). 
 Another key mechanism by which microbial components could dampen the 
intestinal inflammation is induction of oral (mucosal) tolerance to immunologically 
related antigen. If there is an aberrant immune response to gut commensals in IBD, 
induction of oral tolerance to these components might be a useful tool to modulate the 
mucosal immune system. Inducing oral tolerance is an attractive approach for treatment 
of other autoimmune and inflammatory diseases, such as allergy, diabetes, multiple 
sclerosis, and graft rejection, as reviewed by Faria and Weiner (2005). Induction of oral 
tolerance in vivo is dependent on the function of regulatory T cells. We found 
a significant increase in Tregs in MLN of mPd treated animals, but there were no changes 
in Tregs numbers in the spleen or Peyer’s patches. It has been shown recently that both gut 
microbiota and the sterile diet contaminated with microbial components could induce the 
expansion of Tregs in MLNs (Hrncir et al., 2008), however, it had not been precisely 
determined which part of the microbe is responsible. Unlike with mPd, we have not found 
any changes in Tregs in MLN, spleen or Peyer’s patches after treatment with Lc or mLc. 
These results point to the possible induction of oral tolerance in the gut compartment of 
mPd, but not Lc or mLc treated mice. Interestingly, So et al. (2008) found that oral co-
administration of live L. casei with collagen significantly augmented oral tolerance to 
collagen in rat model of collagen-induced arthritis, increased number of Tregs and 
expression of TGF-β and IL-10 in isolated CD4+ cells in vitro. However, although 
administration of L. casei or collagen alone also decreased the severity of arthritis, this 
effect was less pronounced and the increase in Treg was not statistically significant in 
either case. This is in agreement with what we found in Lc and mLc lysates, and suggests 
that L. casei could potentiate the induction of oral tolerance through bystander 
suppression, but only when specific conditions are met. 
 The fine tuning of the gut mucosa with cytokines is of utmost importance for oral 
tolerance induction as well as for keeping the anti-inflammatory programming of the cells 
of innate immunity. Since the microbial components show marked influence on mucosal 
immune response, they may act as special “tolerizing adjuvants”. We showed that Lc, 
mLc, Pd and mPd decrease the activation of NF-κB cascade and the production of TNF-α 
by LPS activated macrophages in vitro. This direct effect on macrophages could lead to 
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decrease of pro-inflammatory readiness in gut mucosa, rendering it less responsive to 
other pro-inflammatory stimuli. These anti-inflammatory changes were not observed with 
another bacterial lysates, such as L. plantarum or E. coli O83 (data not shown). In the 
similar in vitro model, Pena et al (2004) found that L. johnsonii, the only lactobacillus 
isolated from the gut of colitic IL-10KO mice, does not decrease the TNF-α production as 
does L. reuteri or L. murinus, both isolated from the gut of healthy C57/BL6 mice. The 
striking differences among the individual isolates further support the notion that the 
fundamental probiotic unit should be the bacterial clone and not genus or species, as 
discussed earlier. 
 Our experiments with ex vivo tissue fragments cultivation showed, that there are 
pronounced changes in the cytokine production after treatment with bacterial lysates. We 
showed that there is an overall decrease in cytokine production (in both pro- and anti-
inflammatory) after the mPd treatment in the key compartments of gut mucosal immune 
system – PP and large intestine. Using protein array, we found that this general decrease 
in cytokine production covers also growth factors (e.g. GCSF) and enzyme inhibitors (e.g. 
TIMP-1) in colon tissue. Global decrease in cytokine production may be the result of 
lower degree of pro-inflammatory and compensatory anti-inflammatory mechanisms 
caused by a different mechanism, e.g. elimination of the antigen by antibodies. 
Nevertheless, the decrease in TGF-β after the mPd treatment was apparent even in mice 
without DSS, suggesting that all these changes were not related to the immune response 
to the inflammation. Moreover, we found that the changes in cytokine production are 
different after Lc as compared to mPd treatment, but all these changes were in the same 
gut compartments (PP and large intestine), suggesting that both inductive and effector site 
of the immune system play an important role in therapeutic effects of both lysates. The 
anti-inflammatory phenotype is more apparent after Lc treatment, with the decrease in IL-
6, IFN-γ and IL-10. Different molecules included in these two different lysates probably 
interact with the different cells of the mucosal immune system, which could explain the 
different response of the gut mucosa after Lc and mPd therapy. Nevertheless, we could 
not say with enough confidence, whether these changes are caused directly by therapy or 
simply by lower amount of pro-inflammatory stimuli. The therapy could improve the gut 
barrier function, decreasing the amount of pro-inflammatory stimuli and thus decreasing 
the severity of the inflammation. This is indeed supported by our findings that oral 
treatment with Lc or mLc significantly improves the gut barrier function during acute 
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DSS inflammation. There is yet another chicken-egg paradox, because the lower 
intestinal permeability could be caused by decrease in IFN-γ, cytokine known to increase 
gut epithelium permeability (Madara and Stafford, 1989). Indeed, probiotic or commensal 
microbes can change the gut barrier integrity in vivo, but both increase and decrease in the 
barrier integrity is possible (Garcia-Lafuente et al., 2001). Furthermore, oral treatment 
with either Ec Nis or L. plantarum has been found to enhance mucosal integrity, by 
modulating the TJs proteins, and this mechanism was proposed as a key mechanism of 
probiotic function (Ukena et al., 2007; Chen et al., 2010).    
                                                       
8.5 FUTURE PERSPECTIVES 
Human microbiota has been indicated as a new player in ethiopathogenesis of many 
human diseases, including IBD. The studies presented in this thesis suggest several 
possibilities for further investigations into the mechanisms of host-microbe and microbe-
microbe interactions during the intestinal inflammation.  
 Overall, numerous studies regarding both the beneficial and deleterious role of 
particular microbe have recently led to many important discoveries, explaining their role 
in disease ethiology and pathogenesis. Several pathogens have been identified, such as 
Adhesive-invasive E. coli (AIEC) or M. avium subspecies paratuberculosis (MAP), as 
mentioned in chapter 3. Now, there is a growing interest in how to decrease the human 
exposition to these noxious microbes. We believe that development of mucosal vaccine 
and vaccination of the subjects at risk against these microbes might be a good strategy. 
There are, however, many questions regarding the antigen and suitable adjuvants and 
safety of this measure. The vaccine composed of recombinant MAP HSP70 has already 
been successfully used as a subunit vaccine against bovine paratuberculosis, a disease 
with pathological findings similar to human CD (Koets et al., 2006). Moreover, although 
the role of MAP in CD pathogenesis is still debated (Mendoza et al., 2009), minimizing 
human exposure to MAP by controlling the disease in cattle, might actually have the 
same effect as vaccinating humans. This is an open field that should be addressed once 
the causative agent of IBD is identified. 
 While the role of microbiota in various diseases is starting to be appreciated, more 
scientists are trying to characterize the gut microbiota and to understand its role in health 
and disease, using high-throughput metagenomic and metabolomic methods (Backhed 
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and Crawford, 2010; Booijink et al., 2010). These advanced methods can not only 
analyze the composition of gut microbiota in health and disease, but they can also bring 
an insight into the functional changes of this complex microbial community. Other 
approaches, such as gnotobiology, must be chosen to address the questions regarding the 
interactions between host and particular microbe (Tlaskalová-Hogenová, 1997). 
 Pro- and pre-biotics are now starting to be used in therapy of several diseases, and 
their beneficial properties have been showed in numerous experimental models (Petrof, 
2009). However, the use of live bacteria should be considered with caution, because they 
can cause severe complications in immunocompromised patients (Besselink et al., 2008). 
This clearly shows, that we need to develop a better understanding of microbes intended 
to be used as probiotic and that bacterial components that could exert all the beneficial 
properties of the probiotics might be a safer alternative to probiotics.  
 Here, we show that local GC metabolism is changed during intestinal 
inflammation. Interestingly, there are no data on whether probiotics or some microbial 
component could enhance this natural protective mechanism by directly interfering with 
11HSDs. After all, this could be the mechanism by which some probiotics exert their 
immunomodulatory properties. This is another goal worth pursuing, because knowledge 
of the molecular mechanisms of probiotics is still insufficient, yet it holds the key to 
therapeutic use of microbial components. Therefore, our further effort will be focused on 
the detailed characterization of the anti-inflammatory mechanisms of our bacterial lysates, 
and on isolation of the active immunomodulatory component. 
 
8.6 CONCLUSIONS 
The severity of intestinal inflammation can be decreased using certain live bacteria or 
their components. This is achieved by different mechanisms; each could be unique for 
a particular bacterial component. These mechanisms comprise a) correcting the dysbiosis, 
b) modulation of the mucosal immune response and c) improving the gut barrier function. 
It is clear from the results presented in this thesis, that certain bacterial components can 
trigger these mechanisms, and that the spectrum of these anti-inflammatory mechanisms 
is strain, or even clone dependent. Oral treatment with these “immunomodulatory” 
bacterial components can be a good strategy for therapy, or even prevention, of severe 
inflammatory diseases, such as IBD. The striking differences between anti-inflammatory 
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properties of two different microbial components presented here suggest that their utility 
in the IBD therapy will depend on the stage of the disease and which mechanisms the 
component should trigger in a particular patient. Our findings presented here enhance the 
basic knowledge on how microbial components can modulate the immune system, which 
might help to individualize the therapy. However, we still need much deeper 
understanding of the underlying mechanisms of host-microbe and microbe-microbe 
interactions, before the fruits of this fascinating research can be used for the benefit of all 
patients.  
 
Figure 8.1 Manifesto... 
 
“Ce sont les microbes qui auront le dernier mot” (Louis Pasteur) 
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Appendix A – Abbreviations 
11HSD – 11β-hydroxysteroid dehydrogenase 
Ab – Antibody 
AP-1 – Transcription factor Activator protein-1 
APCs – Antigen presenting cells 
BALT – Bronchus-associated lymphoid tissue 
CD – Crohn's disease 
cPd – cytoplasmic fraction of P. distasonis lysate 
CPs – Cryptopatches  
CTAB – Cetyltrimethylammonium bromide 
CTLs – Cytotoxic T cells 
DCs – Dendritic cells 
DSS – Dextran-sulfate sodium 
Ec Nis – Escherichia coli Nissle 1917 O6:K5:H1 
Ec O83 – Escherichia coli O83:K24:H31 
ELAM-1 – endothelial-leukocyte adhesion molecule 1  
ELISA – Enzyme-linked Immunosorbent assay 
FAE – Follicle-associated epithelium 
FITC – Fluorescein-iso-thiocyanate 
FoxP3 – Forkhead box P3 
GC – Glucocorticoid (GC) 
GF – Germ-free 
H&E – Hematoxylin and eosin 
HRP – Horse radish peroxidase 
IBD – Inflammatory bowel disease  
ICAM-1 – Intracellular adhesion molecule 1  
IECs – Intestinal epithelial cells 
IEL – Intraepithelial lymphocytes 
IFA – Incomplete Freund’s adjuvant 
IFN-γ – Interferon gamma 
Ig – Immunoglobulin 
IL – Interleukin 
Lc – Lactobacillus casei DN-114 001  
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Lp – Lamina propria 
LPL – Lamina propria lymphocytes 
LPS – Lipopolysaccharide 
MAdCAM-1 – Mucosal vascular addressin cell adhesion molecule 1  
MALT – Mucosa-associated lymphoid system 
MAP – Mycobacterium avium subsp. paratuberculosis 
MCP-1 – Monocyte chemotactic protein 1 (CCL2) 
MHC – Major histocompatibility complex 
MICA – MHC class I-related molecule A 
MICB – MHC class I-related molecule B 
MLCK – Myosin light chain kinase 
MLNs – Mesenteric lymph nodes 
mLc – Membranous fraction of Lactobacillus casei DN-114 001 
mPd – Membranous fraction of Parabacteroides distasonis 
MyD88 – Myeloid differentiation primary response gene (88) 
NAD(H) – Nikotinamid adenin dinukleotid 
NADP(H) – Nikotinamid adenin dinukleotid fosfát 
NF-κB – Transcription factor Nuclear factor kappa B 
NOD – Nucleotide-binding oligomerization domain containing 
OD – Optical density 
MAMP – Microbe-associated molecular patterns 
PBS – Phosphate-buffered saline 
PCR – Polymerase chain reaction 
PCR-DGGE – Polymerase chain reaction-denaturing gradient gel electrophoresis 
Pd – Parabacteroides distasonis 
pIgR – Polymeric Ig receptor 
PP – Peyer’s patches 
PRR – Pattern recognition receptor 
qPCR – Quantitative PCR 
SBTI – Soybean trypsin inhibitor 
SC – Secretory component 
SCID – Severe combined immunodeficient  
SED – Subepithelial dome 
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SIgA – secretory IgA 
SIgM – secretory IgM 
TCR – T-cell receptor 
TDA – Thymus-dependent area 
TECK – Thymus-expressed chemokine (CCL25) 
TGF-β – Transforming growth factor 
Th – T helper 
TJ – Tight junction 
TLR – Toll-like receptor 
TMB – 3,3',5,5'-tetramethylbenzidine 
TNF-α – Tumor necrosis factor 
Treg – Natural regulatory T cells 
TSLP – Thymic stromal lymphopoietin 
UC – Ulcerative Colitis 
UPGMA – Unweighted pair-group method with arithmetic averages 
ZOT – Zonula ocludens toxin  
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